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Abstract
Recent studies have suggested that hepatic iron stores and the response to anaemia and 
inflammation are dependent on the mouse strains used and their Hfe status. Hepcidin and 
iron transporters such as DMT1 and Iregl are regulator molecules important in the pathology 
and physiology of iron metabolism. The aim of these studies was to produce Hfe KO mice on 
a strain known to have higher basal hepatic iron levels and study iron homeostasis in relation 
to variable dietary iron and inflammation in these mice. The regulation of hepcidin was 
investigated in Huh7 cells exposed to various stimuli such as iron, inflammation and hypoxia. 
In addition, Huh7 cells were exposed to conditioned medium obtained from HH1 patient's 
macrophages. Results obtained from these studies are described and discussed in this thesis.
In brief, it was found that the disruption of the Hfe gene causes a preferential accumulation 
of iron in the caudate lobe of the mouse liver. Contrary to previous findings, iron loaded diet 
does not have an effect on hepddin expression in wt SWR mice while in Hfe KO SWR mice it 
significantly upregulates hepcidin expression. Furthermore, the upregulation of hepcidin by 
turpentine oil-induced inflammation in SWR mice is Hfe-dependent. Hepcidin expression is 
down regulated by hypoxia and anaemia and conditioned medium from patients with HH1 
macrophages have no effect on hepcidin expression levels.
In conclusion, the results show that SWR Hfe KO mice is not an accurate model for the study 
of HH1, the studies described here, however, contribute to the understanding of how 
hepatocytes respond to iron status, hypoxia and inflammation and the relevance of the Hfe 
gene in the regulation of hepcidin expression levels as well as hepatic DMT1 and Iregl 
expression levels.
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1.1 Iron metabolism
The word "iron" comes from the Anglo-Saxon word "irerl' and the symbol Fe comes from the 
Latin word "ferrurrf meaning "iron" Possibly the word iron is derived from earlier words 
meaning "holy metal" because it was used to make the swords used in the Crusades.
Iron has been used by physicians to treat several conditions throughout history. According to 
Nicholas Monarde, a 16th century physician in Seville, the uses of iron as a medicine included 
treatment of disorders such as Tuberculosis, Fevers, Acne and Weakness. In 1713, Lemery 
and Geoffroy demonstrated the presence of iron in the blood, but only two centuries later the 
metabolism of iron in the body began to be understood. In 1925, Fontes and Trivolle (Fontes 
and Thivolle 1925) documented the existence of non haemoglobulin iron in serum and 
suggested that there was a circulating form of iron. Over the next two decades, the transport 
protein, transferrin, was identified and the fact that iron dissociated from it at low pH was 
established. In a dassic 1937 article, Widdowson and McCance (Widdowson and McCance 
1937) summarised the experimental findings showing that the main site of absorption was 
the upper intestine or duodenum and that very small amounts of iron were absorbed from 
the entire intestinal tract. Though how the mucosal iron absorption is regulated was not then 
understood.
In the first part of the 20th century, the study of Whipple on haemoglobin regeneration by 
means of liver and other foods in anemia due to blood loss in dogs (Whipple and Robscheit- 
Robbins 1925a;Whipple and Robscheit-Robbins 1925b) demonstrated the role of food in the 
enhancement of blood formation. This finding led Minot and Murphy (Minot 1934;Minot and 
Murphy 1926) to develop the first effective and life-saving therapy for pernicious anaemia 
thus winning the 1934 Nobel Prize for Medicine and Physiology. Once radioactive iron 
(radioiron) was available it was easier to assess how the mucosal regulation of iron 
absorption occurs. In 1963, Conrad and Crosby noted that radioiron appeared to enter 
mucosal cells but the cells were sloughed off with the iron they absorbed when the body iron
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needs were low (Conrad, Jr. and Crosby 1963). This suggested that the regulation of Iron 
absorption occurred at the level of transfer from the mucosal cell to the blood. This concept is 
still widely held today, but the mechanisms by which the transfer is regulated are still being 
studied and therefore not fully understood.
It is known that iron is recycled continually by the breakdown of dying red cells in 
macrophages and release of iron to serum transferrin (about 20-30mg/day). Iron is lost from 
the body by processes such as sloughing of skin, and menstruation (about l-2mg/day of 
Iron) (Demaeyer 1980). Apart from these small losses, there is no physiological iron excretion 
system in mammals to regulate body iron levels and therefore the primary mechanism by 
which the total body iron level is controlled is through the regulation of iron uptake from the 
diet (Cavell and Widdowson 1964).
It  is, therefore, necessary to fully understand the mechanisms of the systematic homeostasis, 
which requires the coordination of iron absorption, transport, storage, recycling and utilisation 
throughout the body, in order to prevent iron deficiency diseases such as anaemia and iron 
overload diseases such as hereditary Haemochromatosis (HH).
1.2 Iro n  circulation in the body
Iron is an essential element for cellular growth and development as it is essential for many 
fundamental biochemical reactions such as DNA synthesis, transport of oxygen and electrons 
and cellular respiration. Under most physiological conditions the Fe atom exists in its oxidized 
ferric state. If  not appropriately shielded, iron (Fe) can readily participate in one-electron 
transfer reactions that can lead to the production of extremely toxic free radicals. Fe2+ (via 
the Fenton reaction) and Fe3+ (via the Haber-Weiss reaction) can generate toxic oxygen 
radicals in the presence of oxygen derivatives (H202, 0 2) (Imlay and Linn 1988) (Halliwell 
1994;Stadtman and Wittenberger 1985). To prevent "free" iron from reaching toxic levels, 
higher organisms have developed Fe-binding proteins known as the transferrins (Tfs)
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(Richardson and Ponka 1997;Sahlstedt et al. 2002). After absorption, ferric iron binds to 
transferrin in the serum and is carried to the bone marrow to be used for erythropoiesis. Here 
the iron binds transferrin receptors in red cell precursors and is internalised by 
endocytocytosis. The transferrin cycle will be discussed in section 1.2.1.1.
A well-balanced diet must contain sufficient iron to meet the body requirements. About 1-2 
mg of dietary iron is absorbed each day, and this is sufficient to balance the daily losses 
(Cook et al. 1973), and maintain a relatively constant amount of body iron throughout life. 
Adults have normally around 2-4 g of total body iron. About 2 g of this total is found in red 
blood cells as haeme in haemoglobin, and 1 g occurs as storage iron (haemosiderin or 
ferritin), with the remainder in muscle myoglobin and in tissue enzymes that require iron. The 
main site of iron storage is the liver (Fig. 1.1).
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Figure 1.1 Iron circulation in the human body.
D ietary iron gets absorbed into the plasma a t the proxim al duodenum. In  the 
erythroid marrow, iron gets incorporated in to  haemoglobin o f the red blood cells 
which are then released into circulation. Senescent red blood cells are taken up by 
macrophages tha t then recycle the iron in to  circulation. Surplus iron is stored in the 
live r (Finch e t at. 1950;Wessiing-Resnick 2006). Figure adapted from  (Andrews 
1999).
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1.2.1 Transferrin
Transferrin (Serum TF) is a protein from the Transferrin family which also includes lactoferrin, 
and ovotransferrin. Serum TF functions to transport iron between sites of absorption, storage, 
and use while ovotransferrin from egg white and lactoferrin from milk and other secretions 
have bacteriostatic functions.
Human TF is a monomeric glycoprotein with a molecular mass (Mr) of 80 kDa. It consists of 
two homologous domains, each of which contains one high-affinity Fe3+-binding site (Bailey 
et al. 1988). Affinity of iron to transferrin is pH-dependent; in plasma (approximately pH 7.4), 
transferrin binds iron very strongly, whereas virtually no binding occurs at pH <4.5. This 
property plays an important role in the physiological mechanism of iron release from 
transferrin.
Figure 1.2 Ribbon representation of the transferrin receptor-transferrin 
(TFR-TF) complex
Iro n  circulates in  the blood bound to  transferrin. Transferrin binds two atoms o f Fe?+ 
w ith high affin ity. Taken from  htto ://crysta l, harvard. edu/structures.php) on 
25/02/2007.
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Transferrin binds two atoms of Fe3+ with high affinity, but only when concomitant binding of 
carbonate or bicarbonate occurs. Binding and release of iron by transferrin are accompanied 
by dramatic conformational changes in the protein. In the absence of iron, the two domains 
involved in the binding are widely separated and assume an "open" configuration. On the 
other hand, insertion of iron brings the two domains of the binding cleft close toward the 
metal, and transferrin assumes a "dosed" conformational state.
Transferrin is normally about one-third saturated with iron, with approximately 10% present 
as diferric transferrin. In healthy adults, the total plasma iron pool (approximately 3 mg) 
remains remarkably constant despite being turned over more than 10-fold every day and is 
virtually unaffected by iron in stores (ferritin and haemosiderin) that can vary from 350 to 
900 mg in females and males, respectively. There seems to be a control mechanism that 
guarantees that the rate of iron release from stores perfectly matches the one with which the 
iron is taken up by tissues, but the nature of this regulation is still unknown.
In vertebrates, the major protein involved in iron uptake of TF-bound iron into cells is the 
plasma membrane transferrin receptor (TFR). There are two molecules of TFR, TFR1 and 
TFR2; both receptors deliver iron to the cells and bind diferric transferrin in a pH dependent 
manner (Richardson and Ponka 1997).
1.2.1.1 Transferrin receptor 1 (TFR1) and TFR1 mediated iron uptake
Apart from mature red blood cells, all cells have TFR1 on their surface, with its highest 
numbers being in the erythron, placenta and liver. The TFR is a disulphide-linked 
homodimeric type II transmembrane protein, which has two identical subunits each of them 
having a binding site for TF. Following the binding of the two proteins (TF-TFR) (Fig. 1.2), 
the complex (TF-Fe3+-TFR1), is internalised through clathrin-coated pits into specialised 
endosomes (Killisch et al. 1992). Upon maturation and loss of the dathrin coat, the decreased 
of pH leads to a protonation of the Fe-binding sites of TF and the release of Fe (Fig. 1.4). Fe
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is then released into the cytosol through DMT1, which is selective for ferrous iron, Fe2+ 
(Fleming et al. 1998;Gruenheid et al. 1999). As TF carries ferric iron (Fe3+), iron must be 
reduced in the TF cycle endosome. The erythroid reductase that carries out this activity has 
recently been identified as STEAP3, the epithelial antigen of the prostate 3 (Ohgami et al. 
2005).
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Figure 1.3 Transferrin Cycle
Following the binding o f (TF-TFR) - Fe?+f on the surface o f erythroid precursors, the complex 
is  internalised through clathrin-coated p its  in to  specialised endosomes. Upon m aturation and 
loss o f the dathrin coat, a proton pump decreases pH leading to  conform ational changes in  
proteins tha t result in  the release o f Fe. Iron  is then reduced by the newly described erythroid  
reductase 5TEAP3 before DMT1 moves iron across the endosomai membrane, to  enter the 
cytoplasm. Once in the cytosol iron is either stored o r u tilised by the cell. Following the 
release o f the iron, the transferrin-TFR l complex is recycled to the ce ll surface, where each 
can be used fo r fu rthe r cycles o f iron binding and iron uptake (Andrews 1999).
Once in the cytosol iron is either stored or utilised by the cell. Following the release of the 
iron, the Transferrin-TFRl complex is then recruited through exocytic vesicles back to the cell 
surface (van Weert et al. 1995). At physiological pH apotransferrin (iron-free TF) dissociates 
from the receptor and returns to the circulation where it is reutilised in further cycles 
(Richardson and Ponka 1997;Salter-Cid et al. 1999;Dautry-Varsat et al. 1983).
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1.2.1.2 TFR2
A second human transferrin receptor gene, TFR2 has been cloned (Kawabata et al. 1999). 
TFR2 has significant sequence homology with the classical transferrin receptor (TFR1), and 
also mediates the cellular uptake of transferrin-bound iron. Although both TFR1 and TFR2 are 
capable of transporting transferrin-bound iron into the cell, their properties differ in several 
critical ways. TFR2 has a lower affinity for diferric transferrin than does TFR1 (Kawabata et al. 
1999;West, Jr. et al. 2000). While TFR1 is expressed in almost all cells, TFR2 is expressed at 
much higher levels in liver compared with other tissues (Fleming et al. 2000;Kawabata et al. 
2001). The receptors also differ in their response to changes in cellular iron status. The TFR1 
transcript contains multiple iron-responsive elements in the 3'-untranslated region (UTR) 
while the TFR2 does not have these elements and thus TFR2 message and TFR2 protein 
levels vary little with changes in iron status (Fleming et al. 2000;Kawabata et al. 2000).
Recent data suggests that TFR2 senses the body iron status by sensing the concentration of 
diferric transferrin also called holotransferrin or iron-saturated transferrin (Aisen 
2004;Camaschella 2005;Johnson and Enns 2004;Robb and Wessling-Resnick 2004;Scheiber- 
Mojdehkar et al. 2003). In hepatocyte-derived cell lines and animal models, increasing 
concentrations of holotransferrin but not apotransferrin increases TFR2 protein levels 
(Johnson and Enns 2004; Robb and Wessling-Resnick 2004). It has also been recently 
reported that the cytoplasmic domain of TfR2 is essential for its stabilization by diferric TF 
(Chen and Enns 2007).
Mutations in the TfR2 gene have been found to responsible for HFE4 (Girelli et al. 
2002;Roetto et al. 2001), whereas functional loss of TfRl (TfRl KO mice) produces an 
embryonic lethal phenotype (Levy et al. 1999a). This indicates that the roles for TFR1 and 
TFR2 in iron homeostasis are not redundant.
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1.3 Dietary Iron uptake
1.3.1 Structure of the duodenum
The proximal portion of the small intestine, starting at the lower end of the stomach and 
extending to the jejunum is called the duodenum. The name duodenum comes from the latin 
duodenum digitorum , twelve fingers' breadths due to its length (Duthie 1964;Johnson et al. 
1983;Wheby et al. 1964). The lumen surface of the duodenum is covered by millions of small 
projections called villi which extend about 1 mm into the lumen (Fig. 1.4).
Lumei
Hepatic 
portal vein
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bed ^
Epithelium
Lacteal
Intestine
Figure 1.4 Structure and physiology of the duodenum
The lumen surface o f the duodenum is covered by m illions o f sm all projections called v illi 
which extend about 1 mm in to  the lumen.
Villi are covered predominantly with mature enterocytes, along with occasional mucus- 
secreting goblet cells. Intestinal mucosal mature enterocytes lining the villi close to the 
gastroduodenal junction are responsible for all the dietary iron absorption. The precursor cells 
differ from mature enterocytes in their expression of proteins. While mature enterocytes are
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specialized for absorption and transport of iron, its precursor acts only as a sensor of body 
iron needs.
Figure 1.5 Life Cycle of the duodenal enterocytes
Stem cells present in  the crypts o f the duodenum proliferate and give rise to  
precursor cells tha t fu rthe r differentiate in to  absorptive cells o r enterocytes. These 
enterocytes are highly specialised fo r absorption o f m icronutrients from  the in testina l 
lumen. Their apical membrane is structured w ith m icrovilli and contains enzymes tha t 
facilita te  transport o f nutrients through the epithelia l ce ll layer. The m ajority o f iron  
absorption is facilita ted  by these specialised cells. The process o f d ifferentiation  
occurs sim ultaneously w ith m igration out o f crypt and onto the villus. Zones o f cells 
in  sim ilar stages are evident when the crypt/villus junction  is viewed in  cross section. 
A fte r the cells have m igrated to the v iiia r tip , they are exfoliated and excreted (Roy 
and Enns 2000).
Enterocytes originate from undifferentiated cells in the crypts of Lieberkuhn (Ito and Terao 
1994). From here they migrate apically along the villi and are finally lost by exfoliation and 
apoptosis (Fig. 1.5). By the time cells reach the mid-villus they have become mature (Morgan 
and Oates 2002;Roy and Enns 2000).
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1.3.2 Duodenum iron uptake
To reach the plasma, iron must pass from the gut lumen through the apical and basolateral 
membranes of the mature enterocyte. Iron obtained from food is not bound to transferrin, 
instead, the low pH of gastric effluent helps dissolve ingested iron and provides a proton-rich 
milieu. This facilitates enzymatic reduction of ferric iron to its ferrous form.
Dietary iron compounds can be divided into two types, haem and non-haem. Haem iron is 
absorbed more efficiently than non-haem iron in humans (Bothwell and Charlton 1979). 
Consequently, haem iron may contribute more to the absorbed iron even though it represents 
a lesser fraction of ingested iron. The absorption of haem and non-haem iron differs in the 
initial uptake step. Haem iron enters mucosal cells through the brush border membrane 
probably by endocytosis or via HCP1, as the intact iron-protoporphyrin complex, and within 
the cells the iron is released by the action of the microsomal enzyme, haem oxygenase. From 
then on the iron enters the same intracellular pool as newly absorbed non-haem iron and 
therefore will be affected by the same factors (Morgan and Oates 2002).
Regulation of iron uptake into the body occurs at both the apical and basolateral membranes 
of the intestinal epithelium. The apical membrane of the differentiated (mature) enterocyte, 
which faces the intestinal lumen, is specialized for transport of haem and ferrous iron into the 
cell. Three pathways have been reported for this transport process: haem-iron uptake 
pathway involving HCP1, iron uptake pathway involving DMT1 and iron uptake involving 
mucin and mobilferrin. The most extensively characterized uptake pathway is via the divalent 
metal transporter, DMT1 (previously named Nramp2 and DCT1) which will be described in 
section 1.3.3.
Iron can also be absorbed by the haem-iron uptake pathway which involves the recently 
described iron-regulated intestinal haem transporter, HCP1 (Shayeghi et al. 2005). In this 
pathway, haem binds to the brush-border membrane of duodenal enterocytes, intact 
molecules are translocated across the membrane by HCP1 and in the cytoplasm haem is 
contained in membrane-bound vesicles (Conrad et al. 1966;Weintraub et al. 1965;Wheby 
1970;Wyllie and Kaufman 1982). Haem is then degraded by haem oxygenase (HO) to yield
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ferrous iron (RafRn et ai. 1974), which enters the pool of low molecular weight iron and the 
iron absorbed as non-haem iron (Abboud and Haile 2000;Donovan et al. 2000;McKie et al.
2000). More recently HCP1 has been shown to have a role in proton-coupled folate transport 
required for folate homeostasis in man, suggesting that this gene has several functions (Qiu 
et al. 2006).
Thirdly, Conrad et al have proposed a model in which iron would bind to mucin in the 
intestinal lumen, then transfer to integrin at the cell surface, and then transfer to the 
intracellular protein mobilferrin, which is a calreticulin homologue (Conrad et al. 1991;Conrad 
et al. 1992;Conrad et al. 1993;Conrad and Umbreit 1993). Calreticulin is a multifunctional 
calcium binding protein involved in the folding of endoplasmic reticulum synthesized proteins. 
It is also a shock protein induced by heat, food deprivation and chemical stress (Szewczenko- 
Pawlikowski et al. 1997). When the intracellular iron increases there is a significant increase 
in calreticulin. As an oxidative stress-induced protein it is thought that this iron-induced 
calreticulin protects the ER, cytosol and nucleus against oxidative damage (Nunez et al.
2001).
1.3.3 The molecular mechanism of duodenal non-haem iron uptake fFia.l.fri
As previously mentioned at physiological pH, and in the diet, iron is predominantly in the 
highly insoluble ferric (Fe3+) form, whereas iron transport systems take up the ferrous (Fe2+) 
form. Thus iron needs to be reduced by the ferric reductase Dcytb (Duodenal cytochrome b) 
or some other mechanism e.g. by ascorbate, before it can enter the cell. Non-haem is then 
transported into the cell mainly by the Divalent Metal Transporter 1 (DMT1). Once inside the 
cell, iron can either be stored as ferritin or be transferred across the basolateral membrane to 
reach the plasma. These fates are not mutually exclusive and the determining factor is 
thought to be decided when the enterocytes develops from the crypt cell. Iron stored as 
ferritin returns to the lumen when the enterocyte completes its limited life cycle and is 
sloughed off. The basolateral iron exporter was identified by three groups, one of whom 
named it Iregl. Iregl is thought to require Hephaestin, a ferrous oxidase that converts Fe2+
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to Fe3* facilitating the iron transport across the basolateral membrane of intestinal 
enterocytes into the bloodstream.
The proteins required for the non-haem iron absorption, transport into the enterocytes across 
the brush border membrane, movement of iron through the cells; transport across the 
basolateral membrane and passage through the intestinal space and capillary wall are 
described in more detail below.
1.3.3.1 Dcytb
The ferrous form of iron (Fe2+) is very unstable and quickly oxidises to ferric iron. To prevent 
this from happening, ferric reductases (or ferric-chelate reductases) which are specialised 
transmembrane electron transport systems have evolved. These redox systems use 
intracellular reducing cofactors to reduce ferric iron (Fe3+) to ferrous iron (Fe2+) at the 
extracellular surface.
Although described since 1992 (Raja et al. 1992;Simpson et al. 2003) it was not until 2000 
that the ferric reductase was isolated, cloned and named duodenum CYTochrome B (Dcytb) 
(McKie et al. 2001). As expected from a protein involved in iron transport, Dcytb mRNA and 
protein levels in the duodenum respond to changes in iron status. Both mRNA and protein 
levels increase in conditions that stimulate iron absorption, such as iron deficiency and 
hypoxia, and are reduced in iron loading conditions (Collins et al. 2005). Dcytb is highly 
expressed in the brush-border membrane of duodenal enterocytes but also in other tissues 
such as spleen, liver and brain (McKie et al. 2002).
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1.3.3.2 DMT1
Ferrous Iron is then transported across the apical membrane (Fig. 1.8) by the Divalent Metal 
transporter 1 (DMT1), also called Nramp2, SLC11A2, or DCT1. DMT1 is a member of the 
"natural resistance-associated macrophage protein" (Nramp) family and was identified by two 
groups in 1997 (Fleming et al. 1997;Gunshin et al. 1997). The phenotype of microcytic 
anaemia mice (gene symbol mk), characterised by an impairment in iron absorption that 
leads to iron deficiency, suggested that the causative mutation was likely to be in an 
intestinal transporter functioning at the brush border. Eventually Fleming (Fleming et al. 
1997), localised the DMT1 mutation unique to the mk mice. In parallel experiments, Gunshin 
et al searched for an intestinal iron transporter using a Xenopus oocyte expression cloning 
system and found a single cDNA that stimulated iron transport. This cDNA encoded rat DMT1 
and they went on to show that DMT1 transported not only iron but also a variety of other 
heavy metals including cobalt, manganese, lead, zinc, and copper (Gunshin et al. 1997).
DMT1 mRNA expression is ubiquitous and has been detected in most tissues and cell types 
analysed; however, it is higher in brain, thymus, proximal intestine, kidney, and bone marrow 
(Gunshin et al. 1997).
Two spliced products were identified for DMT1 in several species. One transcript contains a 
sequence that resembles an iron responsive element (IRE) within its 3'-UTR, whereas the 
alternatively spliced counterpart lacks this sequence and encodes a protein that is seven 
amino acids longer at the C-terminus (DMT1-IRE) (Fleming et al. 1997;Gunshin et al. 1997). 
Only the splice form containing the IRE (DMT1+IRE) is responsive to iron, both in cultured 
cells and in the human intestine (Byrnes et al. 2002;Canonne-Hergaux et al. 1999;Zoller et al.
1999). The level of regulation in intestine was higher compared to other tissues such as liver, 
kidney, heart and brain (Gunshin et al. 1997) and in iron deficiency, hypoxia, or stimulated 
erythropoiesis, the expression of DMT1 mRNA and protein in the duodenum is increased 
leading to an increase in iron absorption (Canonne-Hergaux et al. 1999).
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1.3.3.3 Ferritin and Haemosiderin
Once inside the cell, iron can either be stored as ferritin or be transferred across the 
basolateral membrane to reach the plasma. Ferritin is a ubiquitously expressed protein and 
sequestration and storage of iron is its main function (Theil 1983;Theil 1990). Ferritins 
constitute a broad supeifamily of iron-storage proteins in organisms as diverse as bacteria, 
fungi, plants and vertebrates and this wide distribution among living species implies a 
fundamental and ancient role in iron metabolism.
Ferritin (Fig. 1.7), is a large cytoplasmic protein consisting of symmetrically related subunits 
of two types, a light subunit (L-subunit) and a heavy subunit (H-subunit) (Arosio and Levi 
2002;Harrison and Huehns 1979;Harrison et al. 1986;Harrison 1977) which assemble to form 
a shell of 24 subunits with a cavity capable of storing up to 4500 iron atoms as hydrous ferric 
oxide (Mann et al. 1986;Theil 1983;Theil 1990). The mechanism by which ferritin obtains Fe 
remains unknown but in vitro experiments have suggested that Fe2+ is more rapidly 
incorporated into the protein than Fe3+. The protein shell seems to play an essential role in 
the initial oxidation of the incoming Fe (Richardson and Ponka 1997).
The amino acid sequences of the H- and L-subunits differ by approximately 50%, and the 
contents of the two chains vary according to the organ and its iron requirements. It appears 
that while H chains confer ferroxidase activity to the heteropolymer, L chains confer 
nudeation sites for iron binding (Levi et al. 1988;Levi et al. 1992). Despite this differences, 
synthesis of both subunits is translationally controlled by common cytoplasmic proteins, iron 
regulatory proteins (IRP-1 and IRP-2), which bind to the iron-responsive element (IRE) in the 
5'-untranslated region (UTR) of messenger RNA (mRNA) (Huang et al. 1999). How IRPs with 
IREs regulate cellular iron uptake will be discussed in section 1.5.1.
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Figure 1.7 Ribbon representation of the Ferritin molecule
Ferritin is a large cytoplasmic protein consisting o f sym m etrically related subunits o f 
two types, a lig h t subunit (L-subunit) and a heavy subunit (H -subunit) which 
assemble to form  a shell o f 24 subunits w ith a cavity capable o f storing up to  4500 
iron atoms as hydrous fe rric oxide. Taken from  http ://w w w . chemie. tu- 
darmstadt.de/akDienio/moDroc/eisen/uebersicht.htm  on 25/02/2007.
At normal levels of body iron, the expression of ferritin in the average cell (e.g. fibroblasts) is 
quite low, which contrasts with cells from tissues that have specialised functions in iron and 
possible oxygen homeostasis (e.g. liver and heart). Apart from storage, ferritin seems to have 
a protective 'anti-oxidising' function by sequestering the iron inside the cavity (Theil 2003). 
Ferritin has also been detected in the circulation of normal subjects but the origin and 
possible physiological role of plasma ferritin in normal individuals remain elusive. Linder 
(Linder et al. 1996), identified a number of unexpected differences between plasma and 
tissue ferritin, and it has been suggested that the serum ferritin may not be the product of 
the same genes as those encoding intracellular ferritin. The serum ferritin is a universally 
available and well-standardized measurement that has been the single most important 
laboratory measure of iron status during the past quarter century. It is used to diagnosis of 
patients who are suspected to have an iron overload disease (mainly hereditary 
haemochromatosis), or iron deficient anaemia (Beutler et al. 2003).
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Haemosiderin is a poorly defined iron-protein that forms an insoluble iron storage system. 
Under normal homeostatic conditions the body tissues contain low amounts of haemosiderin, 
however under primary and secondary iron overload conditions; content of haemosiderin 
dramatically increases in tissues, particularly in organs such as the liver, heart and pancreas.
1.3.3.4 Hephaestin
Hephaestin (Hp) is a member of the blue multicopper oxidase family which is found in 
organisms as diverse as bacteria and humans. The Hp protein was found to have significant 
sequence identity to ceruloplasmin (Cp), a serum multicopper ferrioxidase with the ability to 
convert Fe2+ to Fe3+ (Syed et al. 2002). Further insights into the mechanism of hephaestin 
(after the Greek god of metal-working) have been obtained from the study of the sex-linked 
anaemia (s/a) mouse (Bannerman et al. 1973;Chen et al. 2004b;Vulpe et al. 1999). A partial 
deletion of the hephaestin (Hp) gene in these mice leads to systemic iron deficiency but also 
iron accumulation in the enterocytes (Chen et al. 2004b;Manis 1971;Vulpe et al. 1999). The 
similarity between the Hp and Cp, along with the phenotype of s/a mice, led to the conclusion 
that the ferrioxidase activity of Hp is critical in converting Fe2+ to Fe3+ and thus allowing iron 
to be released from enterocytes through the basolaterally located transporter Iregl prior to 
incorporation into transferrin (Chen et al. 2004b;Kuo et al. 2004;Syed et al. 2002;Vulpe et al.
1999).
Despite the sequence similarities, Hp expression contrasts that of Cp. Hp expression in the 
intestine is limited to the villi, the site of iron absorption while Cp is not expressed in the 
intestine but is highly expressed in liver and to a lesser extent expressed in other tissues 
including brain (Klomp et al. 1996;Klomp and Gitlin 1996) and lung.
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1.3.3.5 Iregl
Iregl (Iron-regulated transporter-1), also called ferroportinl, MTP1 (Metal Transporter 
Protein 1) and Slc40al, was identified independently by three laboratories and was shown to 
play a role in the export of iron (Abboud and Haile 2000;Donovan et al. 2000;McKie et al.
2000) (Fig. 1.8).
Iregl like DMT1 is a member of the NRAMP family of metal transporters and was found to be 
expressed in cells that play a critical role in mammalian iron metabolism, including placental 
syncyotrophoblasts, duodenal enterocytes, hepatocytes, and reticuloendothelial (RE) 
macrophages (Montosi et al. 2001). In the placenta, Iregl is involved in transfer of iron 
between the maternal and foetal circulations; in the macrophages of the spleen and in 
Kupffer cells of the liver, iron released from the breakdown of haem is transported out of the 
cell to the plasma via Iregl. Duodenal Iregl is expressed at the basolateral membrane of 
mature absorptive epithelial cells of the villus (Abboud and Haile 2000) where it facilitates the 
transport of iron from the enterocyte to the circulation.
Iregl contains a functional iron responsive element (IRE) within its 5' UTR and therefore is 
regulated by iron. Iron deficiency, anaemia and hypoxia increase Iregl mRNA and protein 
levels in the duodenum (Chen et al. 2003;McKie et al. 2000;Pietrangelo 2005).
In the spleen and alveolar macrophages Iregl is up-regulated by iron loading rather than iron 
deficiency indicating that there are tissue-dependent differences in the regulation of Iregl. 
The protein also has been shown to be down-regulated in macrophages in mice with acute 
inflammation. This provides an explanation of how iron may be retained in RE cells during 
inflammation. The mechanism by which inflammation down-regulates Iregl is not yet known 
but recently, the protein has been shown to be the molecular target of Hepcidin the major 
negative regulator of duodenal iron absorption and release of iron from macrophages (Delaby 
et al. 2005;Means 2004;Nicolas et al. 2002b;Park et al. 2001;Pigeon et al. 2001).
Iregl mutations have been found to be responsible for the Ferroportin disease. In this 
disease iron accumulates in enterocytes, splenic macrophages but mainly in Kupffer cells. 
This location of iron loading probably reflects the lack of Iregl function in recycling iron from
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the breakdown of haem. The resulting iron becomes trapped in the macrophage and thus 
makes it unavailable for synthesis of new haemoglobin. This confirms the physiological role of 
Iregl as the major efflux route for iron in macrophages.
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Figure 1.8 Duodenal iron transport
Three pathways have been described fo r the iron transport across the apical 
membrane also called brush border membrane. The m ost extensively characterised 
pathway involves the divalent m etal transporter DMT1 which transports iron in to  the 
ce ll a fte r Dcytb reduces iron to  its  ferrous form  (Fe?+). Iron  can also bind mucin and 
be transferred in to the ce ll by integrin. Recently it  has been reported tha t HCP1 could 
be the transporter tha t carries haem in to  the cell. Once inside the ce ll the iron can 
e ither be stored as fe rritin  o r be transferred across the basolateral membrane by 
Ire g l coupled w ith hephaestin which converts iron in to  its  fe rric form  (Fe3*). Once in  
the plasma iron circulates bound to  transferrin.
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1.3.4 Hepatic iron metabolism
The liver has three functions in iron metabolism. The first function is iron storage, the liver 
being the main storage site of iron in the body. The second function of the liver in iron 
metabolism is the regulation of iron trafficking into and around the body through the 
production of Hepcidin (section 1.3.4.2) and the third function is synthesis of proteins such as 
transferrin and ceruloplasmin, major proteins in iron metabolism.
A normal adult human male contains approximately 4 to 5 g of iron in his body and of this 
approximately 10% is stored in the liver. Under normal circumstances the vast majority of 
this iron is found in hepatic parenchymal cells with the remainder found in Kupffer cells, and 
very small amounts in stellate cells, endothelial ceils, and bile duct cells.
The most prominent cell type in the liver is the hepatocyte, making up to 80% of the liver 
mass. In iron overload conditions such as Hereditary Haemochromatosis (HH) hepatocytes 
are the dominant site of iron deposition.
As the main storage site, hepatocytes have a high capacity to synthesize ferritin (Harrison 
and Arosio 1996) but also Transferrin (TF) (Ponka et al. 1998), Ceruloplasmin (Cp) (Heilman 
and Gitlin 2002), haptoglobin (Wassell 2000), and hemopexin (Tolosano and Altruda 
2002;Wassell 2000). As the main site of expression of the regulatory proteins HFE, transferrin 
receptor 2 (TFR2) and Hepcidin (Frazer and Anderson 2003;Wassell 2000) hepatocytes also 
play a major role in the regulation of body iron homeostasis.
Iron can be taken up by the liver in several forms and by several pathways (Figure 1.9). As 
the vast majority of circulating iron is Tf-bound, the dominant source of iron for the liver is 
diferric Tf (Trinder et al. 19%;Wassell 2000). However, in iron overload conditions when the 
capacity of plasma Tf to bind iron is exceeded, iron can also be taken up as non-transferrin- 
bound iron (NTBI) (Craven et al. 1987;Parkes et al. 1995;Randell et al. 1994;Thorstensen 
1988;Thorstensen and Romsk) 1988;Wright et al. 1986).
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As described in section 1.2.1, uptake of iron from transferrin occurs by receptor mediated 
endocytosis of transferrin, release of iron within the acidic vesicles and extrusion of iron- 
depleted transferrin [Fig. 1.9, TfRl Cycle (1) and TfR2 Cycle (2)].
The divalent metal transporter DMT1 responsible for iron uptake in the enterocytes is also 
expressed at low levels in the liver mainly in hepatocytes (Trinder et al. 2000b). In the 
hepatocytes, DMT1 is involved in the uptake of Tf-bound iron through the TfRl and TfR2 
pathways (Trinder and Morgan 1997) and it is thought to contribute to the uptake of NTBI at 
the cell surface however evidence for this is lacking. Both DMT1 splice forms (DMT1+IRE and 
DMT1-IRE) are expressed at similar levels in the liver (Tchemitchko et al. 2002) unlike in the 
duodenum, where the IRE- containing splice form is more abundant. In the duodenum DMT1 
expression is upregulated by iron deficiency but in the liver DMT1 levels are enhanced by iron 
loading (Scheiber-Mojdehkar et al. 2003;Trinder et al. 2000b;Trinder et al. 2002a). The 
reason for this opposite response is unclear but it is possible that this upregulation may help 
reduce the circulating NTBI and therefore prevents its toxic effect in iron overload conditions. 
The liver can also take up iron from circulating haem, haemoglobin, and ferritin. The levels of 
these molecules in the plasma is very low under normal conditions but in case of hemolysis or 
ferritin release from damaged tissues, the liver has a scavenging role in removing them from 
circulation. Haemoglobin in the circulation is readily bound to haploglobin (liver derived 
plasma protein) and the protein complex is taken up by macrophages by receptor-mediated 
endocytosis. Once inside the cell, the haemoglobin/haploglobin complex is degraded in 
lysosomes and haem is released. The haem is then degraded by haem oxygenase (HO) to 
release iron.
As excess haem is potentially toxic, most haem and its associated iron are sequestered by 
hemopexin, a liver derived protein. In addition, specific binding sites for hemopexin and a 
receptor for haem-hemopexin complexes (LRP/CD91) have been found on the plasma 
membrane of hepatocytes.
Another potential source of iron for the liver is ferritin. As described in section 1.3.3.3, ferritin 
is expressed in all body cells and is the major iron storage protein (Harrison and Arosio
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1996). At normal levels of body iron, the expression of ferritin is quite low, but in various 
pathological situations where there is cellular damage, tissue ferritins are released into the 
circulation. These tissue ferritins are rapidly removed from the plasma by the liver and 
studies have suggested the possibility of a specific receptor for tissue ferritin (Halliday et al. 
1994;Mack et al. 1981). Apart from storing iron, ferritin seems to have a protective 'anti- 
oxidising' function by sequestering the iron inside the cavity, away from dioxygen, hydrogen 
peroxide and superoxide, thus assuming a detoxification of intracellular iron function (Theil 
2003).
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Figure 1.9 Pathways of iron homeostasis in the liver
Representative schaem showing some o f the pathways o f iron uptake and e fflux by 
the hepatocyte: uptake o f iron through the TfR l pathway (1 ) and TfR2 pathway (2), 
uptake o f NTBI (3), cellular iron export through Ire g l (4), uptake o f fe rritin  (5 ); and 
its  components: D ivalent m etal transporter 1 (DMT1), Iron  regulatory elem ent 1 
(Ire g l) and Haem oxygenase (HO).
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All the iron that enters the hepatocyte, Irrespective of its source enters the same intracellular 
pool (cellular iron pool). From here Iron possibly will be used for metabolic functions, may be 
stored within ferritin, or may contribute to the regulation of cellular iron metabolism by 
influencing the activity of IRPs and likely other factors. The physical nature of this cellular 
iron pool, although present in most cells is poorly defined. It is unclear what happens to 
ferritin once inside the liver; some is probably directed to the bile but most is expected to 
remain within the cell to be either degraded or join the endogenous ferritin pool (Halliday et 
al. 1994;Ramm et al. 1994).
The level of ferritin within the cell is determined by its iron content and many studies have 
shown a positive correlation between the hepatic ferritin content and body iron levels 
(Halliday et al. 1994;Harrison and Arosio 1996). In cases of heavy iron overload in the liver, 
iron can also be stored as haemosiderin as described in section 1.3.3.3 (Iancu 1990;Iancu et 
al. 1997). This stored iron can be mobilized readily if it is required to meet metabolic needs 
and in hereditary haemochromatosis type 1 (HH1), when patients undergo phlebotomy 
therapy iron from their liver stores is released for the synthesis of new haemoglobin.
It has also been shown that Kupffer cells (liver macrophages) can release ferritin from 
phagocytosed senescent red blood cells that is taken up by hepatocytes (Knutson and 
Wessling-Resnick 2003); in which case ferritin acts as an intercellular iron transport protein.
The molecule responsible for iron efflux across the enterocyte plasma membrane, Iregl is 
also expressed in the Kupffer cells, where it clears large quantities of erythrocyte-derived 
iron. Iregl is also highly expressed in hepatocytes and hepatic stellate cells, with lower levels 
in sinusoidal endothelial cells (Zhang et al. 2004). How iron is released from intracellular 
ferritin and haemosiderin and delivered to Iregl is still unknown. The liver-derived plasma 
protein Cp also plays an important role in iron release from the liver.
The newly discovered peptide Hepcidin also plays a major role in the regulation of iron efflux. 
Several studies have shown that Hepcidin inhibits iron release from several cell types, such as
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macrophages, enterocytes and hepatocytes (Ganz 2002;Rivera et al. 2005a). It has also been 
reported that Hepcidin binds to Iregl, facilitating its internalisation thus removing it from the 
cell surface so that it can no longer participate in iron release (Nemeth et al. 2004b). 
Hepcidin will be described in more detail in the section 1.3.4.2.
The processes of hepatic iron uptake, storage, and release are vital, not just for the 
maintenance of hepatocyte iron homeostasis, but for the body as a whole. However, the 
central role played by the liver in the regulation of body iron homeostasis has only become 
apparent with the recent discovery of the iron regulatory hormone Hepcidin and therefore 
requires further investigation.
1.3.4.1 Caeruloplasmin (Cp)
Caeruloplasmin is an abundant a-glycoprotein that contains >95% of the copper found in the 
plasma of all vertebrate species. Surprisingly, rather than playing a role in copper 
metabolism, the main function of this protein appears to be to facilitate iron efflux from cells. 
This multicopper oxidase can oxidise several substrates in vitro, but early studies suggested a 
distinct role for caeruloplasmin as a ferroxidase. In these experiments, caeruloplasmin was 
shown to play a role in the mobilisation and oxidation of iron from tissue stores with 
subsequent incorporation of ferric iron into transferrin (Morgan and Oates 2002;0saki and 
Johnson 1969).
The role of caeruloplasmin in iron metabolism was further confirmed as the loss of function 
mutations in this gene leads to acaeruloplasminemia, a disorder characterised by iron 
accumulation in the parenchymal and reticuloendothelial cells of the liver and pancreas. This 
iron overload could be the result of an inability of the cells to release iron due to the lack of 
the ferroxidase. It is possible that caeruloplasmin may facilitate cellular iron release by 
promoting the oxidation of Fe2+, the redox form of intracellular iron.
Cp is regulated predominantly at the transcriptional level and its synthesis is enhanced by 
iron deficiency, some cytokines, and hormones (Anderson and Frazer 2005). Caeruloplasmin 
does not seem to be essential for export of iron from all cells of the body as dietary iron can
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still cross the intestine to enter the blood of individuals with acaeruloplasminemia. This is 
probably due to the copper oxidase activity of hephaestin, mentioned in section 1.3.3.4 which 
has significant homology to caeruloplasmin in its structure and presumed function.
1.3.4.2 Hepcidin
Hepcidin was identified by two groups while they were investigating novel antimicrobial 
peptides in body fluids. Whilst screening human blood ultrafiltrate for antimicrobial peptides, 
Krause et al found a peptide that was synthesised by the liver and named it, Liver Expressed 
Antimicrobial Peptide 1 (LEAP-1) (Krause et al. 2000). Another group lead by CH Park 
identified the peptide they called Hepcidin (Aepatic bactericfafel prote//?) in urine (Park et al.
2001). Even though the peptide was first isolated from urine and blood, hepcidin is 
predominantly expressed in liver of mice and humans. To a much less extent expression was 
also detectable in the intestine, stomach, colon, lungs, heart, kidney and brain (Kulaksiz et al. 
2005;Pigeon et al. 2001).
The human hepcidin gene (HAMP) comprises three exons and maps to the long arm of 
chromosome 19 (19ql3) (Park et al. 2001). The human gene encodes 84-amino acid pre-pro- 
hepcidin with two cleavage sites. This is then further processed to give a 25 amino acid form 
found in blood and urine (Ganz 2005b). The 25 amino acid contains four intra-chain disulfide 
bonds and eight cysteine residues that are conserved among species (Fig. 1.10).
A slightly truncated 20 amino add peptide was also found. Hepcidin has been found to be a 
member of the family of cysteine rich, cationic, antimicrobial peptides which includes the 
defensins due to its antibacterial (Park et al. 2001) and antifungal activities (Krause et al.
2000). Members of this family of peptides have been shown to be involved in inflammation 
and hepcidin has been shown to be a type II acute phase protein (Nemeth et al. 2003).
The role of hepcidin in iron homeostasis was revealed by two French groups working 
independently on mice. Pigeon (Pigeon et al. 2001) were searching for new genes
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upregulated during iron overload. They found that hepcidin mRNA was increased in the liver 
of experimentally (carbonyl iron) and spontaneously (B2-m'/- mice) iron-overloaded mice.
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Figure 1.10 Amino acid sequence and a model of the major form of human 
hepcidin. The amino and carboxy term ini are labelled as N and C, respectively. 
Disulphide bridges are in yellow, basic amino acids in blue, and acidic in  red. The 
pattern o f disulphide linkages between the 8 cysteines is  also shown in the amino 
acid sequence (Park e t ai. 2001).
The group also found that the amount of mRNA was directly linked to liver iron concentration 
as evidenced by the dose dependence of mRNA induction in the carbonyl-iron-treated mice 
and the decreased expression of hepcidin when B2-m~/' mice were fed a low iron diet. From 
this data they concluded that hepcidin expression increases with iron overload and decreases 
with iron depletion (Pigeon et al. 2001).
The other group to identify the relevance of hepcidin in iron metabolism was lead by Nicolas 
(Nicolas et al. 2001). This group identified the murine hepcidin gene as having a role in iron 
homeostasis by generating USF2 null mice (Table I, appendix I) and accidentally removing
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the neighbouring hepcidin genes. The USF2 null mice spontaneously became loaded with iron 
and the pattern of iron loading mimicked that seen in hereditary haemochromatosis (HH) 
(Nicolas et al. 2001). That hepcidin rather than USF2 was involved in iron homeostasis was 
confirmed by the same group, by showing that mice transgenic for hepcidin were severely 
anemic (Nicolas et al. 2002c).
Hepatic disruption of C/EBPa, a liver-enriched nuclear factor that regulates several hepatic 
metabolic processes in mice leads to a decrease in hepcidin gene expression, iron 
accumulation in periportal hepatocytes and consequently iron overload resembling HH 
(Courselaud et al. 2002). It has also been reported that during iron overload both C/EBP a 
and hepcidin increase. Taken together this data could represent a novel mechanism for cross­
talk between the C/EBP signalling pathway and iron metabolism.
Mutations in the hepcidin gene (HAMP) have also been found responsible for HH2 also called 
juvenile haemochromatosis. Patients with this disorder develop severe haemochromatosis 
associated with profound deficiency of hepcidin (Nicolas et al. 2001;Roetto et al. 2003;Viatte 
et al. 2005).
Only one hepcidin gene exists in humans, whereas two hepcidin genes (hepcidin 1 and 
hepcidin 2) were reported in mice (Nicolas et al. 2001;Pigeon et al. 2001). Both hepcidin 1 
and hepcidin 2 are predominantly expressed in the liver; hepcidin 2 is also present at high 
levels in the pancreas. The expression of both genes is controlled by USF2 transcriptional 
factor but whereas the role of hepcidin 1 gene product on iron metabolism is established, 
biological functions of hepcidin 2 remain to be fully characterised.
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1.4 Iron metabolism diseases
1.4.1 Iron Deficiency diseases: Iron deficient Anaemia and Anaemia of Chronic disease fAO
When the intake iron is not sufficient to compensate the daily losses, iron deficiency (also 
called "sideropenia"), develops. Iron deficiency is the most common haematological disorder 
encountered in general practice (World Health Organisation 2003). Worldwide, up to a billion 
individuals suffer adverse effects from insufficient body iron with children and women being 
the most susceptible. Children often become iron deficient because their rapid growth 
outstrips the iron supply. Similarly, premenopausal woman become iron deficient because 
they regularly experience menstrual blood loss. Chronic parasitosis can result in intestinal 
blood loss, as well as tumours, inflammation, infections, and congenital malformations, which 
can lead to iron deficiency (Andrews 2000).
The most common iron deficiency condition is iron deficient anaemia. This anaemia is 
characterized by decreased or absent iron stores, tow serum iron concentration, tow 
transferrin saturation, and tow haemoglobin concentration or haematocrit value. Clinical 
symptoms of anaemia include paleness, fatigue, poor exercise tolerance, and decrease work 
performance (Leventhal and Stohlman, Jr. 1966).
Congenital and acquired abnormalities in the intestinal epithelium can also result in iron 
deficiency, though these are still poorly understood on a molecular level. 
Hypotransferrinemia, also called atransferrinemia, is a condition in which little or no plasma 
transferrin is produced. Although this rare disorder leads to severe iron deficiency anaemia 
the fact that is it characterised by parenchymal iron overload classifies it as a primary iron 
overload disorder and as such it will be further described in the iron overload diseases 
section.
In 1932, Locke et al observed that hypoferremia (tow serum iron) was associated with 
infection which explained why it was common to find anaemia in patients with chronic 
infections. Later, Cartwright and Wintrobe (Cartwright and Wintrobe 1952) showed that the
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anaemia associated with infection was indistinguishable from the anaemia of inflammation, 
and so anaemia of chronic disease (ACD) is currently known as anaemia of inflammation (AI) 
(reviewed in Weiss and Goodnough 2005). AI is characterised by inadequate erythrocyte 
production in the setting of low serum iron and low iron-binding capacity (i.e. low transferrin) 
despite preserved or even increased macrophage iron stores in the bone marrow. Patients 
with AI despite having low serum iron and low transferrin, have high serum ferritin 
concentration. The anaemia is caused by increased inflammation cytokines and changes in 
iron metabolism are due to the effects of these cytokines as they have been shown to 
modulate the expression of iron transport and storage proteins (Andrews 2004).
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1.4.2 Iron Overload diseases: Primary and secondary iron overload diseases
Iron overload diseases are disorders characterised by an excessive storage of iron. This could 
be a result of excessive absorption of dietary iron or an inability of the body to properly 
transport iron. There are two types of iron overload diseases, primary or genetic iron 
overload diseases (Table 1.1) and secondary iron overload diseases. Only primary iron 
overload diseases will be discussed in this thesis.
Disease Causative
gene
mutations
Clinical
features
Mode of 
Inheritance
Haemochromatosis
HFE1 
(Type 1 or HH1)
Hfe Iron overload, 
late onset
AR
HFE2
(Juvenile Haemochromatosis)
Hemojuvelin
(Hjv)
Iron overload, 
early onset
AR
hepddin (HAMP) AR
HFE3 
(TfR2-related HH)
TfR2 Iron overload, 
late onset
AR
HFE4
(Ferroportin Disease)
IREG1
(SLC40A1) Variable*
AD
Acaeruloplasminemia
caeruloplasmin
(Cp)
Anaemia, iron 
overload
AR
Atransferrinemia
transferrin
(Tf)
Anaemia, iron 
overload
AR
Table 1.1 Primary iron overload diseases.
Causative gene mutations, clinical features and mode of inheritance (AR-Autosomai recessive, 
AD-Autosomai dominant). *  There are two forms of Ferroportin disease each of them having 
very distinct clinical manifestations. Adapted from (Bacon etai. 2006).
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1.4.2.1 Haemochromatosis
Haemochromatosis was first described by Armand Trousseau in an article on diabetes, in 
1865 (Trousseau 1865). In this article Trousseau included the notion that it was a 
manifestation secondary to diabetes, that it was an intrinsic liver disease, that it was due to 
haemolysis, to toxins, or that it was a metabolic disorder. The link of the disease with iron 
accumulation was not made as it was unclear whether the presence of iron was the cause of 
the disease or a secondary manifestation. The link was made by Daniel von Recklinghausen 
(von Recklinhausen 1889) who believed that the iron pigment was derived from the blood 
and created the term "haemochromatosis" used to this day.
The view that Haemochromatosis might be due to an inborn error of metabolism was first 
expressed by Joseph Harold Sheldon in 1927. in 1935 Sheldon published a monograph 
entitled "Haemochromatosis" describing the clinical features of the disease, suggesting 
mechanisms for the symptoms, a description of the metabolism of iron and other compounds, 
the pathological appearance of every organ system, chemical analyses of the tissues and, 
most important, a discussion of theories about the causes of the disease including the 
inability of humans to excrete iron. Despite Sheldon's complete monograph some researchers 
still believed that all cases of idiopathic haemochromatosis were actually acquired from 
ingestion of iron. Continuing support for Sheldon's genetic hypothesis was to come nearly 40 
years later, when a study established a close association between haemochromatosis and 
HLA-A3 haptotype (Simon et al. 1976). However another 20 years were to pass before the 
identification of the gene that is mutated in hereditary haemochromatosis type 1, HLA-H 
(Burke et al. 1998;Feder et al. 1996;Jazwinska and Powell 1997). Because of the similarities 
between its proposed gene product and proteins of the major histocompatibility complex, the 
name HLA-H was soon mutated to HFE.
Most HH is caused by mutations in the Hfe gene but pathological mutations causative of the 
disease have been discovered in another four genes: TfR2 (encoding transferrin receptor-2), 
SLC40A1 (encoding Iregl, also called ferroportin,), hepcidin or HAMP (encoding hepcidin), 
and HJV (encoding hemojuvelin).
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Haemochromatosis caused by mutations in the TfR2, hepcidin and Hjv genes are 
characterized by increased intestinal iron absorption and increased levels of serum iron 
suggesting a defect that affects both absorptive enterocytes and tissue macrophages, which 
supply most of the serum iron primarily through recovery of the metal from senescent 
erythrocytes. Human subjects with these three disorders also produce inappropriately low 
amounts of the iron-regulatory hormone hepcidin. Haemochromatosis disorders due to Hfe 
and TfR2 mutations tend to have a later clinical onset and be less severe than those caused 
by hepcidin and Hjv gene mutations. Haemochromatosis caused by mutations in the Iregl 
gene can be divided into two forms of the disease, in one form patients manifest the loss of 
iron export function while in the other form patients retained full iron export activity 
(Camaschella 2005;Schimanski et al. 2005).
Organ Manifestations Complications
Liver Enzyme alterations Fibrosis, Cirrhosis,
hepatocellular
carcinoma
Heart Arrhythmia, failure Cardiomyopathy
Pancreas Hyperglycemia Diabetes mellitus
Pituitary Decreased libido, 
impotence in men; 
amenorrhea in women
Hypogonadism
Thyroid gland Decreased thyroid 
hormone
Hypothyroidism
Joints Arthralgia Arthropathy
Skin Pigmentation None
Table 1.2 Hereditary Haemochromatosis manifestations in the different 
organs. (Adams et al. 1991;Adams et al. 1997;Bacon and Sadiq 1997;Camaschella 
2005;Moirand et al. 1997;Pietrangek) 2004c).
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Hereditary haemochromatosis (HH) is now considered a group of genetic disorders 
characterised by increased transferrin (Tf) saturations, systemic iron overload with deposition 
of excess iron in parenchymal cells of the liver, heart, pancreas, and other endocrine tissues, 
with reticuloendothelial iron sparing. The most predominant features include hepatomegaly, 
hepatic dysfunction, heart failure, skin pigmentation, testicular atrophy, diabetes mellitus, 
and arthropathy (Table 1.2).
In haemochromatosis the total iron content of the body is usually between 20g and 40g. 
Particularly in the liver and pancreas, the iron concentrations may be 50 to 100 times normal 
(Table 1.3). If untreated, liver cirrhosis, heart disease, hepatic cancer and diabetes can 
develop which leads to an increased morbidity and mortality (Feder et al. 1996;Trousseau 
1865). Only a fraction of patients with a haemochromatosis genotype develop iron overload 
and environmental factors seem to affect the disease penetrance. Other genetic factors are 
likely to determine individual susceptibility to iron loading.
1.4.2.1.1 Hereditary haemochromatosis Type I  or Hfe-related Haemochromatosis
Hereditary haemochromatosis type 1 (HH1 or HFE1) is an autosomal recessive disorder of 
iron metabolism common in populations of north-west European ancestry. The estimated 
carrier frequency within the Caucasian population is between 1 in 8 and 1 in 10.
The causative gene of HH1, designated Hfe, was identified in 1996 by Feder et al (Feder et al. 
1996). Feder described mutations associated with hereditary haemochromatosis in the MHC 
dass I-like gene Hfe. The Hfe gene is located at 6p21.3 and the Hfe protein is a 343 residue 
type I transmembrane protein that associates with class I light chain p-2-microglobulin (Fig. 
1.11).
Over 83% of haemochromatosis patients are homozygous for a guanine to adenine transition 
at nucleotide 845 in the coding sequence of HFE, resulting in the substitution of a tyrosine for 
cysteine at position 282 (C282Y) of the unprocessed polypeptide (Feder et al. 1996). This 
mutation prevents the correct folding of the alpha3 (a-3) domain altering the Hfe protein
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structure, the assembly with beta-2-microglobulin (P-2m) and presentation at the cell surface 
(Feder 1999;Feder et al. 1996;Waheed et al 1997).
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Figure 1.11 The HFE structure
HFE includes a large extracellular domain consisting o f three loops (a-1 to  a-3), a 
single transmembrane domain and a short cytoplasmic ta il. S im ilar to  other MHC 
class 1 molecules, Hfe physically associates w ith p-2-m icroglobulin (p-2m ) via its  a-3 
loop, (adapted from  Bennett e t al. 2000).
The functional importance of such interplay in HH between P2m and some class I-type HLA 
molecule was suggested by studies of p-2m-deficient mice (p-2m'/ ), which develop 
progressive hepatic iron overload as described below.
A second mutation was found in HH1 patients, resulting in the substitution of an aspartic acid 
for histidine at position 63 (H63D). In contrast to C282Y, this mutation does not appear to 
prevent p2-microglobulin association or cell surface expression, indicating that C282Y 
mutation results in a greater loss of protein function than H63D. The H63D mutation is 
present in 17% of the normal chromosomes and was also found in a number of patients who 
carried only one copy of the C282Y mutation (Feder et al. 1996). These two mutations are in 
linkage disequilibrium and have not yet been found together in the same haplotype.
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The cases reported of patients with haemochromatosis with the C282Y mutation or at least 
homozygous for this mutation are far from the estimated frequency of 1 in 150 in people of 
northern European descent (Feder et al. 1996), leading us to think that this mutation has a 
low penetrance and that there are a lot of asymptomatic cases of haemochromatosis 
(Bomford 2002). This low penetrance can lead us to consider that there are gene modulators 
contributing to the incomplete penetrance of the gene.
There is now a comprehensive panel of diagnostic measurements for HH 1 (Table 1.3), 
including serum iron indices (transferrin saturation and ferritin), hepatic iron concentration 
and hepatic iron index, genetic testing for Hfe mutations and evaluation of liver biopsy with 
iron stain. The first histological abnormality in homozygous HH1 patients is the appearance of 
stainable iron in periportal hepatocytes. Over time, parenchymal iron deposition increases, 
fibrosis develops and evolves into the characteristic cirrhosis of untreated HH1. The 
histological pattern of iron accumulation in HH1 will be further described in chapter 3.
Measurements
Normal
subjects HH1 subjects
Blood (fasting)
Serum iron (pg/dL) 60-80 180-300
Serum transferrin level (mg/dL) 220-410 200-300
Transferrin saturation (% ) 20-50 80-6000
Serum ferritin level (ng/mL)
20-200 (M) 
15-150 (W)
500-6000 (M) 
500-6000 (W)
Liver
Hepatic iron 
concentration
pg/g dry weight 300-1500 8000-30 000
pmol/g dry weight 5-27 140-550
Hepatic iron index* <1.0 >1.9
Liver histology Peri's Prussian blue stain 0-1+ 3+,4+
Table 1.3 Diagnostic measurements in the diagnostic of Haemochromatosis type 1 
(H H 1). *  Hepatic iron index (H II) is calculated by dividing the hepatic iron concentration (in 
pmol/g dry weight) by the age of the patient (in years). With the availability of genetic
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testing for Hfe mutations, the utility o f H II has diminished. Serum ferritin values are given for 
women (W) and men (M) (Bacon etai. 2006).
If a course of phlebotomies is initiated before patients developed cirrhosis, 
haemochromatosis manifestations can be reverted to normal. Even among those patients 
with cirrhosis, phlebotomies can increase the life expectancy.
As human population studies and ex vivo biochemical studies had not yielded consistent 
results regarding the consequences of the Hfe mutations and a confirmation that it was 
indeed Hfe the sought after gene responsible for Haemochromatosis, Zhou and his colleagues 
(Zhou et al. 1998) reported the production of a mouse model in which the Hfe gene was 
disrupted. This knockout (KO) mouse showed increased serum transferrin saturation and 
increased hepatocellular iron deposition, the symptoms that are characteristic of human 
haemochromatosis. This Hfe KO mouse also established that the HFE gene mutations that 
produce HH1 in humans do so by causing a deficiency of the Hfe protein, not by changing its 
characteristics or location in the cell (Beutier 1998).
Further support for a causative role of HFE in HH1 disease came from the observation that p- 
2-microglobulin knockout (p-Zm 7 ) mice, develop iron overload (De SM et al. 1994;Santos et 
al. 1998). As with other MHC-I molecules, Hfe needs to associate with p-2m for appropriate 
expression at the cell surface. This study showed that p-2m7 mice, which fail to express cell 
surface HFE protein, shared similarities with HH1 patients.
The role of the two most common Hfe mutations, C282Y and H63D were more 
comprehensively studied when Tomatsu et al generated mouse models carrying the murine 
analogous mutations C294Y and H67D, respectively (Tomatsu et al. 2003). These mutations 
allowed the Hfe mutations to be investigated in an environment free of potential risk factors. 
Tomatsu et al demonstrated that mice homozygous for C294Y had significant higher levels of 
hepatic iron followed by compound heterozygous for H67D and C294Y and H67D 
homozygotes (Tomatsu et al. 2003). To further investigate the effect of homozygosity for the 
C282Y and whether this mutation results in total loss of protein function, Levy et al created
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two mutant mouse strains (Levy et al. 1999b). Homozygosity for the C282Y equivalent 
mutation resulted in postnatal iron loading similar to the one seen in Hfe KO mice. The effects 
of this mutation were less severe than the effects of the null mutation; therefore, the group 
concluded that the C282Y mutation does not result in a null allele (Levy et al. 1999b).
The HFE null mutation has now been highly back-crossed onto an array of inbred mouse 
strain backgrounds (Table I, appendix I). These strains provide an approach for investigating 
the extent to which modifier genes play a role in normal and pathological iron regulation in 
the HFE deficient mouse model. Lebeau et al (Lebeau et al. 2002) showed that C57BL/6 Hfe 
KO mice mimic the typical features of HH in short term studies. Duodenal iron absorption and 
hepatic iron load were two or three times higher in C57BL/6 Hfe KO mice than in 
corresponding C57BL/6 controls (wt). Iron was found preferentially in periportal hepatocytes 
and plasma iron concentrations and transferrin saturation were elevated accordingly. The iron 
distribution between organs and microscopic iron deposition in the tissues of these Hfe KO 
mouse models resembled the patterns described in HH1. One difference between the mouse 
model and the HH1 patients is that Hfe KO mice do not develop fibrosis or cirrhosis despite 
the severe iron overload (Knutson et al. 2001). Thus, the role of iron in initiating liver fibrosis 
in iron overload diseases such as HH1 is not understood and an animal model that can 
produce the full pathological picture of the cirrhotic liver seen in HH1 is still needed. It is 
known that iron overload enhances liver injury, and mildly accelerates the process of fibrosis 
(Arezzini et al. 2003) but it is believed that other factors may be involved in this process.
In HH1 patients, the combination of iron and ethanol results in greater liver damage, than 
iron alone (Bassett et al. 1986;Olynyk et al. 1995;Tavill et al. 1990;Tector et al. 
1995;Tsukamoto 1993). Although this does not occur in rats to the same extent, when iron 
acts in concert with other hepatotoxins (e.g. CCU and alcohol), liver injury is enhanced 
(Olynyk et al. 1995;Stal and Hultcrantz 1993). In the presence of a damaging event it is 
possible that the pro-oxidant action of iron is amplified and the initial toxic effect is 
propagated.
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The variation in phenotypic expression of HH1 between patients may be attributed to 
nongenetic factors, such as diet, alcohol intake, and iron loss (menstruation or pregnancy). 
However, population studies suggest that the variation in severity of iron loading in HH1 may 
be also caused by the additive or interactive effect of other genes (Bulaj et al. 2000;Pratiwi et 
al. 1999;Whitfield et al. 2000). This conclusion was also taken from Hfe KO mice studies. 
Inbred mouse strains exhibit considerable variability in several parameters of iron metabolism 
(Clothier et al. 2000;Leboeuf et al. 1995;Morse et al. 1999). Serum iron, serum transferrin 
saturations, and hepatic iron stores vary as much as 2-fold among inbred strains such as 
C57BL/6 and AKR on a basal diet (Fleming et al. 2001;Levy et al. 2000;Sproule et al. 2001). 
The finding that hepatic iron stores failed to reflect transferrin saturation also suggests that 
different genetic factors control transferrin saturation and hepatic iron stores. When mice 
were fed a high-iron diet, the concentration of carbonyl iron required to completely saturate 
transferrin with iron was 10 times greater for C57BL/6 and BALB/c mice than for DBA/2 and 
AKR mice (Leboeuf et al. 1995). It is hypothesized that modifier genes modulate the 
regulatory capacity of the Hfe gene. These modifiers could interact with HFE directly or, more 
likely, modify iron loading through independent mechanisms to magnify or dampen the 
effects of HFE. (Ajioka et al. 2002;Fleming et al. 2001). The understanding of these modifier 
genes will be addressed in this thesis.
1.4.2.1.2 Haemochromatosis Type 2 or Juvenile Haemochromatosis
Juvenile haemochromatosis (JH) or type 2 haemochromatosis (HFE2) is a hereditary condition 
characterised by severe iron overload and organ damage typically before age 30 years (De et 
al. 2002;Lamon et al. 1979;Rivard et al. 2003b;Rivard et al. 2000). JH is a heterogeneous 
genetic disorder, related to at least 2 distinct loci. The first maps to a chromosome lq21 
(Roetto et al. 2003) recently identified gene Hemojuvelin (Hjv) while the second one maps to 
chromosome 19ql3 and is responsible for a rare subset of HH2 due to mutations in hepcidin 
(HAMP) gene (Camaschella et al. 2002;Papanikolaou et al. 2004;Roetto et al. 1999;Roetto et 
al. 2003) (Papanikolaou et al. 2001;Papanikolaou et al. 2004;Rivard et al. 2003b;Rivard et al.
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2000;Roetto et al. 2002;Roetto et al. 2004). Most patients with HH2 have mutations in the 
Hjv gene (Lanzara et al. 2004;Papanikolaou et al. 2004).
The clinical course of HH2 is rapid and severe compared to HH1 (Feder et al. 1996;Levy et al. 
2000) and transferrin receptor 2 (TFR2)-related Haemochromatosis (HH3) (Camaschella et al. 
2000), indicating that the JH protein is an important regulator of iron absorption (De et al. 
2002). Ginical symptoms are similar to HH1 but hypogonadism and cardiac disease are more 
frequent presenting symptoms. Premature deaths due to heart failure or major arrhythmias 
are reported in untreated or undiagnosed patients with cardiac involvement.
1.4.2.1.3 Haemochromatosis Type 3 or TFR2 -related Haemochromatosis
The first association between TfR2 gene mutations and iron overload was made by 
Camaschella et at in a study of Italian patients with no Hfe mutations but with the diagnostic 
criteria of HH (Camaschella et al. 2000). This new type of Haemochromatosis was named 
HH3. Like HH1 the clinical parameters of HH3 are increased serum iron due to increased iron 
absorption at the duodenal level that leads to parenchymal iron overload. TfR2 
haemochromatosis seems less severe than juvenile haemochromatosis but more severe than 
the Hfe-related disease. The progression of iron overload is slow in HH3 patients but a 
constant feature is the persistently high transferrin saturation, even after treatment 
(Camaschella 2005).
1.4.2.1.4 Ferroportin Disease
The iron-regulated transporter 1/ferroportin/metal transporter protein 1 (IREG1/FPN/MTP-1; 
gene symbol SLC40A1) was reported simultaneously by three groups in 2000 (Abboud and 
Haile 2000;Donovan et al. 2000;McKie et al. 2000). IREG1 (the term used for the purpose of 
this thesis) protein is expressed in Kupffer cells and at the basolateral membrane of
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enterocytes, macrophages, placental cells, and hepatocytes, where it likely plays the role of 
iron exporter.
At least twelve mutations in the SLC40A1 gene (previously called SLC11A3) have been 
implicated in an autosomal dominant inherited disorder of iron metabolism now referred as 
type 4 haemochromatosis (HFE4) or Ferroportin disease (Arden et al. 2003;Montosi et al. 
2001;Pietrangelo et al. 1999;Pietrangelo 2006;Pietrangelo 2004b). Heterozygosity for 
mutations of Iregl generated a controversy as to whether these mutations might cause a 
gain or a loss of the metal exporter function (Camaschella 2005). Thus, patients with Iregl 
mutations can be separated into two groups: one group manifested the loss of iron export 
function; the other retained full iron export activity (Schimanski et al. 2005). One group of 
patients is characterized by an early rise in ferritin levels with low to normal transferrin 
saturation and iron accumulation predominantly in macrophages (Arden et al. 2003;Beutler et 
al. 2003;Cazzola et al. 2003;Devalia et al. 2002;Gordeuk et al. 2003;Jouanolle et al. 
2003;Montosi et al. 2001;Njajou et al. 2001;Pietrangelo 2006;Rivard et al. 2003a;Rivard et al. 
2003b;Robson et al. 2004;Roetto et al. 2002;Wallace et al. 2002;Wallace et al. 2004). The 
absence of an apparent increase in total body iron in this group of patients, suggests a partial 
loss of Iregl similar to that observed in mice lacking one Iregl allele (Donovan et al. 2005). 
In the other group, patients have a different constellation of Iregl missense mutations and 
present symptoms that are more similar to those of the other haemochromatosis disorders 
such as high transferrin saturation and prominent parenchymal iron loading (Arden et al. 
2003;Cazzola et al. 2003;Njajou et al. 2001;Njajou et al. 2002;Schimanski et al. 2005;Sham 
et al. 2005;Wallace et al. 2004). Hyperferritinemia has been reported in patients with this 
type of Ferroportin disease, and in these cases a less aggressive regimen of phlebotomies is 
therefore needed (Jouanolle et al. 2003;Pietrangelo et al. 1999).
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1.4.2.2 Acaeruloplasminemia
Acaeruloplasminemia is a late onset autosomal recessive disease of iron overload that results 
from loss of function mutations in the caeruloplasmin (Cp) gene (human chromosome 3q23- 
q24). While the iron overload associated with haemochromatosis results from increased iron 
absorption, the iron overload associated with acaeruloplasminemia results from aberrant iron 
distribution. Without caeruloplasmin iron cannot be efficiently recycled from storage sites in 
the liver and a seemingly inconsistent collection of iron-related symptoms develops (Harris et 
al. 1995). Serum ferritin is elevated, but serum iron remains low because iron is not efficiently 
loaded onto transferrin. Iron accumulates in the parenchymal and reticuloendothelial cells of 
the liver and pancreas, but anaemia results because iron is not efficiently delivered to red 
blood cell precursors.
1.4.2.3 Hypotransferrinemia
Hypotransferrinemia, also called atransferrinemia, is a rare autosomal recessive disease 
condition in which little or no plasma transferrin is produced. As previously mentioned severe 
iron deficiency anaemia in this disease is accompanied by iron loading of the liver and other 
parenchymal organs (Andrews 1999;Beutier et al. 2000;Pietrangelo 2004a). The condition 
emphasizes the key role of the transferrin-TFRl pathway for iron uptake in erythroid cells and 
indicates the existence of alternative mechanisms for hepatocyte iron uptake. Transferrin KO 
mice die in utero from severe anaemia (Levy et al. 1999a), while hypotransferrinemic 
(TRfhpx/hPx) mjce (Table I, appendix I)) show a small amount of TF protein in the plasma and 
survive past birth (Bernstein 1987;Trenor, I II  et al. 2000). The TRfhpx/hpx mouse shows 
cytological features similar to the human congenital atransferrinemia (Raja et al. 1999). This 
mouse model also presents extremely low hepcidin levels which explain the intestinal iron 
hyperabsorption that leads to iron overload (Pietrangelo 2004a).
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Other primary iron overload diseases include Neonatal haemochromatosis and African iron 
overload but descriptions of these disorders are beyond the scope of this thesis.
1.5 Regulation of iron uptake
Iron homeostasis depends on the regulated absorption of dietary iron as no mechanisms for 
the regulated excretion of iron exist. Three different regulators, namely dietary, stores and 
erythropoietic regulator were hypothesised almost 50 years ago to govern duodenal iron 
absorption. The store regulator was thought to act on a pathway that facilitated a slow 
accumulation of non haem dietary iron (about 1 mg/day) (Hunt and Roughead 2000) and to 
act in order to prevent iron overload after ensuring iron needs were met. A soluble 
component was hypothesized for this regulator as it must signal between the sites of 
absorption, usage and storage (duodenum, muscle and liver, respectively).
The fact that individuals with normal, or even increased iron stores up-regulated iron 
absorption as marrow iron requirements increased led to the conclusion that a erythropoietic 
regulator communicated the erythropoietic demand of the organism rather than reflecting the 
iron stores. Iron absorption in this case was not increased by erythropoiesis alone; rather, the 
imbalance between the rate of erythropoiesis of the marrow and its iron supply was thought 
to induce the iron absorption. The absorptive pathway targeted by the erythropoietic 
regulator was thought to be a distinct from the pathway targeted by the stores regulator but 
like the stores regulator, the erythropoietic regulator was hypothesized to be a soluble 
component of the plasma, as it must signal between the erythroid marrow and the intestine 
(Roy and Enns 2000).
In recent times it became clear that a more complex regulatory network is responsible for 
iron regulation through regulating iron traffic rather than deposition as previously thought. 
Today iron uptake is considered to be regulated at the mRNA, cellular and body level. Several 
genes appear to be involved in the feedback regulation between sites of iron utilization 
(primarily marrow), storage (spleen and liver), and absorption (duodenum), and the
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expression of these genes seems to be regulated by the iron content of the diet, changes to 
the rate of erythropoiesis, hypoxia, inflammation, and pregnancy (Morgan and Oates 2002). 
The molecules HFE, TF, TFR2, and the antimicrobial peptide Hepcidin are now accepted to be 
important regulators of iron uptake and to maintain iron homeostasis for the entire organism. 
On a cellular level, iron uptake regulation is controlled by iron responsive proteins (IRP-1 and 
IRP-2) that work in conjunction with iron regulatory elements (IRE). Iron uptake regulation 
by these genes and the cellular iron regulation will be described in detail in the following 
sections.
1.5.1 Regulation of cellular iron levels by IRE-IRP interactions
In mammalian cells, cellular uptake and storage of iron are normally controlled post- 
transcriptionally by two cytoplasmic proteins, iron regulatory protein IRP-1 and IRP-2 that 
recognise iron responsive elements (IRE) on mRNA (Fig. 1.12) (Hentze and Kuhn 1996). IRP 
activity is determined in response to cellular iron levels and independently by signalling 
through nitric oxide (NO) and reactive oxygen intermediates, particularly hydrogen peroxide 
(H20 2). IRP-1 activity is controlled by all three effectors by a mechanism involving the 
conversion of 4Fe4S IRP-1 into 3Fe3S apoIRP-1. IRP-2 activity is regulated in response to 
iron levels and NO and by changes in the stability of the protein.
IREs were first identified in the 5'-UTR of ferritin H and L chain mRNAs and found to mediate 
inhibition of ferritin mRNA translation in iron-deprived cells. When cellular iron is abundant, 
ferritin synthesis is not repressed, instead newly made ferritin baskets assemble increasing 
the iron storage capacity of the cells (reviewed in Thomson A 1999). IREs were also found in 
the 3' UTR of the transferrin receptor 1 (TfRl) mRNA.
In iron deficient states, IRPs bind IREs in the 5' LTTR of ferritin mRNA and the 3' UTR of 
transferrin receptor mRNA. Ferritin synthesis is prevented and transferrin receptor numbers 
increase (Casey et al. 1988;Hentze and Kuhn 1996;Koeller et al. 1989;Mullner et al. 1989). In 
iron overload states IRPs no longer bind IREs and ferritin is synthesised allowing storage of
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excess iron and transferrin receptor number to decrease, limiting further iron uptake (Fig. 
1.12).
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Figure 1.12 Two posttranslational controls mediated by iron
When iron concentration in  the cytosol increases, the synthesis o f fe rritin  is increased 
in  order to bind the extra iron and the synthesis o f transferrin receptors is suppressed 
in  order fo r less iron to be im ported across the plasma membrane. These responses 
are mediated by cytosolic aconitase, an iron-responsive regulatory protein. Aconitase 
recognises common features in  a stem -loop structure in  the mRNA encoding fe rritin  
and transferrin receptor and dissociates from  the mRNA when it  binds iron. Although 
fe rritin  and TFR are regulated by the same iron-responsive regulatory protein, the ir 
levels respond d ifferently to  iron concentrations as they are regulated by d ifferent 
types o f mechanisms. The binding o f aconitase to the 5 '-UTR o f fe rritin  mRNA blocks 
translation in itia tion ; its  binding to  the 3 ' -UTR o f the transferrin receptor mRNA 
blocks an endonuclease cleavage site  and thereby stabilizes the mRNA (Adapted from  
H entzeeta l. 1988).
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The intracellular level of Iron is thus tightly regulated to permit the uptake of essential 
quantities of iron and to prevent the toxic effects of higher amounts by storing iron into 
ferritin. The interplay of IRP1 and IRP2 has been studied in mice where one of these genes is 
disrupted. Loss of IRP2 leads to dysregulation of iron metabolism in the intestinal mucosa. 
Loss of IRP2 and one copy of IRP1, leads to development of a progressive neurologic 
syndrome and other abnormalities (Rouault 1998). IREs have also been found in Iregl and in 
DMT1 which partly explain how these two proteins are iron regulated (Hubert and Hentze 
2002). As IREs are present in various mRNAs that encode proteins functioning in either of 
these pathways, IRE-IRP interactions affect virtually all major aspects of iron metabolism.
1.5.2 Regulation of duodenal iron absorption
With the discovery of the antimicrobial peptide hepcidin and the finding that hepcidin is a key 
regulator of iron homeostasis, the liver is now considered to play a central role in iron 
metabolism. Variations in body iron stores, changes in rate of erythropoiesis, hypoxia, 
inflammation and pregnancy result in changes at the protein and mRNA level of the duodenal 
expression of the major enterocyte iron transport molecules, particularly, DMT1, Dcytb, and 
Iregl (Frazer and Anderson 2005).
1.5.2.1 Regulation by hepcidin
The identification of hepcidin has provided compelling evidence against the long-supported 
crypt hypothesis for the regulation of iron absorption. Since the 1960's it had been proposed 
that signals from the body to alter iron absorption were detected by enterocytes in the 
crypts of the duodenum, thus programming them to absorb more or less iron after they 
matured. This hypothesis was based on the presence of a lag period of several days between 
a stimulus to alter iron absorption and the actual change in absorption. The lag period was 
interpreted as the time required for the programmed crypt cells to mature and become
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absorptive enterocytes on the villus. At the molecular level, programming in the crypt cell was 
presumed to involve the modulation of the gene expression of the key factors involved in iron 
transport. This model predicted that iron deficiency would lower crypt cell iron status such 
that gene expression of critical transport factors would be upregulated on cellular 
differentiation and migration to the villus tip. However, it has now been shown that this "lag 
period" for changes in iron absorption reflects the time required by the body to detect the 
need for a change in absorption and alter hepcidin expression (Frazer et al. 2004a). It now 
appears that hepcidin might be the stores regulator, the erythropoietic regulator and the 
"inflammation" regulator of iron absorption and recycling (Fleming and Sly 2001;Nicolas et al. 
2002c;Nicolas et al. 2002a;Nicolas et al. 2002b). The changes in iron efflux due to hepcidin 
expression have not yet been shown but a decreased serum iron has been shown within 4 
hours in mice after a single injection of Hepcidin (Rivera et al. 2005b) and a decrease in iron 
absorption was observed after multiple injections of Hepcidin (Laftah et al. 2004).
This small antimicrobial peptide is secreted into the circulation where it acts as an inhibitor of 
iron release from a variety of cell types, including the hepatocytes and Kupffer cells of the 
liver via its interaction with Iregl (Ganz 2005b;Nemeth et al. 2004b;Nicolas et al. 2001). The 
relevance of the interaction with Iregl is not yet fully understood but the fact that hepcidin is 
interacting with a protein expressed in the enterocytes confirms that signals from the body 
can be detected by mature villus enterocytes and does not have an absolute requirement for 
crypt cells to detect changes in body iron status (Nemeth et al. 2004b).
In humans, as described in section 1.4.2.1.2, disruption of hepcidin gene causes the most 
severe form of iron overload—juvenile haemochromatosis (Roetto et al. 2003) while hepcidin 
deficiency in mice resulted in iron overload (Nicolas et al. 2001). Conversely, overexpression 
of hepcidin-1 in transgenic mice caused severe iron-deficiency anaemia (Lou et al. 
2004;Nicolas et al. 2004). Both dietary and parenteral iron load induced hepcidin mRNA in 
humans and in mice (Nemeth et al. 2004b;Pigeon et al. 2001). All these observations indicate 
that hepcidin is a negative regulator of iron absorption, recycling and release from iron stores 
and is homeostatically regulated by iron and anaemia (Millard et al. 2004;Nicolas et al.
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2002c;Pigeon et al. 2001). Hepcidin has also been shown to be regulated by inflammation 
and hypoxia.
In hereditary haemochromatosis caused by homozygous disruption of HFE, transferrin 
receptor 2 (TFR2) and hemojuvelin (HJV), Hepcidin production has been found to be low in 
spite of iron overload, suggesting that all these molecules act as direct or indirect regulators 
of Hepcidin synthesis.
1.5.2.1.1 Regulation of Iregl expression
Iregl is found in all the tissues that export iron into plasma: basolateral membranes of 
duodenal enterocytes, and cell membranes of placental cells, hepatocytes and macrophages 
(Donovan et al. 2005). Here, Iregl is in a unique position to regulate the inflow of iron into 
plasma from dietary or maternal sources, from hepatic stores and from macrophages 
engaged in recycling senescent erythrocytes. Thus the transport of iron by Iregl across the 
enterocyte basolateral membrane determines whether iron is delivered to plasma transferrin 
or removed from the body with shed enterocytes.
When iron stores are high, high levels of Hepcidin are produced causing Iregl to be 
internalised, therefore blocking the pathway for the transfer of iron from the enterocyte to 
plasma. When iron stores are low, Hepcidin production is suppressed and Iregl molecules are 
displayed on basolateral membranes of enterocytes, where they transport iron from the 
enterocyte cytoplasm to plasma transferrin (Ganz and Nemeth 2006). This proposed model 
explains how iron recycled in macrophages is regulated and how macrophages containing 
iron in inflammatory status lead to high Hepcidin production. The high levels of Hepcidin 
block iron export and the iron remains trapped within the macrophages (Yang et al. 2002). 
The expression of Iregl on the cell membrane has also been found to be regulated by iron 
(Frazer et al. 2002;McKie et al. 2000). In iron deficiency conditions Iregl expression in the 
duodenum is upregulated and thus iron absorption is increased. Interestingly in the Kupffer 
cells of the liver, spleen and alveolar macrophages, Iregl protein expression is downregulated 
by iron deficiency and up-regulated by iron loading (Abboud and Haile 2000;Yang et al.
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2002). This indicates a tissue-dependent difference in the regulation of Iregl protein levels. 
As the regulation observed in the Kupffer cells is similar to that of ferritin and both Iregl and 
ferritin contain a 5'TRE, it is possible that the 5’-IRE may be functional in these cells.
Recently and contrasting with previous immunohistological studies, Iregl has been reported 
to localise to the apical brush border of duodenum enterocytes, where it could be modulating 
iron absorption possibly by modulating the activity of DMT1 (Donovan et al. 2000;McKie et al. 
2000;Thomas and Oates 2004). In addition to directly regulating Iregl expression and thus 
iron export, hepcidin is expected to have an indirect effect on cellular iron intake. This 
indirect effect would be the result of increased iron concentrations in enterocytes, 
macrophages or hepatocytes that would suppress the synthesis of the splice variant of DMT1 
containing an IRE (Ganz and Nemeth 2006).
1.5.2.1.2 Regulation of cellular iron intake
The mechanism by which the brush border iron uptake molecules DMT1 and Dcytb are 
regulated by hepcidin is not clear. It is unlikely that hepcidin has a direct effect on these 
molecules as these molecules seem to respond to the cell iron concentration whereas 
systemic signals such as hepcidin appear to modulate preferably the export of iron across the 
basolateral membrane which leads to alterations in enterocyte iron levels and subsequently to 
changes in the expression of the brush border uptake components (Abboud and Haile 
2000;Frazer et al. 2001;Frazer and Anderson 2003;McKie et al. 2000). In the enterocytes the 
majority of DNTT1 present is the splice variant containing an IRE motif and the binding of IRPs 
to DMT1 mRNA when intracellular iron levels are low appears to stabilize this message, 
increasing the level of DMT1 protein. As Dcytb does not contain an IRE motif, it cannot be 
regulated by the IRP activity. Although Dcytb is regulated by intracellular iron levels in the 
same direction as DMT1 the regulatory mechanism involved remains unknown.
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1.5.3 Regulation of Hepcidin Synthesis
Different studies have revealed that hepcidin synthesis is regulated by three main factors: 
inflammation, oxygen concentration and iron levels (Nicolas et al. 2002b). These factors will 
be discussed in detail in the sections below and in the chapters 4, 5 and 6.
1.5.3.1 Inflammation and infection
Hepcidin synthesis is markedly induced by infection and inflammation. In animal models and 
human subjects, injection of lipopolysaccharide (LPS) (Pigeon et al. 2001), or Freund's 
adjuvant increased significantly hepatic hepcidin mRNA expression (Frazer et al. 
2004b;Kemna et al. 2005;Nemeth et al. 2004a). Although the up regulation of hepcidin as a 
response to inflammation and infection is beneficial for an organism during the course of an 
infection (the sequestration of iron in cellular stores makes iron less accessible for invading 
microorganisms), this has a deleterious effect leading to the development of the anaemia of 
inflammation (AI).
LPS treatment stimulates IL-6 which induces an increase in production of Hepcidin by 
hepatocytes as mentioned previously. This Hepcidin leads to the internalisation and 
degradation of Iregl which blocks the release of iron from macrophages causing a decrease 
in serum iron (hypoferremia) characteristic of AI (Ganz 2006).
Turpentine oil injections in mice also increase liver hepcidin gene expression, cause 
hypoferremia and the resulting in anaemia (Nicolas et al. 2002b;Weinstein et al. 2002). This 
hypoferremic response to turpentine-induced inflammation is absent in the USF2/Hepcidin- 
deficient mice, confirming that this response is fully dependent on hepcidin. Neutralising 
antibodies against IL-6 block hepcidin in vitro, and IL-6 KO mice fail to up-regulate hepcidin 
in response to turpentine showing a direct effect of IL-6 on Hepcidin expression (Lee et al. 
2004;Nemeth et al. 2004a). The data demonstrates that Hepcidin is a type II acute phase 
protein that plays a major role in the dysregulation of iron homeostasis during inflammation 
(Nemeth et al. 2003).
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1.5.3.2 Hypoxia and Anaemia
In humans iron absorption is mainly regulated by iron stores and the rate of erythropoiesis. 
Erythropoiesis regulates iron absorption regardless of iron stores to provide an adequate iron 
supply for the production of erythrocytes. When oxygen is lacking, erythropoietin (EPO) is 
produced which in turn leads to the production of erythrocyte precursors in the bone marrow. 
The development of these erythrocyte precursors then depends on an adequate supply of 
iron from the diet. Previously it was thought that stimulated erythropoiesis was necessary for 
the induced iron uptake seen in hypoxic conditions but now it has been shown that hepcidin 
has a more crucial role than EPO in the response to hypoxia (Nicolas et al. 2002b;Vokurka et 
al. 2006). In hypoxic conditions hepcidin levels decrease, its inhibitory effects on iron 
absorption diminish, and more iron is made available from the diet and from the iron stores 
(Nicolas et al. 2002b;0'Riordan et al. 1995;Raja et al. 2005). The iron absorbed in the 
duodenum is then delivered to bone marrow to sustain the erythrocyte production. 
Interestingly, it has been shown that turpentine-treated mice exposed to 3 days of hypoxia 
failed to show an increase in iron absorption. This observation can be explained by the 
positive response of the hepcidin gene to inflammation counterbalancing the hypoxia- 
dependent downregulation of this gene (Raja et al. 1990).
The human hepcidin promoter contains several binding sites for the hypoxia-inducible factor 
1 (HIF-1) (Ganz 2005b) but these binding sites do not seem to be conserved in other 
mammals, and their role has not yet been experimentally tested. Therefore, the exact 
mechanism by which hypoxia down-regulates hepcidin gene is still unknown.
Anaemia regulates Hepcidin levels in a similar manner to hypoxia. In iron deficiency hepatic 
hepcidin mRNA levels decrease leading to an increase in iron absorption (Bondi et al. 
2005;Latunde-Dada et al. 2004;Nicolas et al. 2002b;Vokurka et al. 2006). Cases of anaemia 
with ineffective erythropoiesis, such as (3-thalassemia major are characterised by increased 
iron absorption and consequently iron overload (Nemeth and Ganz 2006;Papanikolaou et al.
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2005). Thus, showing that anaemia is dominant over iron overload in regulating hepcidin 
expression in the thalassemia setting (Andrews 1999).
Although in these cases, hepcidin levels correlate with parameters of erythropoiesis and 
anaemia they do not correlate with indices of iron overload such as liver iron concentrations, 
ferritin, serum iron or transferrin saturation. There was however, a negative correlation 
between Non-transferrin bound iron (NTBI) and hepcidin levels, suggesting that low levels of 
hepcidin allow the increase of iron flow into plasma, leading to saturation of transferrin and 
NTBI formation.
Mice lacking the transferrin (Tf) gene develop severe iron deficiency anaemia but also 
develop an increased pool of non-transferrin-bound iron and tissue iron overload. Although 
hypotransferrinemic mouse (TrRhpx/hpx) present extremely low hepcidin levels, in this case the 
hyperabsorption of iron is not solely because of the anaemia but also due to the effect of 
transferrin levels probably on the intestinal mucosa (Pietrangelo and Trautwein 2004;Raja et 
al. 1999;Trenor, I I I  et al. 2000). The low levels of hepcidin in hypotransferrinemic mice 
support the notion of a dominant erythroid signal in hepcidin regulation (Roy CN 2002). One 
possible candidate for this dominant erythroid signal in hepcidin regulation is the soluble TfRl 
(sTfRl). sTfRl is produced by proteolytic cleavage of TfRl, and circulates in blood as a 
monomer bound to transferrin. When iron availability is reduced and when erythropoiesis is 
stimulated sTfRl levels were found to be high (Beguin 2003;Nemeth et al. 2005). The 
reasons why overexpression of sTfRl in mice did not alter hepcidin expression remains to be 
studied (Flanagan et al. 2006).
Recently a model has been proposed whereby TfR2, the second human transferrin receptor 
gene is involved in the detection of diferric TF and subsequently activation of a signal 
transduction pathway regulating hepcidin expression (Frazer and Anderson 2003;Johnson and 
Enns 2004). It is therefore possible that the low TF seen in TrFhpx/hpx mice leads to low 
hepcidin via a TfR2 signalling pathway.
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1.5.3.3 Iron Overload and Transferrin
Mice Injected with Iron dextran presented hepcidin mRNA expression levels 4 times higher 
than control mice (Pigeon et al. 2001). In addition, dietary iron supplementation to both 
humans and mice lead to an increase in hepcidin mRNA which in turn blocks iron absorption 
until the normal plasma iron levels are restored (Nemeth et al. 2004b;Pigeon et al. 2001). 
Interestingly, in vitro exposure of hepatocytes to iron did not have a significant effect on 
hepcidin mRNA levels (Pigeon et al. 2001), this could be due to hepatocyte phenotypic 
changes that occur with time in culture, as hepatocytes when maintained for a few days in 
primary cultures without differentiation promoting factors lose the expression of several liver- 
specific genes (Glaise et al. 1998;Ilyin et al. 1998).
The hepcidin gene does not contain any iron responsive elements (IREs), suggesting that the 
iron status of the body is not signalled through iron regulatory proteins (IRPs), but by other 
signalling pathways. One suggested signalling pathway already mentioned involves diferric Tf 
in the circulation could provide the necessary signal for the hepatocytes to detect body iron 
demand and subsequently alter hepcidin expression (Frazer and Anderson 2003), but this 
pathway is still not fully understood.
While a role for diferric TF in the regulation of hepcidin expression remains speculative, the 
molecules HFE, transferrin receptor 2 (TFR2), and Hemojuvelin (HJV), are now accepted to 
be important regulators of Hepcidin production by hepatocytes. In Haemochromatosis 
disorders due to mutations in these genes, Hepcidin levels are inappropriately low, 
suggesting that these molecules act as direct or indirect regulators of hepcidin synthesis.
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1.5.3.3.1 HFE
Changes in cellular iron status appear to have little effect on the expression of Hfe but the 
expression of Hfe has profound effects on cellular iron status. Haemochromatosis due to 
mutations in the Hfe gene is characterised by an inappropriate high iron absorption and 
reticuloendothelial cell iron release that leads to excess iron entering the circulation and 
subsequent deposition in parenchymal cells such as hepatocytes (Fleming et al. 2004). While 
the precise function of the Hfe protein remains unknown, recent studies have shown that Hfe 
gene mutations result in an inappropriately low level of hepcidin expression (Ahmad et al. 
2002;Bridle et al. 2003;Muckenthaler et al. 2003). Moreover, when Hfe KO mice were crossed 
with mice overexpressing hepcidin their iron overload status was normalized (Nicolas et al.
2003). These studies suggest that Hfe participates in the regulation of intestinal iron 
absorption by modulating hepcidin expression. The fact that Hfe and Hepcidin are both 
expressed in the liver (Hfe in the Kupffer cells and hepcidin in hepatocytes) encourages this 
link (Bastin et al. 1998;Mura et al. 2004).
The decrease of circulating Hepcidin results in increased ferroportin-mediated iron efflux from 
reticuloendothelial cells and duodenal enterocytes increased circulating iron concentrations 
and eventually the saturation of TF. This leads to NTBI to be taken into tissues with a high 
capability for NTBI uptake such as the liver. In HH1 patients and Hfe KO mice, the increased 
enterocyte iron export leads to secondary increases in the expression of genes involved in 
intestinal iron uptake (e.g., Dcytb, DMT1) suggesting that the increased intestinal iron 
absorption, increased circulating iron, and sparing of RE iron loading seen in iron homeostasis 
abnormalities, such as HH1 are caused by an inappropriately low expression of hepcidin. 
Despite the low levels of hepcidin, Hfe KO mice maintain the ability to regulate hepcidin 
expression when iron status changes, suggesting that Hfe loss only attenuates the signal 
between iron status and hepcidin expression in these mice. It has been proposed that other 
gene products such as TfR2 and hemojuvelin may serve as transducers to this signal. 
Whether HFE acts by modulating the function of either of these two molecules or acts 
independently of them to influence hepcidin expression is still unknown.
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The Hfe gene has been identified as the second ligand for TfR. HFE lowers the affinity for Fe- 
TF by directly competing for TFR binding sites (Feder et al. 1998;Parkkila et al. 
1997b;Waheed et al. 1999). Although previous studies have shown that HFE and TFR2 did 
not interact in vitro (West, Jr. et al. 2000), Andrews and her colleagues recently have shown 
that TFR2 competes with TFR1 for binding to HFE. It has also been found that the two 
molecules interact and that disease-associated mutations of Hfe and TfR2 do not abrogate 
this interaction (Goswami and Andrews 2006). Hence this interaction may be part of the 
hepatocytes mechanism of iron sensing.
Before the discovery of Hepcidin, it was thought that duodenal crypts sensed the body iron 
status and programmed the absorptive activity of daughter enterocytes, this way regulating 
the iron uptake by the duodenum. As HFE is expressed in duodenal crypt cells in physical 
association with TfRl, it was suggested that Hfe influences the ability of crypt cells to sense 
body iron status by modulating their Tf-mediated uptake of iron. This model postulates that 
HFE in duodenal crypt cells facilitates the TfRl-mediated uptake of plasma iron and that 
mutant HFE lacks this facilitating effect. The loss of functional Hfe would thereby result in a 
relatively iron-deficient state in these cells and daughter enterocytes which in turn would lead 
to an increase in expression of iron-regulated genes participating in dietary iron absorption, 
including DMT1, Dcytb, and/or Iregl. This "crypt cell hypothesis" was supported by the 
observations that in Hfe KO mice, iron uptake from plasma TF by the duodenum is 
significantly decreased and that expression of the iron transport genes are increased in Hfe 
KO mice (Dupic et al. 2002b).
In summary, HFE clearly interacts with TFR1, changes the iron status of cells in which it is 
expressed, and influences hepcidin expression. However, there are difficulties in 
distinguishing the primary effects of Hfe on cellular iron status and its secondary effects 
resulting from changes in hepcidin expression. Developing cell-specific Hfe KO models may be 
useful is separating these influences as HFE is broadly expressed and its effects seem to be 
cell specific.
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1.5.3.3.2 TFR2 and Hemojuvelin
The second molecule known to regulate hepcidin expression is TFR2 (Fleming et al. 
2000;Kawabata et al. 2005). The disruption of the TfR2 gene leads to iron loading that is 
phenotypically very similar to HH1 (Camaschella et al. 2000). It has also been shown that 
that mutations in TfR2 also lead to inappropriately low Hepcidin levels (Nemeth et al. 2005), 
suggesting that like HFE, TFR2 is involved in the regulation of hepcidin expression and the 
two molecules may be part of the same regulatory pathway (Ganz and Nemeth 2006; Nemeth 
et al. 2005).
Hemojuvelin is the most recently discovered molecule in this pathway and like Hfe is 
expressed in hepatocytes (Papanikolaou et al. 2005;Papanikolaou et al. 2004;Roetto et al. 
2001;Roetto et al. 2003). JH due to mutations in the hemojuvelin gene do not produce 
detectable levels of Hepcidin despite severe iron overload, suggesting that hemojuvelin is 
absolutely required for the production of hepcidin (Frazer and Anderson 2005). As 
hemojuvelin is a glycosylphasphatidylinositol (GPI)-linked plasma membrane protein that can 
enhance the signal produced from certain receptors, it was thought that it may also be 
involved in the signal transduction pathway that regulates hepcidin expression (Niederkofler 
et al. 2005). Recently, Babitt et al showed that Hemojuvelin (HJV) was also a coreceptor for 
BMPs and suggested that the Hjv/BMP complex regulated hepcidin expression through a BMP 
signal transduction pathway (Babitt et al. 2006;Truksa et al. 2006). Bone morphogenetic 
proteins (BMPs) are cytokines of the TGF-p superfamily that play a crucial role in the 
development of tissues, in regulating cell proliferation, cell differentiation, and apoptosis 
(Chen et al. 2004a;Gambaro et al. 2006;Varga and Wrana 2005). After activating their 
transmembrane receptors, TGF-p signalling is transduced into the nucleus by SMADs. SMAD4 
is a tumour suppressor gene often found mutated in many cancers. Recently a group has 
shown that disruption of SMAD4 in mouse livers results in a significant decrease in hepcidin 
expression and accumulation of iron in many organs. They have also shown that SMAD4- 
deficient hepatocytes do not show transcriptional activation of hepcidin in response to iron
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overload, TGF-p, BMP, or IL-6 (Wang et al. 2005). This new data reveals a novel role for 
TGF-p/BMP signalling in induction of hepcidin expression and shows that SMAD4 is required 
for this activity although the pathway and physiological relevance of these stimuli remains 
undefined. The significance of the role of Hemojuvelin in regulating hepcidin expression and 
systemic iron homeostasis also remains unclear.
In conclusion, Hepcidin is a key iron regulatory hormone in iron homeostasis that is up- 
regulated by iron and inflammation and down-regulated by anaemia and hypoxia. Two 
pathways are now known to be important for transcriptional regulation of Hepcidin, 
BMP/SMAD and IL-6/STAT3 signalling but it remains to be determined how these pathways, 
or others, transduce the physiologic signals (inflammation, oxygen concentration and iron 
levels) and regulate Hepcidin.
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1.6 Aims
The discovery of the Hfe gene, the role of Hfe gene mutations as the main cause of 
Hereditary Haemochromatosis and the establishment of Hepcidin as the key regulator of iron 
homeostasis have contributed to our understanding of the molecular control of iron 
metabolism. The study of human diseases and animal models has led to the discovery and 
identification of new genes involved in iron homeostasis but much remains to be understood. 
The scope of this thesis is to further understand the mechanism of regulation of hepcidin 
mRNA expression and to study the role of HFE in the regulation of body iron levels, either in 
conjunction with hepcidin or as part of a cascade of modulators of hepatic iron 
concentrations. First, a novel animal model for Haemochromatosis type 1 (SWR Hfe KO) was 
created and characterised (Chapter 3). This animal mouse models was then studied in 
different iron status conditions (iron deficiency and iron overload) for hepcidin and iron 
transporter genes mRNA expression levels. The effect of transferrin in the expression of 
these genes was also investigated (Chapter 4). The effect of cytokines and acute 
inflammation on Hepcidin and iron transporter genes and the role of Hfe in the regulation of 
hepcidin by inflammatory settings were described (Chapter 5). The effect of anaemia and 
hypoxia on hepcidin and iron transporter genes mRNA expression levels in vivo and in vitro is 
presented and the effect of hepcidin on iron uptake is investigated (Chapter 6). Finally, in 
Chapter 7 the significance of the presented findings is discussed together with future studies.
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C hapter 2 
G eneral M eth o d s
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2.1 Gene expression levels by Reverse-Transcription Polymerase Chain reaction 
(RT-PCR)
2.1.1 RNA extraction
Precautions against contamination of sampies with RNAses were taken. The bench working 
area was wiped with RNAse Zap (Ambion Ltd., UK), disposable gloves were worn at all times, 
glassware and pestle and mortar were baked at 150°C for at least 4 hours prior to use and 
sterile disposable plastic wear and pipettes reserved for RNA work only were used.
Fresh tissues were snap frozen in liquid nitrogen and ground to powder using a cold pestle 
and mortar.
2.1.1.1 RNA extraction by the TRIzol® method
RNA was extracted using the TRIzol®/chloroform extraction and isopropyl alcohol 
precipitation. Powdered tissue or cells were incubated in TRIzol® reagent (Invitrogen, Ltd., 
Renfrew, UK) for 5 minutes at room temperature to complete the dissociation of 
nucleotide/protein complexes. Two hundred pi of chlorophorm (Sigma, Poole, UK) was added 
to the samples (20%v/v) and samples were shaken vigorously for 20 seconds. Samples were 
incubated at room temperature for 5 minutes then centrifuged at 12,000g for 15 minutes at 
4°C. The mixture separated into a lower red phenol chloroform phase which contained DNA 
and protein and an upper aqueous phase containing the RNA. The upper aqueous phase was 
removed to a separate clean tube and the lower organic phase was discarded.
The RNA was precipitated from the aqueous phase by incubating the samples with 500 pi of 
isopropyl alcohol (Sigma, Poole,UK) (30% v/v), for 20 minutes at room temperature (RT); 
and then centrifugated at 12,000 g for 15 minutes at 4°C.
The resulting RNA pellet was washed in 75% ethanol and centrifuged at 8,000 g for 5 
minutes at 4°C. The supernatant was removed; the RNA pellet was air-dried at room 
temperature and resuspended in DEPC treated water (Promega UK Ltd., Southampton, UK). 
RNA samples were kept at -80° C until required.
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2.1.1.2 RNA extraction by the Qiagen kit method
RNA was extracted using the Qiamp RNA blood Mini Kit (Qiagen, Crawley, UK). Samples were 
resuspended in Qiamp RTL buffer (Qiagen, Crawley, UK) with added p-mercaptoethanol and 
centrifuged at 12,000 g for 2 minutes in a Qiamp Shredder. The supernatant was transferred 
to a new and clean tube and the pellet was discarded. An equal volume of ice-cold 70% 
ethanol was added to the supernatant and transferred to the Qiamp spin column. This was 
centrifuged at 6,000 g for 20 seconds to bind the RNA to the column membrane. RNA bound 
to the membrane was washed with RW1 buffer. Contaminating DNA was digested by 
incubation of the membrane with Qiamp RNAse-free DNAse Set (Qiagen, Crawley, UK) for 15 
minutes at room temperature. Membranes were rewashed with RW1 buffer, followed by two 
washes in RPE buffer containing 80% ethanol to remove contaminants. Columns were 
centrifuged at 12,000 g for 2 minutes to remove all traces of ethanol. RNA was reconstituted 
into 30 pi of DEPC treated water (Ambion Ltd., UK); this was added onto the membrane and 
centrifuged at 6,000 g for 2 minutes to elute. RNA samples were kept at -80° C until required.
2.1.1.3 RNA concentration and purity
The RNA concentration and purity were determined by measuring the absorbance of RNA in 
water at 260nm using a spectrophotometer (Beckman DU 650 Spectrophotometer, High 
Wickam, Bucks., UK). RNA concentration was calculated using the formula A26o*40 = pg 
RNA/ml. In distilled water, the RNA had an A26o/2ao ratio of 1.9-2.1 indicating RNA free of 
contamination.
2.1.2 cDNA synthesis
Complementary DNA was synthesised using ABgene Reverse-iT 1st Strand Synthesis Kit 
(ABgene, Surrey, United Kingdom) using the PTC-100 thermocycler (MJ Research, NV, USA), 
lpg of total RNA was used as a template and incubated with 500nM oligodT primer and H20
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for 5 minutes at 70° C. to denature any secondary structure. 1st strand synthesis buffer, 
dNTPs and reverse transcriptase were added. Reaction components were incubated at 47° C. 
for 60 minutes and then at 70° for 10 minutes to inactivate the Reverse-iT™ RTase Blend. 
Complimentary DNA was stored at -20°C.
2.1.3 PCR
The resulting cDNA transcripts of the cells' mRNA were used for PCR amplification using the 
PCR Core System II (Promega UK Ltd., Southampton, UK) according to the manufacture's 
protocol. Each PCR reaction contained 5.0pmol of forward primer, 5.0 pmol of reverse primer,
1.5 mM MgCl2, 500 pM each of dATP, dCTP, dGTP, dTTP, 0.5 units of Taq polymerase and 
lxPCR buffer in a 20 pi reaction. The cycling parameters were initial denaturing at 95°C for 3 
minutes, unless stated 30 cycles of denaturing at 95°C for 30 seconds, annealing for 1 minute 
and extension at 72°C for 1 minute, followed by a final extension step at 72°C for 5 minutes 
using a thermocycler (MJ Research, NV, USA). See table 2.1 for primer sequences, annealing 
temperatures and expected product sizes. The primers were synthesised by Sigma-Genosys 
Ltd. (Poole, Dorset, UK) according to the specific sequences. The house keeping genes (3- 
actin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and 
hypoxanthinephophoribosyltransferase (HPRT) were designed to incorporate areas of 
sequence that were highly conserved between species of rat, mouse and human. Primer 
specificity was determined by performing a BLAST search where the primer sequence can be 
checked against a database of all published genomic sequences (web 
address:httD://www.ncbi.nlm.nih.oov/blast/T
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2.1.4 Aaarose electrophoresis
The PCR products were resolved on a 1.2% (w/v) agarose gel in TAE buffer (Tris-Acetate 
EDTA) containing 0.5 pg/ml ethidium bromide (Sigma-Aldrich Co., Ltd., Poole, UK). Samples 
were run alongside molecular weight markers (Bioline, London, UK) using a horizontal gel 
apparatus (BioRad, Hemel Hempstead, UK). The PCR bands were observed under ultraviolet 
illumination and images were captured using the Fluor-S Multilmager (Bio-Rad, Hemel 
Hempstead, UK).
Bands of the expected size were further analysed using MultiAnalyst (Bio-Rad, Hemel 
Hempstead, UK) imager analysis software. The amount of mRNA was standardised to that of 
the housekeeping gene. Results are therefore expressed as arbitrary optical density units of 
(gene of interest/housekeeper gene). In all the experiments, the presence of possible 
contaminants was investigated using control RT-PCR assays of samples in which either RNA 
had been excluded (blank) or reverse transcriptase had been omitted from the RT mixture.
2.2 Detection of gene expression mRNA levels using real-tim e PCR
Real time PCR allows continuous monitoring of PCR product information. Fluorescent double­
stranded DNA dyes such as SYBR Green I can be used to monitor PCR product accumulation 
after each cycle of amplification (Wittwer et al. 1997). Real time PCR can be conducted either 
as a one-step or a two-step reaction. Two step RT-PCR, in which cDNA is produced in a 
separate reaction tube to the PCR, has the advantage over one step RT-PCR, in which the 
reverse transcriptase and the PCR are conducted in the same reaction tube. The cDNA 
template is more stable than RNA and there is often enough cDNA to perform a number of 
subsequent PCR reactions. Moreover, since the cDNA reaction product used as a starting 
template for the PCR is the same for both the control gene and for the gene of interest this 
eliminates variations due to fluctuations in efficiency of the reverse transcriptase step. For 
these reasons, the two step protocol for real time PCR was used.
81
2.2.1 Extraction of messenger RNA for real-time PCR
RNA was extracted by either using the TRIzol®/chloroform extraction and isopropyl alcohol 
precipitation as described in section 2.1.1.1; or by the Qiagen kit method, described in 
section 2.1.1.2.
2.2.2 cDNA synthesis
One pg of total RNA was reverse transcribed with a first-strand cDNA kit (ABgene Reverse-iT 
1st Strand Synthesis Kit, ABgene, Surrey, United Kingdom) as described in section 2.1.2.
2.2.3 Real-Time PCR amplification
The resulting cDNA transcripts of the samples were used for Real Time PCR amplification 
using the QuantiTect SYBR® Green PCR kit (Qiagen, West Sussex UK) on a LightCycler Real 
Time PCR instrument (version 3.5, Roche Diagnostics, Mannheim, Germany). QuantiTect 
SYBR® Green I PCR master mix contains SYBR® Green I, HotStart Taq DNA Polymerase and a 
dNTP mix (including dUTP). SYBR® Green I present in the PCR mix only emits light when it 
binds to double stranded DNA, once bound it is excited at 494nm and emits light at 521nm. 
Monitoring of emissions at 521nm following excitation at 494nm, allows indirect quantification 
of the double stranded DNA concentration within the reaction capillary. Fluorescence at 
521nm is quantified within each reaction capillary following the completion of every PCR 
extension step. The PCR cycle at which the fluorescence (product) reaches a threshold value 
is used as a measure of the original template concentration. When back calculated against a 
standard curve, the number of mRNA templates in the initial sample can be calculated. SYBR 
green does not interfere with PCR cycling as it dissociated from the product DNA during the 
denaturation step of the following PCR cycle. Each PCR reaction mix contained 1.0 pi of cDNA 
template, 5.0pmol forward and 5.0pmol reverse primers, 10 pi 2x QuantiTect SYBR® Green I 
PCR master mix and distilled water to a final volume of 20 pi.
Primers were designed using LightCycler Probe Design software version 1.01 (Roche 
Molecular Biochemicals, Mannheim, Germany) and synthesised by Sigma-Genosys Ltd. (Poole,
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Dorset, UK) according to the specific sequences. The genes of interest and the house keeping 
genes were designed to incorporate areas of sequence that were highly conserved between 
species of rat, mouse and human. BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) searcher 
were conducted on all primers to ensure unique specificity to the gene of interest.
Suitability of primers was determined by producing a single product of the correct length, 
determined by agarose gel electrophoresis, after PCR cycling with the protocol described 
(section 2.2A.2). A single peak on the meltcurve analysis (section 2.2.4.3) was also required 
to determine suitability of primers. For primer sequences see Table 2.1.
2.2.4 Real-Time PCR cycling parameters
The RT-PCR reaction conditions were as suggested in the manufacturers protocol, this 
included an initial hot-start at 95°C for 15 minutes, followed by PCR cycling of denaturation at 
94°C for 15 seconds, annealing at 60°C for 20 minutes, extension at 72°C for 30 seconds. The 
temperature of fluorescence acquisition was set at 2°C below the product melting 
temperature and held for 5 seconds. The product melting temperature was determined in a 
test run by examining the melting curve (described in section 2.2.4.3). All experiments were 
performed in duplicate and for each sample the gene of interest and the control gene were 
run in parallel. A ratio of relative abundance of the gene of interest to the constitutively 
expressed gene was calculated by the Lightcycler Relative Quantification software version 1.0 
(Roche Diagnostics, Germany).
2.2.4.1 The second derivative maximal method
The Lightcycler software version 3.5 (Roche Diagnostics, Germany) calculates the PCR cycle 
at which the maximal increase in fluorescence occurs in the log/linear phase of cycling. This 
is known as the second derivative maximal method, and the cycle at which this occurs can 
be, and is usually different for each sample. The cycle number at which maximal increase in 
fluorescence occurs is compared to that of standards with known concentration of PCR 
product using RelQuant software (Roche Diagnostics, Germany). A standard curve for each
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gene was prepared with PCR products in which the concentration has been determined by 
spectroscopy.
Gene o f interest Prim er sequence
Human
GAPDH
F 5' TGGTATCGTGGAAGGACTC 3' 
R 5' AGTAGAGGCAGGGATGATG 3'
HPRT
F 5' TTGAGCCCTCTGTGTGCTCAAG 3'
R 5' GCCTGACCAAGGAAAGCAAAGTC 3'
Hepcidin
F 5' CTGCAACCCCAGGACAGAG 3'
R 5' GGAATAAATAAGGAAGGGAGG 3'
DMT1+IRE
F 5# AGTGGI 1 1A1G1CCGGGACC 3' 
R 5' TTTAACGTAGCCACGGGTGG 3'
Ire g l
F 5' CGTCATTGCTGCTAGAATCG 3' 
R 5' AGACTGAAATCAATACGAGC 3'
T fR l
F 5' TATAGAAGG1 1 1GGGGGC1G1G 3' 
R 5' GAGACCCTATGAAC11 1 1CCCTA 3'
TfR2
F 5' GAAGGGGCTGTGATTGAAGG 3' 
R 5' GATTCAGGGTCAGGGAGGTG 3'
Mouse
Mouse
p- Actin
F 5' GACGGCCAAGTCATCACTATT 3'
R 5' CCACAGGATTCCATACCCAAGA 3'
Hepddin 1
F 5' CCTATCTCCATCAACAGATG 3' 
R 5' AACAGATACCACACTGGGAA 3'
DMT1
F 5' GGC1 MCI 1ATGAGCATTGCCTA 3' 
R 5' GGAGCACCCAGAGCAGCTTA 3'
Ire g l
F 5' CCAGCATCAGAACAAACACG 3' 
R 5' ACTGCAAAGTGCCACATCC 3'
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Rat
p- Actin
F 5' GACGGCCAAGTCATCACTATT 3' 
R 5'CCACAGGATTCCATACCCAAGA 3'
Hepcidin
F 5'CACGAGGGCAGGACAGAAGGCAAG 3' 
R 5'CAAGGTCATTGCTGGGGTAGGACAG 3'
Table 2.1 Human, mouse and rat primer sequences used in this study
Forward sequences (F) and Reverse sequences (R).
2.2A.2 Preparation of standard curves
PCR products (dsDNA) for each gene were separated on a 1.2% agarose-TAE gel and purified 
using the Geneclean kit (Qbiogene, Cambridge, UK). Approximately 300 mg of the product of 
interest were excised from the gel using a clean scalpel and placed in a 1.5 ml tubes with 
400pl of glassmilk (silica beads in high salt solution), this was incubated at 55°C to melt the 
agarose gel. Glassmilk containing the DNA/gel mix was placed in the GENECLEAN spin filter 
column and centrifuged at 12,000g for 1 minute. DNA was retained by the membrane and 
the glassmilk/gel in the supernatant was discarded. The membrane-filter was washed twice 
with wash buffer and dried by centrifuging for further 2 minutes. DNA was resuspended in 
10-25 pi of distilled water and centrifuged at 13,000 g for 1 minute. The concentration of 
each PCR product DNA was determined using a spectrophotometer (Beckman DU 650 
Spectrophotometer, High Wycombe, Bucks., UK) and calculated using the formula A26o*50 = 
pg DNA/ml. Purified DNA was serially diluted 10-fold covering a dynamic range of 7 
logarithmic orders. 1.0 pi of each standard dilution was amplified by PCR using the 
Lightcycler and specific primers (Fig. 2.1). One set of gene-of-interest standards were run in 
duplicate with the house keeping gene standards to generate two standard curves (Fig. 2.2).
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Figure 2.1 Representative graph of a gene product standard curve.
A set o f standard dilutions covering a dynamic range o f 6 logarithm ic orders was 
am plified per gene o f interest.
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Figure 2.2 Representative graph of the linear regression of a gene product 
standard curve.
2.2.4.3 Analysis of the melting curve
After completion of the PCR amplification cycles, a melting curve was determined for each 
PCR product. Each dsDNA has its own melting temperature (TM) based on the strand length 
and the G-C content. Therefore melting curve analysis can be used to identify unwanted by­
products of the PCR reaction such as primer dimer. The PCR products were heated to 65°C 
and then the temperature was increased slowly (0.5°C per second) whilst fluorescence was 
continually monitored. At low temperatures all DNA is double stranded, SYBR Green I binding 
and fluorescence is maximal. As the temperature is increased, DNA products are denatured,
86
and the fluorescence decreases. A melting curve is produced by plotting fluorescence against 
temperature (Fig. 2.3). Primer dimer and other short non-specific products can be 
distinguished using this method, since they usually melt at lower temperatures than the 
desired product. Increasing the fluorescence acquisition temperature used during PCR to 
above the melting temperature of primer-dimer and non-specific products, eliminates any 
fluorescence due to the presence of these products (Fig. 2.4). PCR products were also 
analysed by gel electrophoresis as described in section 2.1.4, and visualised using a Bio-Rad 
Multilmager (Bio-Rad, Hemel Hempstead, UK).
Figure 2.3 Representative graph of the meltcurve of a gene product
A t low  temperatures a ll DNA is double stranded, SYBR Green I  binding and 
fluorescence is maximal. As the tem perature is increased, DNA products are 
denatured, and the fluorescence decreases.
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Figure 2.4 Representative graph of the meltcurve peak analysis of a gene 
product. Increasing the fluorescence acquisition tem perature used during PCR to  
about 2 degrees above the m elting tem perature o f prim er-dim er and non-specific 
products, elim inates any fluorescence due to the presence o f these products.
2.3 Statistical analysis
Data is presented as Mean±SEM Statistical differences (p<0.05) between groups were 
determined using Student's unpaired t-test or one-way analysis of variance (ANOVA) followed 
by Tukey's post hoc test, where indicated.
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Chapter 3
C h a ra c te ris a tio n  o f iro n  accu m u la tio n  in  th e  liv e r  o f  
w t and H fe  KO SWR mice
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3.1 Introduction
The liver
The liver is the second largest organ and the largest gland within the human body with a 
median weight of approximately 1600g in men and 1400g in women. The human liver lies in 
the right upper quadrant of the abdomen in contact with the diaphragm, under the protection 
of the rib cage. It lies on the right of the stomach and makes a kind of bed for the gallbladder 
(Fig. 3.1).
Esophagus
Liver V
Gall bladder
Stomach
Hepatic artery
Intestines
Figure 3.1 Position of the liver in the right hypochondrium and 
relationships to neighbouring organs and structures. Scheme adapted from: 
httD://www.Hver<ancer.info/  on 1/09/2006.
Apart from a section where it connects to the diaphragm, the liver is entirely covered by 
visceral peritoneum, a thin, double-layered membrane that reduces friction against other 
organs. The peritoneum folds back on itself to form the falciform ligament and the right and 
left triangular ligaments. Traditional gross anatomy divided the liver into four lobes based on 
surface features. The falciform ligament is visible on the front (anterior side) of the liver. This 
divides the liver into a left anatomical lobe, and a right anatomical lobe. When looking at the 
visceral surface of the liver, there are two additional lobes between the right and left. These 
are the caudate lobe (the more superior), and below this the quadrate. From behind, the
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lobes are divided up by the ligamentum venosum and ligamentum teres (anything left of 
these is the left lobe), the transverse fissure (or porta hepatis) divides the caudate from the 
quadrate lobe, and the right sagittal fossa, which the inferior vena cava runs over, separates 
these two lobes from the right lobe.
The liver is supplied by two main blood vessels on its right lobe: the hepatic artery and the 
portal vein. The hepatic artery carries 25% of the liver's blood supply (arterial blood) and the 
remaining 75% (venous blood) comes through the portal vein that carries blood from the 
entire capillary system of the digestive tract, spleen, pancreas, and gall bladder, so that the 
liver can process the nutrients and byproducts of food digestion. The hepatic artery and 
portal vein enter the liver at the porta hepatis invested by a sheath of connective tissue which 
incorporates bile duct branches. The duct, vein, and artery divide into left and right branches, 
and the portions of the liver supplied by these branches constitute the functional left and 
right lobes. In the widely used Couinaud or "French" system (Fig. 3.2, 3.3), the functional 
lobes are further divided into a total of eight segments based on secondary and tertiary 
branching of the blood supply.
Figure 3.2 Diagrammatic representation of Couinaud liver segments. The
anterosuperior view is shown, w ith division o f the porta l and hepatic veins. The 
segments are indicated as: I, caudate lobe; II, I I I  and IV, le ft lobe; V, VI, V II and 
V III, righ t lobe. Scheme taken from : http ://m bi.dkfz-
heideiberg. de/proiects/liver/m edical background, htm i on the 1/09/2006.
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The venous drainage from the liver operates through the hepatic veins that emerge from the 
posterior surface of the liver and open immediately into the inferior vena cava just before it 
pierces the diaphragm. There are three main hepatic veins: the left, the middle and the right. 
The first two usually join to form a short stalk with a common outlet. Inferior vein(s) drain 
the posterior segment of the right lobe and the caudate lobe directly into the vena cava. The 
main left vein drains the two lateral segments of the left lobe (Segments II and III), the 
middle vein drains segment IV and the anteromedial sector of the right lobe (segment V and 
VIII); the right vein drains the remainder of the right lobe (segment VI and VII). The caudate 
lobe has its own venous supply and drainage and so it can be regarded as a separate lobe.
Figure 3.3 MRI images of the Couinaud liver segments
Adapted from http://dpi. radiology, uiowa. edu/nlm/aDD/livertoc/liver/8sea. htmi taken 
on the 10/10/2006
Liver parenchyma
The liver is covered with a connective tissue capsule that branches and extends throughout 
the substance of the liver as septae. This connective tissue tree provides a scaffolding of 
support and the highway which along which afferent blood vessels, lymphatic vessels and bile 
ducts traverse the liver. Additionally, the sheets of connective tissue divide the parenchyma 
of the liver into very small units called lobules. Lobules, consists of a mass of cells, hepatic 
cells, arranged in irregular radiating columns between which are the blood channels
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(sinusoids). These convey the blood from the circumference to the center of the lobule, and 
end in the central vein, which runs through its center, to open at its base into one of the 
sublobular veins. Between the cells are also the minute bile capillaries. At the vertices of the 
lobule are regularly distributed portal triads, containing a bile duct and a terminal branch of 
the hepatic artery and portal vein (Fig. 3.4, 3.6).
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Figure 3.4 Hepatic vasculature and biliary system
Schematic diagram showing the gross arrangement o f the hepatic vascular 
and the bile collecting systems. The hepatic porta l vein and hepatic artery 
branch repeatedly w ithin the liver, the ir term inal branches running w ithin the 
porta! tracts (B urkitt e t ai. 2007).
This basic hexagonal pattern is replicated millions of times throughout the tissue and is held 
together by an extremely fine areolar tissue, in which the portal vein, hepatic ducts, hepatic 
artery, hepatic veins, lymphatics, and nerves ramify; the whole being invested by a serous 
and a fibrous coat. Terminal branches of the hepatic portal vein and hepatic artery empty 
together and mix as they enter sinusoids in the liver. Sinusoids are distensible vascular 
channels lined with highly fenestrated or "holey" endothelial cells and bounded
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circumferentially by hepatocytes. As blood flows through the sinusoids, a considerable 
amount of plasma is filtered into the space between endothelium and hepatocytes (the 
"space of Disse"), providing a major fraction of the body's lymph. Blood flows through the 
sinusoids and empties into the central vein of each lobule (Fig. 3.5). Central veins coalesce 
into hepatic veins, which leave the liver and empty into the vena cava.
Centra)
venule
OhV)
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venule
Central venule
Figure 3.5 Liver simple acinus
Diagrammatic representation w ith the zonal arrangement o f the hepatocyte 
and two neighbouring classic lobules outlined by a discontinuous line (Bacon 
eta/. 2006).
A three-dimensional representation of this organisation is best illustrated by the stereoscopic 
reconstruction of Hans Elias (ELIAS 1949) (Fig. 3.6).
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Figure 3.6 Three dimensional representation of the normal liver 
parenchyma. Schematic diagram m odified from  (ELIAS 1949) showing the porta l 
triad  containing the hepatic artery, porta l vein and bile duct.
Hepatocytes occupy around 78% of the total liver volume in humans (Table 3.1). The 
individual hepatocyte is a polyhedral and highly polarized epithelial cell approximately 30-40 
m3 in diameter. Each cell contains one or more nuclei; binucleation of a minority of 
hepatocytes is a normal finding. Hepatocytes form interconnecting walls or plates separated 
from each other by the sinusoidal labyrinth. Sinusoids are lined by flattened, fenestrated 
endothelial cells which form an incomplete, porous barrier, allowing easy exchange of 
materials between blood and hepatocytes. Within the sinusoidal lumen there are 
phenotypically heterogeneous macrophages. The principal phagocytic reticuloendothelial cell 
in the liver is the Kupffer cell. Kupffer cells are more numerous near the portal tracts and so 
often are in direct contact with the blood. A phenotypically distinctive population of 
lymphocytes is also present in the sinusoidal lumens and in the portal tracts (Sheuer and 
Leftowitch 2000).
95
Relative number and volume of different cell type in the adult liver
Cell type Number (% ) Volume (% )
Hepatocytes 60 78
Non-hepatocytes 40 6.3
Endothelial cells 20 2.8
Kupffer cells 14 2.1
Stellate cells 6 1.4
Extracellular space 15.7
Table 3.1 Relative number and volume of different cell types in liver
As mentioned in chapter 1, the main storage site of iron in the body is in the iiver. 
Approximately 40% of the storage iron, or 400 mg, is located in the liver, and under normal 
circumstances the vast majority of this is found in hepatic parenchymal cells. The remainder 
is found in Kupffer cells, with very small amounts in stellate cells, endothelial cells, and bile 
duct cells. As the major site of iron storage, hepatocytes have a high capacity to synthesize 
not only the iron storage protein ferritin (Harrison and Arosio 1996) but also the plasma iron 
transport protein, Transferrin (TF) (Ponka et al. 1998), Ceruloplasmin (Cp) (Heilman and 
Gitlin 2002), haptoglobin (Wassell 2000), and hemopexin (Tolosano and Altruda 2002). The 
hepatocyte also plays a major role in the regulation of body iron homeostasis as it is the main 
site of expression of the regulatory proteins HFE transferrin receptor 2 (TFR2), Hemojuvelin 
(HJV) and Hepcidin (Frazer and Anderson 2003).
Iron can be acquired by the liver in several ways as described in section 1.4 of Chapter 1. 
Irrespective of its source, it is likely that iron that enters the hepatocyte joins the same 
intracellular pool and from here, iron will be used for metabolic functions, may be stored 
within ferritin, or may contribute to the regulation of cellular iron metabolism by influencing 
the activity of IRPs and likely other factors. Many studies have shown a positive correlation 
between the hepatic ferritin content and body iron levels and so the level of ferritin within the 
cell is determined by intracellular iron levels (Arosio and Levi 2002;Halliday et al. 
1994;Harrison and Arosio 1996). In cases of severe iron overload, iron can be stored in the 
liver as haemosiderin, a breakdown product of ferritin (Iancu 1990;Iancu et al. 1997).
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Although it is known that processes of hepatic iron uptake, storage, and release are vital, not 
just for the maintenance of hepatocyte iron homeostasis but for the body as a whole. The 
central role played by the liver in the regulation of body iron homeostasis has only become 
apparent with the recent discovery of the iron regulatory hormone Hepcidin.
Hepatic iron content and Haemochromatosis
As described in section 1.4.2.1.1 of Chapter 1, hereditary Haemochromatosis type 1 (HH1) is 
an autosomal recessive disorder of iron metabolism caused by mutations in the Hfe gene. 
HH1 is characterised by defective regulation of dietary iron absorption that leads to excessive 
iron accumulation, mainly in the liver. The increased iron absorption in haemochromatosis is 
in part responsible for elevated transferrin saturation and transferrin-bound iron transport, 
which leads to cellular uptake of excess circulating iron and pathological expansion of body 
iron stores. This in turn results in the increased formation of the iron storage molecules 
ferritin and haemosiderin, especially in parenchymal cells of the liver. Progressive hepatic iron 
accumulation in humans leads to fibrosis, cirrhosis and subsequent increased morbidity and 
mortality.
The first histological abnormality in haemochromatosis patients homozygous for the C282Y 
mutation is the appearance of stainable iron in periportal hepatocytes. At this stage the 
diagnosis should be confirmed by genetic testing as heterozygous patients have very sparse 
or absent stainable liver iron. As parenchymal iron deposition increases, fibrosis begins to 
expand the portal tracts and Kupffer cells and portal tract macrophages start to also 
accumulate iron. As fibrosis and hepatocellular hyperplasia start to alter the normal 
architectural relationship of the parenchyma, cirrhosis slowly starts to develop. The onset of 
cirrhosis results In a fall in life expectancy and an increased risk of hepatocellular carcinoma 
(Sheuer and Leftowitch 2000).
Kupffer cells are the principal macrophages of the liver, they are important in phagocytosing 
senescent red blood cells and recycling the iron back to the plasma and around 15% of this 
traffic occurs in the liver. Under iron overload conditions such as HH1, the proportion of
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Kupffer cells storing iron can increase considerably, but hepatocytes remain the dominant site 
of iron deposition. The iron accumulated by Kupffer cells leads to production of cytokines that 
can play an important role in activating hepatic stellate cells and thus in the genesis of liver 
fibrosis.
The presence of iron stores in humans has been characterised by using invasive methods 
such as biopsies and non-invasive techniques such as MRI (Magnetic Resonance Imaging) 
scans. These methods are not able to give a full account of how much and where the iron 
stores are located and therefore the pattern of iron accumulation in the different lobes in the 
liver of patients has not been fully investigated. In clinical practice, the iron concentration 
determined in a small part of a needle biopsy or in a fine needle biopsy is considered to be 
representative of the mean iron concentration in the whole liver. When a non-uniform pattern 
of iron distribution was observed in haemochromatosis and in cirrhosis, the possibility of 
sampling errors was reported (Emond et al. 1999). Emond et al investigated the accuracy of 
iron measurements by taking multiple biopsy-sized and microtome samples at random sites 
from the livers of 11 patients undergoing liver transplantation. They found an average 
coefficient of variation of liver iron concentration of 41% when measured via multiple needle 
biopsies, and 30% when measured from larger microtome samples showing that single 
biopsies are very imprecise to measure hepatic iron concentrations (Emond et al. 1999). 
Ambu (Ambu et al. 1995) and Clark (Clark et al. 2003) had already shown this differential 
distribution of iron in the liver by studying non-cirrhotic B-thalassaemic autopsy liver 
specimens and by studying patients with Thalassaemia major by MRI, respectively. Although 
the hepatic variation of iron accumulation has been reported, there is no information on iron 
levels in the different hepatic lobes.
In order to study Haemochromatosis type 1 (HH1), the Hfe gene was knocked out in several 
mouse strains, such as C57BL/6 and DBA/2 (Lebeau et al. 2002). These strains provide an 
approach for investigating the extent to which modifier genes play a role in normal and 
pathological iron regulation in the Hfe KO mouse model. Duodenal iron absorption and 
hepatic iron load have been found to be two or three times higher in Hfe KO mice (C57BL/6 X
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129/OLa) than in corresponding controls. Iron was found preferentially in periportal 
hepatocytes and plasma iron concentrations and transferrin saturation were elevated 
accordingly. The iron distribution between organs and microscopic iron deposition in the 
hepatocytes of these Hfe KO mouse models resembled the patterns described in HH1. One 
difference between the mouse model and the HH1 patients is that the Hfe KO mice do not 
develop fibrosis or cirrhosis despite the severe iron overload (Knutson et al. 2001). Thus, the 
role of iron in initiating liver fibrosis in iron overload diseases such as HH1 is not fully 
understood and an animal model that can produce the full pathological picture of the cirrhotic 
liver seen in HH1 is still needed. It is known that iron overload enhances liver injury, mildly 
accelerates the process of fibrosis and can be directly carcinogenic in the absence of cirrhosis 
or fibrosis (Arezzini et al. 2003;Asare et al. 2006) but it is believed that other factors may be 
involved in this process (Roberts et al. 1993). The insufficiently high levels of iron 
accumulation might account for the lack of fibrosis and cirrhosis seen in these animal models. 
It has been reported that the severity of iron accumulation when the Hfe gene is disrupted is 
dependent on the mouse strain used (Clothier et al. 2000;Leboeuf et al. 1995;Morse et al. 
1999). The difference in iron loading in different mouse strains is probably dependent on 
modifier genes (Fleming et al. 2001) and in most strains, levels of iron never reach the levels 
seen in HH1. In order to reach high levels of liver iron in a mouse strain model, the murine 
Hfe allele was disrupted in the SWR strain. The SWR mouse strain has been described as 
having a higher basal iron status in the liver (190±6 pg/g dry weight) than other strains, 
namely DBA/2 (103±8 pg/g dry weight), and C57BL/6 (44±3 pg/g dry weight) mouse strains 
(Clothier et al. 2000).
The aim of this study is to accurately characterise the pattern of iron accumulation in wt and 
Hfe KO SWR mice and to investigate if the high levels of hepatic iron content in this mouse 
strain together with the disruption of the Hfe allele lead to fibrosis or other pathological 
abnormalities in the liver making the SWR Hfe KO mice a more accurate animal model for the 
study of HH1.
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3.2 Methods
3.2.1 SWR Hfe Knockout (KO) mice
C57BL/6 mice lacking the Hfe gene were donated by Susan Gilfillan, Department of 
Immunology, Washington University, St Louis, MO). Cloning and sequence analysis of the 
murine Hfe gene from a 129/SvJ library has been previously described (Bahram et al. 1999); 
a 2.5-kb Bglll fragment encompassing the second and third exons (a l and a2 domains) was 
replaced with a 2-kb pgk-neor gene flanked by loxP sites. The targeting fragment was excised 
from the vector and correctly targeted HFE alleles were detected by Southern blot analysis in 
6 of 240 G418-resistant clones, two of which (with normal karyotypes) were subsequently 
injected into C57BL/6 blastocysts. Chimeric, heterozygous, and homozygous mice were 
generated according to standard procedures and were obtained in Mendelian ratios; 
genotyping was assessed by PCR.
SWR mice Hfe KO mice were generated by intercrossing heterozygous animals (with 129/Ola- 
C57BL/6 mixed background) with wt SWR mice (Charles River Lab, Inc., USA) for 9 
generations. This number of generations is expected to generate mice 99.9% Hfe KO when 
homozygous for the Hfe mutation. Wild-type and homozygous Hfe KO littermates were 
identified at 3 to 4 weeks of age. Mice were fed CRM diet (Scientific Diet Supplies (SDS), 
Witham, Essex, United Kingdom) ad lib and males were studied at 12 weeks of age. All 
experimental procedures were conducted in accordance with the UK animals (Scientific 
Procedures), Act, 1986.
3.2.1.1 SWR mice oenotypino
DNA was prepared from mouse tail fragments using a DNeasy Tissue kit (Qiagen, Crawley, 
UK). The tails were digested overnight at 55°C in ATL buffer and protease K. Once the tails 
were fully digested, AL-Ethanol buffer was added to the samples. The samples were then 
centrifuged at 12,000 g for 2 minutes in a Qiamp Shredder. The resulting sample was 
transferred to a new and clean tube and the Qiamp Shredder column was discarded. An 
equal volume of ice-cold 70% ethanol was added to the supernatant and transferred to the 
Qiamp spin column. This was centrifuged at 6,000 g for 20 seconds to bind the DNA to the
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column membrane. DNA bound to the membrane was washed with AW1 buffer to remove 
contaminants. Columns were centrifuged at 12,000 g for 2 minutes to remove all traces of 
washing buffer. DNA was reconstituted into 200 pi of AE buffer; this was added onto the 
membrane and centrifuged at 6,000 g for 2 minutes to elute. The concentration of the DNA 
samples was determined using a spectrophotometer (Beckman DU 650 Spectrophotometer, 
High Wickam, Bucks., UK) and calculated using the formula A26o*50 = pg DNA/ml.
The resulting DNA samples were used for PCR amplification using the PCR Core System II 
(Promega UK Ltd., Southampton, UK) according to the manufacture's protocol. The cycling 
parameters were initial denaturing at 95°C for 3 minutes, unless stated 30 cycles of 
denaturing at 95°C for 30 seconds, annealing for 1 minute and extension at 72°C for 1 
minute, followed by a final extension step at 72°C for 5 minutes using a thermocycler (MJ 
Research, NV, USA).
Radiolabeled primers were designed to amplify the murine Hfe gene: 5'- 
GAATTAACAGGCCGTTTCTAAAG-3'(HFE forward), 5’-CTTGGAGTAGTGGCrCACACr-3' (HFE 
reverse), and S'-GAGATCAGCAGCCrCTGTTCC-S' (pgk-neor). The primers were synthesised by 
Sigma-Genosys Ltd. (Poole, Dorset, UK) according to the specific sequences. Primer 
specificity was determined as stated in section 2.1.3.
The PCR products were resolved on a 1.2% (w/v) agarose gel in TAE buffer (Tris-Acetate 
EDTA) containing 0.5 pg/ml ethidium bromide (Sigma-Aldrich Co., Ltd., Poole, UK). Samples 
were run alongside molecular weight markers (Bioline, London, UK) using a horizontal gel 
apparatus (BioRad, Hemel Hempstead, UK). The PCR bands were observed under ultraviolet 
illumination and images were captured using the Fluor-S Multilmager (Bio-Rad, Hemel 
Hempstead, UK). The disruption of the Hfe gene was confirmed by a single band 350 bp (Fig.
3.2.1).
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Figure 3.2.1 Interpretation of agarose gel band results in SWR mice 
genotyping. SWR w t (band size= 320 bp), SWR heterozygous fo r Hfe disruption (320 
bp, 350 bp) and SWR Hfe KO (350 bp).
3.2.2 Tissue iron quantification in SWR wt and Hfe KO mice by a modified 
Torrance & Bothwell method (Torrance and Bothwell 1980).
In order to characterise the iron accumulation in the whole of the SWR mice liver accurately, 
the livers were divided into five lobes and named A to E (Fig. 3.2.2, Table 3.2.1). Tissue non- 
haem iron determination was performed by a modified Torrance and Bothwell colorimetric 
method (Torrance and Bothwell 1980).
c
Figure 3.2.2 Posterior view of the mouse liver
The mouse live r was sectioned in to five d iffe rent lobes, designated A to  E
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Lobe Couinaud segments S
Caudate 1 A, B
Left 2,3 E
Quadrate 4 D
Right 5, 6, 7, 8 C
Table 3.2.1 Hepatic lobes, corresponding Couinaud Segments and 
corresponding sections used in this study (S).
Tissue samples were dried at 50°C for four days. Dried samples were weighed and digested 
in acid digestion mixture (3 M hydrochloric acid, 10% trichloroacetic acid) at 65°C for 20 
hours. 75pl of each acid extract was mixed with 0.3 ml of bathophenanthroline chromagen 
reagent and the absorbance was measured at 535 nm in a spectrophotometer (Beckman DU 
650 Spectrophotometer, High Wycombe, Bucks., UK). Results are expressed per g dry weight 
of tissue.
3.2.3 Histological stains used on SWR mice tissue sections
3.2.3.1 Peri's Prussian blue stain for ferric iron in tissues
Tissue sections were deparafRnised and hydrated with distilled water, sections were then 
placed in the Peri's solution (1:1, 5% potassium ferrocyanide and 5% HCI) for 10 minutes,
rinsed in distilled water and counterstained with nuclear fast red for 5 min. Sections were
then in rinsed distilled water, dehydrated, and mounted. Ferric iron will be stained blue and 
the nuclei red (Bancroft and Stevens 1982). Grading of the stained hepatic sections was 
performed according to Scheuer's grading table shown on Table 3.2.2.
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Grade Magnification required (eye piecex objective)
0 Granules absent or barely discemable x400
1 Barely discemable x25G 
Easily confirmed x400
2 Discrete granules resolved xlOO
3 Discrete granules resolved x25
4 ..... visible xlO or naked eye
Table 3.2.2 Grading of iron deposition according to Scheuer (personal 
communication by Prof. P. Dhillon).
3.2.3.2 Massom Trichrome stain for the histological hepatic assessment of fibrosis/cirrhosis 
in SWR Hfe KO mice
Liver sections were deparaffinised and hydrated with distilled water. Sections were fixed with 
Bouins solution overnight. Sections were then washed in running water until clear then placed 
in Weigerts hematoxylin for 10 minutes which will stain the nuclei. Sections were then again 
washed in running water for 10 minutes, rinsed in distilled water and placed in Biebrich 
Scarlet-acid fuchsin solution for 15 minutes. After rinsing in distilled water sections were 
differentiated in Phosphotungstic-phosphomolybdic acid for 10-15 minutes (at this point 
sections were checked under the microscope to assess if collagen tissue was clear if positive 
results are expected sections are differentiated for 5-10 more minutes until collagen is clear). 
Sections are counterstained in aniline blue for 2 minutes, rinsed in distilled water, dehydrated 
and mounted. Collagen will be stained blue or green, the nuclei dark brown and the 
cytoplasm red.
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3.3 Results
3.3.1 Perl's Prussian Blue staining of whole liver sections of SWR wt and Hfe KO mice
Histological examination of SWR Hfe KO mice liver with Perl's reaction for ferric iron showed 
iron accumulation is unevenly distributed within the different lobes (Fig. 3.3.1b). Iron in these 
mice accumulated primarily in the hepatocytes with scarce Kupffer cell accumulation (Fig.
3.3.2). No positive staining was observed in endothelial cells or in bile ducts. Representative 
sections of SWR wt mouse liver (a) and SWR Hfe KO mouse liver (b) are shown in Fig. 3.3.1.
Figure 3.3.1 Perl's Prussian blue staining of the whole SWR mouse liver
SWR w t mouse showing no positive staining confirm ing the lack o f iron stores (A), SWR Hfe 
KO showing positive patchy staining showing a d ifferentia l distribution o f iron stores in  
different lobes (B).
a) b)
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Figure 3.3.2 Perl's Prussian blue staining of wt and Hfe KO SWR mouse 
liver. Light microscopy of liver parenchyma showing the portal vein (PV), hepatic 
artery (HA) and bile duct (BD) in wt (a) and Hfe KO SWR mice (b). Positive staining 
for ferric iron was observed in the hepatocytes (H) but not in the endothelial cells (E) 
or Kupffer cells (K) in the Hfe KO SWR mice. No positive staining was seen in wt SWR 
mice for ferric iron (x40 original magnification (OM).
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3.3.2 Histological staining of liver sections for fibrosis in wt and Hfe KO SWR mice
Masson trichrome staining of wt and Hfe KO SWR mice liver sections at 12 weeks of age 
showed no positive staining of collagen fibers signifying that no fibrosis had developed in 
these animals (Fig. 3.3.3).
Figure 3.3.3 Hepatic staining of wt and Hfe KO SWR mice for collagen fibers Liver 
sections were stained using the Masson trichrome staining protocol. No positive staining for 
collagen fibers were seen in wt (a) or Hfe KO (b) mice liver sections (xlO OM).
3.3.3 Hepatic iron content in wt and Hfe KO SWR mice
In SWR wt mice hepatic iron in all the lobes (A-E) ranged from 100 to 290 pg/g dry weight 
(195.4±47.6pg/g dry weight) while in SWR Hfe KO liver iron levels in lobes B to E iron 
content levels ranged from 350 to 500 pg/g dry weight (438±15.6pg/g dry weight). 
Interestingly, lobe A had a significantly higher content of iron than any of the other lobes 
(821.6±102.8pg/g dry weight) as seen in Fig. 3.3.4.
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Figure 3.3.4 Iron stores in the different lobes of SWR w t and Hfe KO mouse. Mouse 
livers were divided into five lobes and named A to E and non-haem iron determination was 
performed by a modified Torrance and Bothwell colorimetric method as described in chapter 
2. In SWR wt mice there is no significant difference between the iron content levels of the 
hepatic lobes, however in Hfe KO mice; lobe A has significantly higher iron levels compared 
to the remaining lobes (B-E). Data is presented as Means±SEM/ n=8 per group, *p<0.05.
3.3.4 Perl's Prussian Blue and haematoxylin and eosin CH&En staining of spleen sections of 
SWR wt and Hfe KO mice
Histological staining of spleen sections with Perl's Prussian blue showed that wt SWR mice 
accumulate iron in the splenic macrophages (Fig. 3.3.5a, b). In contrast Hfe KO mice do not 
accumulate iron significantly in the spleen (Fig. 3.3.5c).
108
Figure 3.3.5 Histological staining of spleen sections of wt and Hfe KO mice. Perl's 
staining of spleen section of wt SWR showed positive staining for iron in the spleen 
macrophages (a=xlO original magnification (OM), b=x40 OM) while staining of spleen section 
in Hfe KO SWR mice was generally non-significant (c=x20 OM). A small number of cases of 
splenomegaly were found in Hfe KO mice, H&E staining showed an enlargement of the white 
pulp of the spleen in this cases (d=x20 OM).
Interestingly, a small number of Hfe KO SWR mice were found to have an enlargement of the 
spleen (splenomegaly) but failed to show any symptoms of the associated pathological 
characteristics (Fig. 3.3.5d).
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3.3.5 Iron content of whole out, spleen, kidney and pancreas in wt and Hfe KO SWR mice
Quantification of tissue iron in SWR mice showed that Hfe KO mice have higher iron content 
levels in the whole gut, pancreas and kidney than wt mice (Fig. 3.3.6). Interestingly in the 
spleen, wt mice had significantly higher levels of iron accumulation than Hfe KO mice.
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Figure 3.3.6 Iron content in the whole gut, spleen, pancreas and kidney of SWR 
mice. Tissues were removed and prepared for iron quantification by a modified Torrance & 
Bothwell method as described in section 3.2.2. Iron content levels are higher in the gut, 
pancreas and kidney of Hfe KO mice compared to wt mice. SWR wt mice however accumulate 
significantly higher levels of iron in the spleen than Hfe KO mice. Data are Mean±SEM, n=5 
per group, *p<0.05.
110
3.4 Discussion
In this chapter the hepatic iron accumulation of wt SWR mice and a novel haemochromatosis 
type 1 mouse model, Hfe KO SWR mice, was characterised. Our data shows that in wt SWR 
mice iron accumulation is evenly distributed between the different hepatic lobes while in SWR 
Hfe KO mice the hepatic iron accumulation is uneven and patchy within the lobes of the liver. 
In addition we have shown that the disruption of the Hfe gene causes a preferential 
accumulation in a specific part of the hepatic caudate lobe and that the knockout of the Hfe 
gene in SWR mice despite causing very high hepatic iron levels is still not sufficient to cause 
fibrosis or other pathological damage to the liver of these mice.
Several animal models have been created to study haemochromatosis type 1 (HH1), however 
no model has yet been able to produce the full pathological picture of the cirrhotic liver seen 
in HH1 patients. Despite severe iron overload being known to enhance liver tissue injury, the 
iron overloaded Hfe KO mice do not develop fibrosis or cirrhosis (Arezzini et al. 2003;Knutson 
et al. 2001). As mice have been found to be intrinsically more resistant to liver damage it is 
believed that other factors may be involved in the development of fibrosis in Hfe KO mice 
such as the severity of iron overload or genetic background. The SWR mouse strain has been 
previously shown to have a higher basal iron status in the liver than other mouse strains 
(Clothier et al. 2000). We hypothesised that, together with the high levels of iron loading 
caused by the disruption of the Hfe allele, the hepatic iron accumulation in SWR Hfe KO mice 
would result in the development of fibrosis.
The present study shows that as previously reported Hfe KO mice like HH1 patients 
accumulate excess iron in the liver but not in the spleen. HH1 patients have also been found 
to accumulate iron in the pancreas (Sherlock and Dooley 2002) however, this was not 
observed in SWR Hfe KO mice. Interestingly here we show that SWR wt mice accumulate 
significantly higher iron levels in the spleen compared to Hfe KO mice with the site of iron 
deposition being splenic macrophages. Untreated and severe haemochromatosis in patients 
often results in an enlarged spleen and this was observed in a small percentage (5%) of SWR
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Hfe KO mice in this study. These mice were excluded from the study despite there being no 
other physiological difference or pathologies such as inflammation observed in these mice.
This study has shown that liver iron content in wt SWR mice is higher (185.8±25.4 pg/g dry 
weight) than hepatic iron levels seen in other mouse strains such as C57BL/6 (35±4 pg/g dry 
weight) and DBA/2 (107±9 pg/g dry weight) as previously demonstrated (Clothier 2000). We 
have also shown that SWR mice liver iron content is 3-fold higher in Hfe KO compared with 
wild type (wt) mice. In addition we have shown that despite this high increase of hepatic iron 
observed in Hfe KO mice, SWR mice did not develop fibrosis or any other liver damage 
pathology due to iron stores suggesting that genetic iron overload does not appear to be 
sufficient for this pathology.
A literature survey on hepatic iron content of wt and Hfe KO mice of different strains reveals 
that an array of methods for the quantification of non-haem iron is used and therefore it is 
difficult to compare the results obtained in this study with previous reports. For this reason 
the results obtained in this study are only compared to studies describing iron content levels 
measured using the Torrance & Bothwell method.
In HH1 patients, the pattern of accumulation of iron in the liver has not been fully 
investigated and so there is no information on iron content levels in the different hepatic 
lobes. In this study the pattern of iron accumulation in the liver of Hfe KO mice is described 
for the first time. The presence of ferric iron in the whole liver tissue was analysed by Perl's 
staining showing that in SWR Hfe KO mice, iron accumulates predominantly in periportal 
hepatocytes with no staining seen in endothelial cells or in the bile duct similarly to other Hfe 
KO mice or HH1 patients. Interestingly, despite the periportal iron accumulation, iron content 
levels within the hepatic lobes were found to be unevenly distributed.
The quantification of the iron stores by the spectrophotometric assay in each lobe not only 
confirmed the differential distribution of iron in the liver of the SWR Hfe KO mice, but it also 
showed that lobe A accumulated significantly more iron (821.6±102.8pg/g dry weight) than 
the remaining lobes (438±15.6pg/g dry weight). Lobe A in the mouse liver corresponds to
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the caudate lobe in the human liver. The caudate lobe is also called Spigelius' lobe and is 
situated upon the posterior surface of the right lobe between the liver and the vena cava. 
This lobe is composed of three different parts based on the portal blood supply: the first 
called Spiegel's lobe includes the caudate lobe and papillary process, the second is termed 
paracaval portion, and the third is called the caudate process. The caudate lobe as a whole 
(or segment I) is unique in its blood supply and venous drainage in that it receives blood 
from both the right and left branches of the portal vein and drains directly into the inferior 
vena cava through the main caudate vein and minor hepatic veins (Kanamura et al. 
2001;Kogure et al. 2000).
In the present study, lobe A consists only of Spiegel's lobe (caudate lobe and papillary 
process) and the paracaval portion of the caudate lobe, while the caudate process, a tail-like 
strip of liver tissue is here considered to be lobe B. In lobe A, it is not possible to know in 
which of the two parts (Spiegel lobe or paracaval portion) of the caudate lobe is the one 
demonstrating particularly high levels of iron accumulation.
Although the iron distribution in HH1 has not been investigated in individual lobes, the 
differential distribution of iron content in the liver has been reported by Ambu et al when 
studying non-cirrhotic p-thalassaemic autopsy liver specimens (Ambu et al. 1995) and by 
Clark et al when studying patients with Thalassaemia Major by MRI (Clark et al. 2003).
In this study, although SWR Hfe KO mice did not develop fibrosis, the finding that the 
caudate lobe accumulates significantly higher levels of iron might help us start to understand 
how fibrosis develops in mice. In human patients one imaging sign for diagnosing cirrhosis is 
the caudate-right lobe ratio (C/RL) (Harbin et al. 1980). When cirrhosis develops it was 
observed that the right lobe exhibited shrinkage, the caudate lobe undergoes a relative 
enlargement (Awaya et al. 2002). Measuring the caudate-right lobe ratio (C/RL) using CT, 
ultrasound, and MRI, has shown to be 94% accurate in diagnosing liver cirrhosis (Harbin et 
al. 1980;Hess et al. 1989;Honda et al. 1990). One cause of hypertrophy of the caudate lobe 
and atrophy of the right is thought to be changes in their blood supply. As mentioned before 
the caudate lobes receives blood from both the right and left branches of the portal vein, and
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therefore it receives blood from the entire gastrointestinal tract, while the right lobe receives 
blood from the right branch of the portal vein only. This differential blood supply might 
account for the different iron accumulation levels of lobe A compared to the remaining lobes. 
Other factors such as gene expression of iron transporters might be responsible for this 
differential iron accumulation between the lobes and this hypothesis will be investigated in 
chapter 4.
Another reason for the lack of liver tissue damage in SWR Hfe KO mice is that fibrosis is 
commonly seen in HH1 patients with hepatic iron levels >8000 pg of iron per gram of dry 
weight (Bassett et al. 1986) and hepatic iron levels in SWR Hfe KO mice levels were not 
found higher than 4000 pg of iron per gram of dry weight (in lobe A). A recent paper by 
Asare and colleagues has shown that dietary iron supplementation for 32 months led to 
hepatocellular cancer in the absence of fibrosis (Asare et al. 2006), suggesting that in order 
to accurately assess if SWR mice develop fibrosis or hepatocellular cancer as a result of iron, 
mice would have to be fed an iron loaded diet and their hepatic iron levels would have to be 
higher than the ones observed in this study. This hypothesis is further investigated in chapter 
4.
In conclusion, this study shows that the disruption of the Hfe gene causes a preferential 
accumulation of iron in the caudate lobe of the SWR mouse liver. Interestingly, the caudate 
lobe is one of the lobes studied when investigating cirrhosis in HH1 patients and 
consequently, although SWR Hfe KO did not develop fibrosis or cirrhosis the significantly 
higher accumulation of iron is this lobe might be of relevance. Overall the data obtained 
suggests that the SWR Hfe KO mouse is not the ideal and most accurate mouse model for 
studying HH1. Furthermore our data confirms the findings of Edmond (Edmond et al. 1999) 
that one measurement of hepatic iron in a single sample results in misleading conclusions 
and that iron levels obtained this way do not correspond to the actual hepatic iron 
accumulation levels.
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Chapter 4
Reg u la tio n  of h e p c id in  mRNA e xp r essio n  levels in  response t o :
•  DIETARY IRON, HOLOTRANSFERRIN AND APOTRANSFERRIN IN
w t  and H fe  KO mice and
•  IRON LOADING AND IRON DEFICIENCY IN HUH7 CELLS AND MOLECULES 
PRODUCED BY HEREDITARY HAEMOCHROMATOSIS MACROPHAGES
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4.1.1 Regulation of hepcidin mRNA expression levels in response to: dietary iron, 
holotransferrin and apotransferrin in w t and Hfe KO mice
Hepcidin an antimicrobial peptide is now accepted to be the key negative regulator of iron 
homeostasis. A detailed description of hepcidin identification and mode of action as a 
regulator of duodenal iron uptake has been described in section I.3.4.2. Hepcidin has been 
found to be upregulated in iron overload conditions and downregulated in iron deficiency 
conditions such as anaemia. Iron dextran injections and dietary iron supplementation were 
shown to increase hepcidin levels in mice (Pigeon et al. 2001) and humans (Nemeth et al. 
2004b) while in iron deficiency conditions such as anaemia, hepatic hepcidin mRNA levels 
were found to be downregulated. The low levels of hepcidin expression seen in anaemia 
remove the inhibitory effects of this peptide on iron absorption and as a result more iron is 
absorbed and delivered to bone marrow to sustain the erythrocyte production. (Bondi et al. 
2005;Latunde-Dada et al. 2004;Nicolas et al. 2002b;0'Riordan et al. 1995;Raja et al. 
1990;Vokurka et al. 2006).
No iron responsive elements (IREs) have been found in the hepcidin gene suggesting that the 
iron status of the body is not signalled through iron regulatory proteins (IRPs), but by other 
signalling pathways.
The decrease in transferrin saturation during iron deficiency and the increase in iron loading 
would make it suitable as an indicator of body iron status (Frazer and Anderson 2003). In 
addition, mice lacking the transferrin (Tf) gene develop anaemia in the presence of iron 
overload and low expression of hepcidin (Roy et al. 2002). Transferrin (TF) exists in the 
serum in three forms: diferric TF, monoferric TF, and apotransferrin (Leibman and Aisen 
1979). The distribution of iron between diferric TF and monoferric TF is dependent on TF 
saturation such that a lowering of TF saturation shifts the ratio of the two forms in favor of 
monoferric TF (Huebers and Finch 1984). All three forms of TF can bind to transferrin 
receptor 1 (TFR1) at the cell surface, although diferric TF has a higher affinity to TFR1 than 
monoferric TF and apotransferrin as described in chapter 1. Despite this higher affinity of 
diferric TF to TFR1 the proportion of iron delivered from monoferric TF increases as TF 
saturation decreases (Huebers and Finch 1984). Under normal conditions there is sufficient
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circulating diferric TF to totally saturate the cell surface TFR1 in the body (Cazzola et al. 
1985) and thus the Tf saturation in normal conditions determines the ratio of diferric to 
monoferric TF that is bound to its receptor at any one time.
A correlation between Hepcidin expression and diferric TF levels (Frazer et al. 2004b;Frazer et 
al. 2002;Frazer and Anderson 2003) has been reported. Therefore it is plausible that the level 
of diferric transferrin in the plasma could provide the signal between the body iron 
requirements and the hepatocytes and consequently the appropriate production of hepcidin.
Several proteins expressed in the liver, such as HFE and transferrin receptor 2 (TFR2), have 
also been implicated in sensing the body's iron status to signal the production of an 
appropriate level of hepcidin (Johnson and Enns 2004;Nemeth et al. 2005). In addition, 
mutations in TfR2, Hfe and hepcidin genes have been found to cause hereditary 
haemochromatosis with similar iron loading of the liver and low levels of hepcidin expression, 
suggesting that these molecules act as upstream regulators of hepcidin synthesis.
In the duodenum HFE has been found to competitively inhibit the binding of diferric 
transferrin to transferrin receptor 1 (TFR1) (Feder et al. 1998;Giannetti and Bjorkman 
2004;Lebron and Bjorkman 1999;Parkkila et al. 1997a;Waheed et al. 1999) suggesting that 
the function of Hfe is to inhibit the uptake of diferric transferrin. This would explain why the 
disruption of the Hfe gene in HH1 patients results in an inappropriate high uptake of iron. In 
HH1 patients, however, the crypt enterocytes and reticuloendothelial cells behave as though 
starved of iron (Andrews 1999;Fleming et al. 1999;Zhou et al. 1998) while hepatocytes of the 
liver accumulate excess iron. As HFE has been detected in all these cell types (Bastin et al. 
1998;Parkkila et al. 1997b) and the exposure of wt HFE to HH1 monocytes in vitro resulted in 
an accumulation of iron and ferritin (Drakesmith et al. 2002;Montosi et al. 2000), the notion 
that HFE is a competitive inhibitor of transferrin binding to TFR1 cannot be accepted. Instead 
the findings suggest that HFE either enhances uptake of iron, as suggested by Waheed and 
colleagues (Waheed et al. 1999) or inhibits the release of iron from cells (Bastin et al. 1998). 
A mechanism for the detection of TF saturation by HFE and TFR2 was proposed (Townsend 
and Drakesmith 2002) with the site of HFE and TFR2 action placed in the crypt cells of the
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duodenum and in the macrophages of the reticuloendothelial system but as there is 
compelling evidence against the direct involvement of the intestinal crypts in the regulation of 
iron absorption this could not be accepted either. More recently, Frazer & Anderson (Frazer 
and Anderson 2003) have suggested yet another model this time shifting the site of HFE and 
TFR2 activity to the liver. Evidence for the important role of Hfe in the liver came from 
transplantation studies. When iron loaded livers from HH1 patients were transplanted into 
normal individuals they retained their iron, whereas normal livers grafted into HH1 subjects 
did not accumulate significant amounts of iron suggesting that the main site of action for the 
Hfe gene is the liver (McCullen et al. 2002). Besides HFE (Frazer et al. 2001) the liver is also 
the main site of expression of TFR2 (Kawabata et al. 1999) and Hepcidin (Pigeon et al. 2001) 
with HFE being expressed mainly in Kupffer cells (Bastin et al. 1998;Parkkila et al. 1997b) 
and TFR2 and Hepcidin being expressed in hepatocytes (Fleming et al. 2000;Pigeon et al. 
2001). HFE has also been shown to be expressed in the hepatocytes (Fleming et al. 
2000;Holmstrom et al. 2003;Zhang et al. 2004), sinusoidal lining cells and bile duct epithelial 
cells in the liver.
In the Frazer & Anderson model of detection of TF saturation by HFE and TFR2, the body iron 
requirements are detected by the liver as alterations in the ratio of diferric TF to TFR1. This 
model assumes that diferric TF can outcompete HFE for TFR1 binding and that TFR1 can 
outcompete TFR2 for diferric TF binding. According to the proposed model, in normal 
situations the levels of diferric transferrin favours the binding to TFR1; the unbound Hfe on 
the cell surface and the binding of TFR2 to excess diferric TF upregulates hepcidin 
expression. In iron deficiency the decreased levels of diferric TF and the increased 
expression of TFR1 on the cell surface allows Hfe to bind to TFR1. This leads to TFR1 to 
outcompete TFR2 for diferric TF binding and therefore the signal from HFE and TFR2 to 
produce hepcidin is decreased. In iron loaded conditions the level of diferric TF is increased 
and the cell surface TFR1 levels are decreased. This greatly reduces the binding of HFE to 
TFR1 and allows TFR2 to be fully saturated with diferric TF. This results in an increase in the 
signal from HFE and TFR2 to produce Hepcidin (Fleming et al. 2000;Frazer and Anderson
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2003). In HH1 patients as no HFE exists on the cell surface; the signal to produce Hepcidin 
does not increase appropriately.
The role of TFR2 sensing the body iron status by sensing the concentration of diferric 
transferrin also called holotransferrin or iron-saturated transferrin has been reported 
(Camaschella 2005;Johnson and Enns 2004;Robb and Wessling-Resnick 2004). In 
hepatocyte-derived cell lines and animal models, increasing concentrations of holotransferrin 
but not apotransferrin increases TFR2 protein levels (Johnson and Enns 2004;Robb and 
Wessling-Resnick 2004). In addition it has been reported that the cytoplasmic domain of TfR2 
is essential for its stabilization by diferric TF (Chen and Enns 2007;Frazer and Anderson 
2003;Johnson and Enns 2004;Robb and Wessling-Resnick 2004).
In this chapter, the effect of iron status on hepcidin 1 expression levels will be investigated 
by feeding different iron content diets ranging from low to high iron to SWR mice. To 
investigate whether the response to iron status is regulated by HFE, Hfe KO SWR mice were 
also investigated for hepatic hepcidin 1 and hepatic iron transporter gene expression. To 
investigate the effect of transferrin on hepcidin and hepatic iron transporter gene expression 
levels, SWR mice were injected with human apotransferrin and holotransferrin (diferric TF). 
These treatments were also performed on Hfe KO mice to investigate the role of Hfe gene in 
the regulation of Hepcidin by transferrin levels.
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4.1.2 Methods
4.1.2.1 Dietary iron studies: iron deficiency and iron supplementation in SWR wt and Hfe 
KO mice
After being weaned at 3 weeks of age, SWR wild type (wt) and Hfe KO male mice were fed 
the stated diet ad lib for 9 weeks. At the age of 12 weeks mice were anaesthetised with 
pentobarbitone sodium (60 mg/kg, i.p.) and sacrificed. Blood was removed by cardiac 
puncture for serum iron measurements by means of a ferrozine-based assay (Randox 
Laboratories Ltd. Antrim, UK).
Fresh liver sections were snap frozen in liquid nitrogen and prepared for Real Time PCR as 
described in section 2.2. Liver samples were also collected for iron quantification by a 
modified Torrance & Bothwell method (described in section 3.2.2). Iron staining of livers was 
performed by using Peri's Prussian blue method, using the standard procedures as described 
in section 3.2.3.1. Experimental procedures were conducted in accordance with the UK 
animals (Scientific Procedures), Act, 1986. The iron content of diets is shown in table 4.1.2.1.
Diet Iron content
Control Diet (CD) 160 mg iron/Kg
Iron Deficient Diet (IDD) 6 mg iron/Kg
Iron Loaded Diet (ILD) 40g carbonyl iron/Kg
Table 4.1.2.1 Diets used in this study and their iron content
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4.1.2.2 Treatment of wt and Hfe KO SWR mice with Apotransferrin and Holotransferrin
Male SWR mice aged 3 weeks were placed on an Iron adjusted diet (44 mg of iron/Kg of diet) 
for 9 weeks. At the age of 12 weeks SWR wt and Hfe KO mice were injected with 
apotransferrin (4 mg), holotransferrin/diferric transferrin (4 mg) or an equivalent volume of 
the diluent (saline). After 5 hours mice were anaesthetised with pentobarbitone sodium (60 
mg/kg, i.p.) and sacrificed. Blood was removed by cardiac puncture for serum iron and 
transferrin saturation measurements.
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4.1.3 Results
4.1.3.1 Effect of different iron content diets in w t and Hfe KO SWR mice
4.1.3.1.1 Changes in serum iron, transferrin saturation and liver iron content in wt and Hfe 
KO mice fed on diets containing variable amounts of iron
4.1.3.1.1.1 Serum iron and transferrin saturation levels in wt and Hfe KO mice fed different 
iron content diets
When fed on normal diet (OD), IDD or ILD, serum total iron levels are higher in Hfe KO SWR 
mice than in wt SWR mice (Table 4.1.3.1). Iron deficiency diet did not have a significant 
effect on serum iron levels or transferrin saturation in wt mice. In Hfe KO mice iron deficient 
diet increased transferrin saturation significantly despite having no significant effect on serum 
iron levels.
Control Diet 
(CD)
Iron deficient 
diet (IDD)
Iron loaded diet 
(ILD)
w t
Serum total iron 
(pm oi/L)
182.8±14.2 (8) 160.0±21.1 (4) 445.8±52.3 § (4)
Transferrin 
Saturation (9b)
78.8±2.8 (6) 75.3±5.0 (4) 93.8±1.7 §'p (5)
Hfe KO
Serum total iron 
(pm oi/L)
265.4±20.5° (20) 208.4±49.0 (5) 630.3±38.0Q§(4)
Transferrin 
Saturation (9b)
84.9±1.9 (7) 91.4±3.6° (4) 88.5±4.5 (4)
Table 4.1.3.1 Total serum iron in SWR w t and Hfe KO mice after being fed 
different iron content diets. SWR mice wt and Hfe KO mice were fed the described diets 
for 9 weeks after weaning. Mice were culled at 12 weeks of age and blood was removed for 
haematoiogicaiparameters by cardiac puncture. ° Denotes a statistical significance of p<0.05 
between serum iron levels/transferrin saturation of wt and Hfe KO SWR mice fed the same 
diet,p denotes a statistical significance of p<0.01 between transferrin saturation in wt SWR 
mice fed CD and ILD, § denotes a statistical significance of p<0.05 between serum 
iron/transferrin saturation levels in SWR mice fed CD and ILD. Data are Means±SEM, number 
of samples analysed per group shown in brackets.
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ILD in wt mice increased significantly the serum iron levels and transferrin saturation. In Hfe 
KO mice however, ILD increased significantly serum iron levels but had no effect on 
transferrin saturation.
4.1.3.1.1.2 Liver iron concentration in wt and Hfe KO mice fed different iron content diets
As described in chapter 3, SWR Hfe KO mice have significantly higher hepatic iron content 
than wt SWR mice. When SWR mice were fed on an iron deficient diet (IDD) for 9 weeks 
after weaning both wt and Hfe KO mice showed a decreased in iron content in the whole liver 
(Fig. 4.1.3.1). SWR wt and Hfe KO mice fed an iron loaded diet (ILD) for 9 weeks showed a 
significant increase in the total liver iron content.
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Figure 4.1.3.1 Hepatic iron content in SWR mice fed different diets
SWR w t and Hfe KO mice were fed either an iron deficient d ie t (IDD) o r an iron 
loaded d ie t (ILD ) fo r 9 weeks a fte r weaning. The whole live r was removed and 
divided in to five lobes. Iron was quantified in each lobe and the average o f the iron 
content in each whole live r was calculated. Hepatic iron content decreased by iron 
deficient d ie t and increased by iron loaded d ie t in w t and Hfe KO mice. Data are 
Mean±SEM, n=4 per group, *p<0.05, **p < 0.005.
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4.1.3.1.1.3 Prussian blue iron staining and pattern of iron accumulation in the liver of wt 
and Hfe KO mice fed different iron content diets
Prussian staining and iron quantification in each lobe showed that SWR wt mice fed on 
normal iron content diet (CD) have an even distribution of iron between the hepatic lobes as 
mentioned in chapter 3. Interestingly in Hfe KO mice iron is not uniformly distributed and has 
a patchy distribution. Iron stores quantification of each lobe confirmed this differential 
distribution of iron in the liver, and showed that a specific lobe, named A has significantly 
higher levels of iron than the rest of the lobes (described in chapter 3).
SWR mice were fed an iron deficient diet (IDD) for 9 weeks after weaning. Using Perl's 
Prussian blue method wt SWR mice hepatic sections showed no positive staining and when 
the iron content of each lobe was quantified, no difference between the five lobes was 
observed.
Perl's Prussian blue staining of whole liver sections of SWR Hfe KO mice fed IDD show that 
iron is not evenly distributed and has a patchy distribution in these animals (Fig. 4.1.3.2). A 
more detailed study of the Perl's stained sections shows that Hfe KO mice accumulated iron 
mainly at the periportal hepatocytes.
Iron stores quantification in each lobe confirmed the differential distribution of iron in the 
liver of SWR Hfe KO mice, and showed that lobe A again, had significantly higher levels of 
iron than the rest of the lobes (Fig. 4.1.3.3).
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Figure 4.1.3.2 Representative section of a whole liver of Hfe KO SWR mice 
fed on IDD. SWR Hfe KO mice were fed on an IDD d ie t containing 6 mg iron/kg fo r 
9 weeks a fte r weaning. Whole live r sections were stained by Peri's Prussian blue 
method. The distribution o f iron between the d ifferent lobes was found to be patchy 
and uneven (orig inal size).
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Figure 4.1.3.3 Iron stores in the different lobes of Hfe KO SWR mice fed 
IDD. The whole live r was removed, divided into five lobes and iron was quantified in 
each lobe as previously described. In  SWR Hfe KO mice hepatic iron content in  lobe A 
was significantly d ifferent to  the rest o f the lobes (B-E) (*p<0.05). Data is presented 
as Means±SEM, n=5 per group.
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SWR mice were also fed an iron loaded diet (ILD) containing 40g carbonyl iron/kg. When 
SWR wt mice were fed a high iron diet, although there was a greater accumulation of iron in 
the liver, no differences were seen between the different lobes. This result was confirmed by 
staining a whole liver section with Perl's Prussian blue staining (Fig. 4.1.3.4). On a higher 
magnification, iron deposition in SWR wt mice fed ILD was predominantly observed in 
periportal hepatocytes. When SWR Hfe KO mice were fed on ILD no difference in iron content 
between the five lobes was observed.
Figure 4.1.3.4 Perl's staining of w t SWR mice fed on ILD. SWR w t mice were 
fed on an ILD d ie t fo r 9 weeks a fte r weaning. Whole live r sections were stained by 
Peri's Prussian blue method. Representative section o f a w t mice fed ILD shows no 
difference in the distribution o f iron between the lobes (a= original size). On higher 
power, iron is seen predom inantly in periporta l hepatocytes (b= x20 OM).
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Duodenum sections of SWR wt and Hfe KO mice fed ILD were also analysed. Perl's Prussian 
blue staining showed that wt mice fed ILD accumulate more iron in the intestinal villus than 
Hfe KO mice on a normal diet (Fig. 4.1.3.5).
Figure 4.1.5 Perl's staining of duodenum sections of wt and Hfe KO mice.
The villus o f w t SWR mice fed ILD (a=xlO  OM; b=x20 OM) showed positive staining fo r fe rric  
iron while Hfe KO (c=xlO  OM; d=x20 OM) fed  a norm al d ie t shown no positive staining fo r 
iron in  the duodenum.
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4.1.3.1.2 Hepatic hepcidin 1. DMT1 and Ireal aene expression in wt and Hfe KO SWR fed on 
control diet (CD)
Analysis of hepcidin 1 gene expression levels showed no significant difference between the 
different lobes in the SWR wt mice (Fig. 4.1.3.6). In the SWR Hfe KO mice, although hepcidin 
levels were lower than the wt, lobe A (which had the highest iron content) had a higher level 
of hepcidin expression but this did not reach statistical significance. Although in lobe A there 
was no significant difference between wild type and Hfe KO mice in all other lobes, hepcidin 
levels were significantly reduced in Hfe KO mice compared to wt mice.
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Figure 4.1.3.6 Hepatic hepcidin 1 mRNA expression in SWR mice
SWR mice fed on control d ie t (CD) were sacrificed a t 12 weeks o f age. Hepatic 
hepcidin expression levels were analysed by Real Time PCR. Although hepcidin levels 
were tower in Hfe KO mice this d id  not reach statistica l significance. Data are 
Mean±SEM/ n=8.
Hepatic DMT1 and Iregl mRNA expression was also analysed in wt and Hfe KO mice. No 
overall difference was found between hepatic DMT1 expression levels of wt and Hfe KO SWR 
mice. When each lobe was analysed for DMT1 levels, once again no difference was seen
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between each lobe in wt mice (Fig. 4.1.3.7a). In Hfe KO mice, lobe C was found to have 
significant higher mRNA expression levels of DMT1 due a small number of samples of Hfe KO 
mice lobe C having high DMT1 expression levels.
a)
2 2 CL <
® c 2
< 3  z <
E P
S o
3 1
Hepatic DMT1 expression in SWR mice
1
wt
T " ~ l
■  A
■  B
■ C
■ D
□  E
Hfe KO
b) Hepatic Iregl expression in SWR mice
Hfe KO
Figure 4.1.7 Hepatic iron transporter mRNA expression in SWR mice
SWR mice fed on control d ie t (CD) were sacrificed a t 12 weeks o f age. Hepatic DMT1 
(a ) and Ire g l (b ) expression levels were analysed by Real Time PCR. No difference 
between Ire g l expression in w t and Hfe KO mice was observed. In  addition, no 
difference was seen between Ire g l levels o f the five lobes in  both w t and Hfe KO 
SWR mice. Data are Mean±SEM, n=8.
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Hepatic Iregl expression levels were not different in wt and Hfe KO mice and in both of these 
mice (Fig. 4.1.3.7b), no difference between each lobe was found regarding Iregl mRNA 
expression levels.
4.1.3.1.3 Hepatic hepcidin 1. DMT1 and Ireol gene expression in wt and Hfe KO SWR 
mice fed on iron deficient diet (IDD1)
4.1.3.1.3.1 Hepatic hepcidinl mRNA expression
SWR wt mice fed iron deficient diet (IDD) for 9 weeks showed a significant decrease in 
hepcidin 1 RNA expression levels compared to wt mice fed on control diet (CD). Feeding iron 
deficient diet (IDD) to Hfe KO mice decreased hepcidin 1 expression levels but this did not 
reach statistical significance (Fig 4.1.3.8).
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Figure 4.1.3.8 Hepcidin expression in SWR mice fed iron deficient diet 
(ID D). SWR mice fed on IDD for 9 weeks were sacrificed at 12 weeks of age. 
Hepatic hepcidin expression levels were analysed by Real Time PCR. In wt SWR IDD 
leads to a significant decrease in hepcidin mRNA expression levels while in Hfe KO 
mice IDD did not have a significant effect on hepcidin expression. Data are 
Mean±SEM/ n=5.
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Hepcidin mRNA expression levels were also analysed in each lobe. In wt SWR mice fed IDD 
no difference between hepcidin expression levels was observed in the five hepatic lobes. In 
Hfe KO mice although lobe A shows a higher expression level of hepcidin this failed to reach 
statistical significance and therefore no significant difference was observed between the 
hepcidin mRNA expression levels in the hepatic lobes (Fig. 4.1.3.9).
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Figure 4.1.3.9 Hepcidin expression in the different lobes of Hfe KO SWR 
mice fed IDD. The whole live r was removed, divided into five lobes and hepcidin 
expression was analysed in each lobe by Real Time PCR. In  SWR Hfe KO mice 
hepcidin in lobe A was not significantly d ifferent to the rest o f the lobes (B-E). Data 
are Mean±SEM, n=5.
4.1.3.1.3.2 Hepatic DMT1 and Iregl mRNA expression
Hepatic DMT1 expression decreased significantly in wt SWR mice fed IDD while in Hfe KO
mice feeding iron deficient diet resulted in an increase in DMT1 mRNA expression levels (Fig.
4.1.3.10a).
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Figure 4.1.3.10 Hepatic iron transporter genes expression in SWR mice fed 
iron deficient diet (ID D ). SWR mice fed on IDD fo r 9 weeks were sacrificed a t 12 
weeks o f age. Hepatic DMT1 and Ire g l expression levels were analysed by Real Time 
PCR. In  SWR mice IDD results in a significant increase in DMT1 and Ire g l mRNA 
expression levels. Data are Mean±SEM, n=5, *p<0.05, **P<0.01.
Feeding wt and in Hfe KO SWR mice an iron deficiency diet for 9 weeks upregulated hepatic 
Iregl mRNA expression levels significantly (Fig. 4.1.3.10b).
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Figure 4.1.3.11 Hepatic DMT1 and Ire g l expression in the different lobes
of wt and Hfe KO SWR mice fed IDD. The whole live r was removed, divided into  
five lobes and DMT1 and Ire g l expression was analysed in each lobe by Real Time 
PCR. No difference was observed between the mRNA expression levels o f DMT1 and 
Ire g l in the five lobes. Data are Mean±SEM/ n=5.
Analysis of DMT1 expression in each lobe of the liver showed no differences in mRNA 
expression levels of the iron transporter in wt and Hfe KO SWR mice (Fig. 4.1.3.11a). There 
was also no difference in Iregl mRNA expression levels in the different lobes in wt and Hfe 
KO mice (Fig. 4.1.3.11b).
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4.1.3.1.4 Hepatic hepcidin 1. DMT1 and Ireal gene expression in wt and Hfe KO SWR 
fed on iron loaded diet (ILD1)
4.1.3.1.4.1 Hepatic hepcidinl mRNA expression in wt and Hfe KO SWR fed on iron loaded 
diet (ILD)
Feeding iron loaded diet for 9 weeks to SWR wt mice had no significant effect on hepcidin 
mRNA expression levels (Fig. 4.1.3.12).
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Figure 4.1.3.12 Hepcidin expression in SWR mice fed iron loaded diet 
(ILD). SWR mice fed on ILD for 9 weeks were sacrificed at 12 weeks of age. Hepatic 
hepcidin expression levels were analysed by Real Time PCR. In wt SWR ILD had no 
significant effect on hepcidin expression whereas in Hfe KO mice iron loaded diet up 
regulated significantly hepcidin mRNA expression levels. Data are Mean±SEM, n=5,
**p<0.01.
In contrast Hfe KO mice fed an iron loaded diet showed a significant increased in hepcidin 
mRNA expression levels (Fig. 4.1.3.12).
134
Hepcidin 1 expression in Hfe KO SWR mice 
fed on ILD
D E
Figure 4.1.3.13 Hepcidin expression in the different lobes of Hfe KO SWR 
mice fed ILD. The whole live r was removed, divided into five lobes and hepcidin 
expression was analysed in each lobe by Real Time PCR. In  SWR Hfe KO mice 
hepcidin in lobe A was not significantly d ifferent to the rest o f the lobes (B-E). Data 
are Mean±SEM, n=5.
Hepcidin mRNA expression levels were also analysed in each lobe in wt and Hfe KO SWR 
mice. Hepcidin expression levels were not significantly different between the five hepatic 
lobes in wt or Hfe KO SWR mice fed ILD (Fig. 4.1.3.13).
4.1.3.1.4.2 Hepatic DMT1 and Iregl mRNA expression
Hepatic DMT1 expression significantly increased in wt SWR mice fed ILD (Fig. 4.1.3.14a) but 
feeding Hfe KO mice on an iron loaded diet had no effect on DMT1 expression levels.
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Figure 4.1.3.14 Hepatic iron transporter genes expression in SWR mice fed iron 
loaded diet (ILD). SWR mice fed on ILD for 9 weeks were sacrificed at 12 weeks of age. 
Hepatic DMT1 (a) and Iregl (b) expression levels were analysed by Real Time PCR. In SWR 
mice ILD results in a significant increase in DMT1 and Iregl mRNA expression levels. Data 
are Means±SEMf n=5, *p<0.05.
In SWR wt mice hepatic Iregl mRNA expression levels did not change significantly with iron 
loading while in Hfe KO mice, Iregl expression levels increased significantly with ILD (Fig. 
4.1.3.14b).
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Figure 4.1.3.15 Hepatic DMT1 and Ire g l expression in the different lobes
of wt and Hfe KO SWR mice fed ILD. The whole liver was removed, divided into 
five lobes and DMT1 (a) and Iregl (b) expression was analysed in each lobe by Real 
Time PCR. No difference was observed between the mRNA expression levels of DMT1 
and Iregl in the five lobes. Data are Mean±SEM, n=5.
When hepatic DMT1 and Iregl expression levels were analysed in each lobe of the liver, no 
difference was found on expression levels of either iron transporter in wt or Hfe KO SWR 
mice (Fig. 4.1.3.15).
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4.1.3.2 Conclusions
4.1.3.2.1 Hepatic hepcidin, DMT1 and Iregl expression levels in SWR wt mice fed iron 
deficient (IDD) and iron loaded diet (ILD)
In SWR wt mice feeding an iron deficient diet (IDD) for 9 weeks after weaning decreased 
significantly hepcidin mRNA expression level while an iron loaded diet did not have an effect 
on hepcidin expression (Fig. 4.1.3.16).
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Figure 4.1.3.16 Dietary iron and hepcidin expression in wt SWR mice
SWR wt mice were fed an iron deficient diet (IDD) and an iron loaded diet (ILD) for 9 
weeks after weaning. Hepcidin 1 mRNA expression levels were analysed by Real Time 
PCR. IDD led to a significant decrease (*p<0.05) while ILD had no effect on hepcidin 
expression levels. Data are Mean±SEMf n=6.
Iron deficient diet decreased significantly DMT1 expression in the liver of wt mice whereas 
iron loaded diet resulted in a significant increase in DMT1 mRNA expression levels in these 
mice (Fig. 4.1.3.17).
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Figure 4.1.3.17 Effect of dietary iron in iron transporter gene expression in 
wt SWR mice. SWR wt mice were fed an iron deficient diet (IDD) and an iron 
loaded diet (ILD) for 9 weeks after weaning. Hepatic DMT1 and Iregl mRNA 
expression levels were analysed by Real Time PCR. Iron deficient diet led to a 
decrease in DMT1 expression and an increase in Iregl expression. Iron loaded diet 
significantly increased hepatic DMT1 and Iregl expression. Data are Mean±SEM, 
n=6r *p<0.05.
Hepatic Iregl expression in wt SWR mice was significantly up regulated by iron deficient diet 
and iron loaded diet (Fig. 4.1.3.17).
4.1.3.2.2 Hepatic hepcidin, DMT1 and Iregl expression levels in SWR Hfe KO mice fed 
iron deficient (IDD) and iron loaded diet (ILD)
In Hfe KO SWR mice, feeding an iron deficient diet did not have an effect on hepcidin 
expression levels whereas feeding an iron loaded diet resulted in a significant increase in 
hepcidin mRNA expression levels (Fig. 4.1.3.18).
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Figure 4.1.3.18 Dietary iron and hepcidin expression in Hfe KO SWR mice.
SWR Hfe KO mice were fed an iron deficient diet (IDD) and an iron loaded diet (ILD) 
for 9 weeks after weaning. Hepcidin 1 mRNA expression levels were analysed by Real 
Time PCR. ILD led to a significant increase (**p<0.001) while IDD had no effect on 
hepcidin expression levels. Data are Mean±SEM/ n=6.
Hepatic DMT1 expression levels were increased significantly when Hfe KO mice were fed on 
an iron deficient diet while an iron loaded diet did not have an effect on DMT1 expression 
(Fig. 4.1.3.19a). Feeding iron deficient and iron loaded diet increased hepatic Iregl 
expression levels in Hfe KO SWR mice (Fig. 4.1.3.19b).
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Figure 4.1.3.19 Effect of dietary iron on iron transporter gene expression in 
Hfe KO mice. SWR Hfe KO mice were fed an iron deficient diet (IDD) and an iron 
loaded diet (ILD) for 9 weeks after weaning. Hepatic DMT1 and Iregl mRNA 
expression levels were analysed by Real Time PCR. An iron deficient diet increased 
significantly DMT1 expression levels while an iron loaded diet had no effect on 
hepatic DMT1 expression. Hepatic Iregl levels were increased significantly by IDD 
and ILD (*p<0.05). Data are Mean±SEM, n=6.
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4.2.1 Effect of Apotransferrin and holotransferrin on haematological parameters, 
liver iron content and hepatic hepcidin, DMT1 and Ire g l gene expression in 
w t and Hfe KO SWR mice
4.2.1.1 Haematological parameters of wt and Hfe KO mice injected with apotransferrin or 
holotransferrin
SWR wt and Hfe KO mice injected with apotransferrin or holotransferrin were culled after 4 
hours. Serum iron levels in saline-treated Hfe KO SWR mice were higher than the ones seen 
in saline-treated wt SWR animals (wt 178.6±5.3; Hfe KO 216.6±27.4, n=4 per group) though 
not significantly while transferrin saturation was not different between wt and Hfe KO mice. 
Serum total iron and transferrin saturation did not change significantly in wt or Hfe KO mice 
following treatment with apotransferrin or holotransferrin (Table 4.2.1).
CONTROL APOTRANSFERRIN HOLOTRANSFERRIN
w t
Serum total iron 
(pm oi/L)
178.6±5.3 (4) 280.7±24.4 (3) 187.3±38.0 (5)
Transferrin 
Saturation (9b)
88.0±3.8 (4) 84.9±4.5 (3) 73.9±4.2 (5)
Hfe KO
Serum total iron 
(um oi/L)
216.6±27.4 (4) 308.6±2.0 (3) 264.7±21.8 (7)
Transferrin 
Saturation (9b)
84.9±3.6 (4) 86.6±3.6 (3) 82.6±3.4 (4)
Table 4.2.1 Serum total iron and transferrin saturation in w t and Hfe KO 
SWR mice treated with saline (controls), apotransferrin or holotransferrin.
SWR mice were injected at 12 weeks of age with apotransferrin (4 mg), 
hoiotransferrin/diferric transferrin (4 mg) or the equivalent volume of the diluent 
(saline). Mice were culled 4 hours later and blood was used for haematological 
parameters. No significant change in serum iron or transferrin saturation was found 
in animals injected with apotransferrin or holotransferrin. Data are Mean±SEM, with 
the number of samples analysed shown in brackets.
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4.2.1.2 Liver iron content in wt and Hfe KO SWR mice injected with apotransferrin and
Injection with apotransferrin or holotransferrin had no significant effect on the hepatic iron 
content of wt or Hfe KO SWR mice (Fig. 4.2.1).
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Figure 4.2.1 Hepatic iron content in response to apotransferrin and 
holotransferrin injections. SWR wt and Hfe KO mice were injected with either 
saline (Control), Apotransferrin or Holotransferrin. Animals were culled after 4 hours 
and hepatic iron content was quantified by modified Torrance & Bothweii method. 
There was no significant change in hepatic iron content after injections in wt or Hfe 
KO SWR mice. Data are Mean±SEM, n=5.
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4.2.1.3 Hepatic Hepcidin 1 gene expression in wt and Hfe KO SWR mice injected with 
apotransferrin and holotransferrin
Hepatic hepcidin 1 in saline treated animals was found to be lower in Hfe KO mice compared 
to controls (Fig. 4.2.2). Injection of apotransferrin and holotransferrin was found to have no 
effect on hepcidin expression in either wt or Hfe KO mice.
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Figure 4.2.2 Hepatic hepcidin 1 mRNA expression in SWR mice injected 
with apotransferrin and holotransferrin
Hepatic hepcidin 1 expression levels were determined by Real Time-PCR analysis. No 
significant difference on hepcidin was found after injection of apotransferrin or 
holotransferrin in wt and Hfe KO SWR mice. Results are expressed as Mean±SEMf 
n=4.
4.2.1.4 Hepatic DMT1 and IREG1 gene expression in wt and Hfe KO SWR mice injected 
with apotransferrin and holotransferrin
Hepatic DMT1 expression did not change with transferrin treatments in either wt or Hfe KO 
mice (Fig. 4.2.3a). Iregl expression levels in wt mice decrease significantly after injection 
with holotransferrin while apotransferrin injection had no effect (Fig. 4.2.3b). In Hfe KO mice 
Iregl expression was not change by either transferrin treatments.
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Figure 4.2.3 Expression of mRNA iron transporter genes after transferrin 
injections. SWR wt and Hfe KO mice were injected with saline (Control), 
apotransferrin (ApoTf) or holotransferrin (HoloTf) and sacrificed after 4 hours. 
Hepatic DMT1 (a) and Iregl (b) expression levels were analysed by Real Time PCR. 
Hepatic DMT1 expression did not change with transferrin injections in either wt or 
Hfe KO animals. Iregl expression levels in wt mice were decreased significantly by 
holotransferrin (*p<0.05) while apotransferrin injection had no effect. Transferrin 
treatments had no effect on Hfe KO mice Iregl expression. Results are expressed as 
Mean±SEM, n=4.
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4.3.1 Regulation of hepcidin mRNA expression levels in response to iron loading, 
iron deficiency and molecules produced by hereditary haemochromatosis 
macrophages in huh7 cells
Although the upregulation of hepcidin levels in response to iron was observed in humans and 
in mice it was not seen when in vitro hepatocytes were incubated with iron (Nemeth et al. 
2003;Pigeon et al. 2001) It is thought that this is due to the loss of expression of several 
liver-specific genes due to phenotypic changes that occur with time in culture (Ilyin et al. 
1998). In this study the effect of high iron and low iron levels on hepcidin expression in vitro 
was investigated using the human hepatoma cell line, Huh7.
As previously mentioned, in HH1 patients reticuloendothelial cells behave as though starved 
of iron (Andrews 1999;Andrews et al. 1999;Fleming et al. 1999;Zhou et al. 1998) with 
Kupffer cells only accumulating iron in very severe cases of the disorder. Reticuloendothelial 
cells, monocytes and tissue macrophages have a central role in regulating iron homeostasis 
as they recognise and phagocytose senescent and damaged erythrocytes, process iron from 
haem and return the iron to circulation for reuse by red cell precursors during erythropoiesis 
(Knutson and Wessling-Resnick 2003).
The importance of the Hfe gene in macrophages is not fully understood. Makui and 
colleagues (Makui et al. 2005) have shown that Hfe in macrophages participates in the 
regulation of splenic and liver iron concentrations and liver hepcidin while Montosi and 
colleagues have shown that when Kupffer cells are inactivated, hepcidin mRNA expression 
fails to respond to inflammation by cytokines. In addition this group has shown that the 
inactivation of Kupffer cells does not abrogate the response of hepcidin expression to iron 
overload suggesting that Kupffer cells are necessary for the hepcidin response to 
inflammation but not to its response to iron overload (Montosi et al. 2005). The relevance of 
Hfe in the upregulation of hepcidin expression in response to inflammation was reported by 
other groups (Roy et al. 2004) however contradictory results by Lou 2005 and Nemeth 2004
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have shown that iron- and inflammation-induced hepcidin gene expression is normal in 
Kupffer cell-depleted mice (Lou et al. 2005;Nemeth et al. 2004a).
In this study, the functional role of Hfe in peripheral macrophages and the contribution of the 
molecules produced by this cell type to the regulation of liver hepcidin are further 
investigated. Macrophages were isolated from HH1 patients with high levels of circulating iron 
and saturated transferrin. A human hepatoma cell line was then incubated with the 
conditioned medium collected from the macrophages culture and hepcidin expression levels 
were determined.
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4.3.2 Methods
4.3.2.1 Iron loading bv ferric ammonium citrate (FAQ and iron deficiency bv 
Desferoxamine (DFOl in human hepatoma cell line
The Huh7 human hepatoma cell line was obtained from Dr. Roozina Rafique (Department of 
Haematology, UCL, London, UK). HuH7 cells were grown in monolayer culture in RPMI 1640 
medium containing L-glutamine and 25 mM HEPES buffer, supplemented with 10% heat- 
inactivated foetal calf serum, 100 U/ml penicillin and 50 pg/ml gentamicin. Cells were seeded 
at a density of 1.5-2.0 x 105 cells per 80-cm2 flask (Nunclon, Nunc Brand) and grown at 37°C 
in a humidified atmosphere of 5% C02 in air. Cell viability was determined by Trypan blue 
dye exclusion.
Iron loaded cells were obtained by incubating Huh7 monolayers (in 60 mm cell culture 
dishes) with supplemented RPMI medium containing 10 pg/ml of Ferric Ammonium Citrate 
(FAC) for 24 hours (as described by Parkes et al (Parkes et al. 1995)). For the iron deficient 
studies, cells were incubated with 100 pM of Desferoxamine (DFO) for 24 hours. At the end 
of the incubation period, the FAC/DFO media was removed and the Huh7 cells were washed 
with PBS extensively and prepared for mRNA analysis as described in chapter 2.2.
4.3.2.2 Preparation of conditioned medium from macrophages of HH1 patients for Huh7 
cell culture
Hereditary haemochromatosis patients attending the Division of Hepatology and 
Transplantation (King's College Hospital, London, UK) homozygous for the C282Y mutation of 
the Hfe gene were selected. Blood samples were taken and mononuclear cells were isolated 
by the Ficoll-Paque Plus method (Amersham Biosciences UK Ltd., UK). These monocytes were 
then incubated with Lipoposaccharide (LPS) (Sigma, Poole, UK) for 20 hours in order to
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isolate and differentiate macrophages. Cell free-medium was collected for treatment of Huh7 
cultures (Ml). Macrophages were cultured for a further 24 hours and the medium was 
collected for treatment of Huh 7 cells cultures (M2). The mediums collected were then used 
in the culture of Huh7 cells with 5% autonomous serum or serum from a subject with a 
different genotype. After further 24 hours the medium was removed and cells were used for 
mRNA analysis (Fig. 4.3.1).
■
Remove 
medium from 
macrophages.
Mononuclear cells
Medium w/FCS +antibiotics and 
LPS (20 hours)
Add normal medium to 
the macrophages
M1 Remove 
medium from 
macrophages
\ Add M1 or M2 to Huh7 cells in culture, supplemented with serum
Figure 4.3.1 Preparation of the conditioned mediums used
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4.3.3 Results
4.3.3.1 Modulation of Iron Status in Huh7 cells: effect of iron on hepcidin and iron 
transporters mRNA expression levels
Huh7 cells were treated with Ferric Ammonium Citrate (FAC) to increase iron content of the 
cell and with Desferoxamine (DFO) to decrease iron content for 24 hours. Hepcidin mRNA 
expression levels were analysed by Real Time PCR. Treatment with FAC for 24 hours was 
shown to significantly decrease hepcidin expression (Fig. 4.3.2) and to stimulate NTBI uptake 
in Huh7 cells. Further investigation from our group has shown that this NTBI uptake 
stimulation occurs in a time- and concentration- dependent manner (personal communication 
by Dr. Roozina Rafique).
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Figure 4.3.2 Effect of iron loading and iron depletion on hepcidin 
expression in vitro. Hepcidin mRNA expression was determined by Real Time-PCR 
analysis on Huh7 cells pre-incubated with 10 pg Fe/mi FAC or 100 pM DFO for 24h at 
37°C. Hepcidin mRNA expression levels decrease significantly in response to iron 
loading but not in response to iron depletion (*p<0.05). Results are expressed as 
Mean±SEM/ n=6.
Our group has also shown that treating Huh7 cells with 100 pM DFO for 24 hours resulted in 
no detectable levels of iron, when measured by the total cellular iron assay (personal 
communication by Dr. Roozina Rafique). In this study we have shown that treatment of Huh7 
cells with DFO does not have a significant effect on hepcidin mRNA expression (Fig. 4.3.2).
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Iron transporters were also analysed in Huh 7 cells treated with FAC and DFO. No statistically 
significant changes were observed in the expression of DMT1 (+IRE) or DMT1 (-IRE) in 
response to iron loading and iron depletion, however DMT1 (-IRE) was down regulated by 
32% in response to 24 hours treatment with 100 fiM DFO. In response to iron depletion a 
significant 3-fold increase in TfRl expression was observed whilst no effect resulted from iron 
loading. TfR2 which is highly expressed in hepatocytes, was unaffected by changes in iron 
status (Table 4.3.1).
Control FAC DFO
DMT1+IRE 0.710 ± 0.09 0.840 ±0.260 0.680 ±0.100
DMT1 -IRE 0.470 ± 0.160 0.380 ±0.180 0.320 ±0.270
T fR l 0.110 ± 0.010 0.104 ± 0.020 0.301 ± 0.05***
TfR2 1.80 ± 0.370 1.70 ± 0.510 1.90 ± 0.380 |
Table 4.3.1 Regulation of mRNA expression of iron transporters in response to 
iron loading and depletion, in HuH7 cells. Real Time-PCR analysis of DMT1 ( +IRE and -  
IRE), TfRl and TfR2 was performed on RNA isolated from cells iron loaded with FAC or iron 
depleted with DFO for 24h and from control cells (no treatment). Results expressed as ratio 
Gene of interest/GAPDH (AU), Mean ± SD, n=4-9. (***p  <0.001)
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4.3.3.2 Regulation of hepcidin mRNA expression levels in response to serum iron levels and
soluble factors produced by hereditary haemochromatosis macrophages
Huh7 cells were incubated with serum from healthy subjects or serum from HH1 patients in 
addition to conditioned medium obtained from macrophages from healthy subjects or HH1 
patients macrophages in the presence (M l) or absence (M2) of LPS. When Huh7 cells were 
incubated with conditioned medium obtained from macrophages from healthy subjects and 
autologous serum or serum from HH1 patients, no difference was found in hepcidin mRNA 
expression levels (Fig. 4.3.3).
Hepcidin expression in Huh7 cells exposed to conditioned 
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Figure 4.3.3 Expression of hepcidin in Huh7 ceils incubated with 
conditioned medium from macrophages of healthy controls in the presence 
of autologous serum or serum from HH1 patients.
Macrophages were isolated from blood samples of healthy controls. Conditioned 
medium from the macrophages in the presence (M l) or absence (M2) of LPS and 
autologous serum (aS) or serum from HH1 patients (hS) was then used to incubate 
Huh7 cells for 24 hours. Hepcidin expression was analysed by Rea! Time PCR. 
Incubating Huh7 cells with macrophage-conditioned medium from healthy controls 
and serum from HH1 patients had no significant effect on hepcidin expression. Data 
are Mean±SEM/ n=5.
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Incubating Huh7 cells with conditioned medium obtained from HH1 patients macrophages 
and serum from healthy subjects upregulated hepcidin mRNA expression levels (Fig. 4.3.4).
Hepcidin expression in Huh7 cells exposed to conditioned 
medium from macrophages of HH1 patients
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Figure 4.3.4 Expression of hepcidin in Huh7 cells incubated with 
conditioned medium from macrophages of HH1 patients in the presence of 
autologous serum or serum from healthy controls.
Macrophages were isolated from blood samples of HH1 patients. Conditioned medium 
from the macrophages in the presence (M l) or absence (M2) of LPS and autologous 
serum (aS) or serum from HH1 patients (hS) was then used to incubate Huh7 cells 
for 24 hours. Hepcidin expression was analysed by Real Time PCR. Incubating Huh 7 
cells with macrophage-conditioned medium from HH1 patients and serum from 
healthy controls significantly increased hepcidin expression. Data are Mean±SEM, 
n=5.
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4.4  Discussion
Regulation of hepatic hepcidin. DMT1 and Ireal mRNA expression levels in response to 
dietary iron, holotransferrin and apotransferrin in wt and Hfe KQ mice
In this chapter the regulation of hepcidin expression by dietary iron, apotransferrin and 
holotransferrin in wt and Hfe KO SWR mice was studied. SWR wt and Hfe KO mice were fed 
different iron content diets ranging from low to high iron in order to investigate whether the 
Hfe gene has a role in the regulation of hepcidin expression in response to dietary iron. Our 
data shows that when fed an iron deficient diet (IDD) both wt and Hfe KO mice showed a 
decrease in serum and hepatic iron content. Interestingly transferrin saturation in wt mice 
decreased with IDD but in Hfe KO mice transferrin saturation increased though not 
significantly. When wt mice were fed ILD serum iron levels, transferrin saturation and hepatic 
iron content levels increased significantly in wt mice while in Hfe KO mice ILD increased 
serum iron levels and hepatic iron content levels but had no effect on transferrin saturation. 
Our data also shows that on a normal diet (OD), hepcidin expression levels are lower in the 
Hfe KO mice compared to wt mice and hepcidin expression is inappropriately low for the 
hepatic iron levels found in these animals. Although these low levels of hepcidin in Hfe KO 
mice have already been described (Ahmad et al. 2002;Bridle et al. 2003), there is no 
information on hepcidin expression levels in relation to different lobes of the liver. In this 
study we have shown that higher levels of hepcidin expression were found in lobe A, the 
hepatic lobe with the highest iron content although this did not reach statistical significance.
In SWR wt mice fed IDD hepcidin expression levels decreased significantly but this iron 
deficiency failed to have an effect on hepcidin expression in Hfe KO mice. Iron deficiency has 
been shown to downregulate hepcidin in other mouse strains (Bondi et al. 2005;Latunde- 
Dada et al. 2004;Nicolas et al. 2002b;Vokurka et al. 2006). It is thought that the low hepcidin 
levels lead to an increase in iron absorption to allow more iron to the bone marrow to sustain 
the erythrocyte production. As Hfe KO mice accumulate higher levels of iron in the liver it is
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possible that these iron stores prevent iron deficiency to upregulate hepcidin expression in 
these mice.
Iron loading by ILD in wt mice did not have an effect on hepcidin expression while in Hfe KO 
mice ILD for 9 weeks upregulated hepcidin mRNA expression levels. In iron overload 
conditions the increased hepcidin expression levels in iron overload conditions is thought to 
block iron absorption until the normal plasma iron levels are restored (Mazur et al. 
2003;Nemeth et al. 2004b;Pigeon et al. 2001). It has also been reported that in Hfe KO mice 
duodenal iron absorption decreases with age suggesting that Hfe KO mice down-regulate iron 
absorption when body iron stores reach certain levels (Ajioka et al. 2002). As hepatic iron 
stores increase in Hfe KO mice with age it is possible that this severe iron stores increases 
hepcidin expression which consequently results in a decrease in duodenal iron uptake. In 
support of this theory, the disruption of the Hfe gene in the AKR mouse strain has been 
found to have no significant effect on hepcidin expression levels in some experiments (Ahmad 
et al. 2002). AKR Hfe KO mice have been reported to have 2-3 fold higher hepatic iron 
content than wt ARK mice. In addition AKR mice like SWR mice have been shown to have a 
higher basal iron level than C57BL/6 or DBA/2 mouse strains (Fleming et al. 2001).
When fed a normal diet (CD) hepatic DMT1 and Iregl expression levels were not significantly 
different in wt and Hfe KO mice and no difference was observed between levels of expression 
of hepatic DMT1 or Iregl in the different hepatic lobes studied. In wt mice fed IDD, hepatic 
DMT1 expression was decreased as previously described (Scheiber-Mojdehkar et al. 
2003;Trinder et al. 2000b) while in Hfe KO mice hepatic DMT1 was upregulated by iron 
deficiency.
Hepatic Iregl expression was found to be upregulated in both wt and Hfe KO mice fed IDD. 
The increased erythropoiesis in mice fed an iron deficient diet might explain the upregulation 
of hepatic Iregl expression as more iron in the circulation would be necessary for the 
production of erythrocytes precursors.
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In wt mice, ILD led to an upregulation of DMT1 expression as previously reported (Scheiber- 
Mojdehkar et al. 2003;Trinder et al. 2000b). Interestingly hepatic DMT1 expression was also 
upregulated in Hfe KO mice fed on ILD. In the liver DMT1 is thought to be involved in the 
uptake of Tf-bound iron through the TfRl and TfR2 pathways (Trinder et al. 2000a;Trinder 
and Morgan 1997) and it has been thought to contribute to the uptake of NTBI at the cell 
surface although further investigation is required. Although DMT1 expression is upregulated 
by iron deficiency in the duodenum, in the liver DMT1 levels have been described to be 
enhanced by iron loading (Scheiber-Mojdehkar et al. 2003;Trinder et al. 2000b). It has been 
hypothesised that this upregulation of hepatic DMT1 in iron loaded conditions helps reduce 
the circulating NTBI and prevents its toxic effect; however DMT1 has been shown to have a 
limited role in iron loading of the liver. Inactivation of DMT1 in animal models (Gunshin et al. 
2005) and DMT1 mutations in humans (Beaumont et al. 2006;Iolascon et al. 2006;Mims et al.
2005) result in severe microcytic anaemia accompanied with severe iron overload. 
Furthermore although DMT1 expression levels in the liver are upregulated by iron loading, 
Trinder et al (Trinder et al. 2002b) have shown that there are no significant differences in the 
rate of NTBI uptake by the liver in the Hfe KO mice compared to control mice. All these 
findings suggest that DMT1 in the liver is not involved in iron uptake and therefore the 
possibility of alternative mechanisms of NTBI uptake into the liver needs to be considered. In 
conclusion the present study and the already published data (Chua et al. 2004) show that to 
date it is not possible to determine whether the increase in hepatic DMT1 expression and the 
increase in uptake by the hepatocytes are the primary cause of iron loading or the secondary 
to iron loading by another mechanism.
Iron loading had no significant effect on hepatic Iregl expression in wt mice but in Hfe KO 
mice ILD for 9 weeks upregulated Iregl expression significantly. As in enterocytes, Iregl is 
considered to be an iron exporter in the hepatocytes. The finding that Iregl was upregulated 
in Hfe KO mice fed ILD suggests that the hepatocytes have an excretion mechanism to avoid 
severe iron accumulation and subsequent liver damage. In support of this hypothesis, 
Bonkovsky et al observed that when iron loaded rats were changed to a carbonyl-free diet
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there was a 50% reduction in total liver iron. More recently Oates et al have shown that 
within two days of changing from an iron loaded diet to an iron deficient diet, non-haem iron 
levels significantly fall by 30%. Bonkovsky and Oates also observed that in animals fed on 
ILD iron accumulation stabilised after falling to a certain level of liver iron with animals fed on 
ILD having 10-times higher liver iron content than animals fed on a normal diet (Bonkovsky 
et al. 1987;Oates et al. 2000).
The upregulation of hepatic Iregl expression seen in the Hfe KO mice in this study has also 
been reported in HH1 patients (Bridle et al. 2003). This finding together with the discovery 
that mutations to a single copy of the Iregl gene result in tissue iron loading and the data 
from Bonkovsky and Oates on iron excretion confirms that Iregl plays a protective role by 
facilitating the release of iron from the liver in iron overload conditions.
The loss of the Hfe gene in Haemochromatosis type 1 patients results in a defective 
regulation of dietary iron absorption that leads to increased serum transferrin saturation. It 
also results in a decrease in circulating hepcidin, which leads to increased ferroportin- 
mediated iron efflux from reticuloendothelial cells and duodenal enterocytes (Ahmad et al. 
2002;Bridle et al. 2003;Muckenthaler et al. 2003). This increased Iregl-mediated iron efflux 
eventually leads to increased circulating iron concentrations and Tf to become saturated. 
Therefore, circulating diferric transferrin is thought to be a candidate for the erythroid 
regulator. It is possible that the levels of diferric Tf in the circulation could provide the 
necessary signal for the hepatocytes to detect body iron demand and subsequently alter 
hepcidin expression (Frazer and Anderson 2003). Here we have shown that injections of wt 
and Hfe KO SWR mice with apotransferrin and holotransferrin (diferric transferrin) have no 
significant effect on serum iron, transferrin saturation or hepatic iron content.
Apotransferrin injection in wt SWR mice had no effect on hepcidin expression mRNA levels 
while holotransferrin upregulated hepcidin expression levels though not significantly. The 
same response was observed in Hfe KO mice suggesting that Hfe is not involved in the 
regulation of hepcidin expression by apotransferrin or holotransferrin.
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Hepatic DMT1 expression did not change in either wt or Hfe KO after apotransferrin and 
holotransferrin injections while hepatic Iregl expression levels decreased significantly after 
holotransferrin treatment. Apotransferrin injection had no effect on the expression of Iregl 
iron exporter in wt or Hfe KO mice. Iron stores have been reported not reflect transferrin 
saturation, suggesting that different genetic factors control transferrin saturation and hepatic 
iron stores. When mice were fed a high-iron diet, the concentration of carbonyl iron required 
to completely saturate transferrin with iron was significantly different between mouse strains 
(Leboeuf et al. 1995) and in this study, injections of apotransferrin and holotransferrin did not 
have an effect on transferrin saturation. It is therefore hypothesized that the concentration of 
holotransferrin in the present study was insufficient to cause a significant effect on hepcidin 
or iron transporter gene expression in the SWR mice. Or that SWR mouse strain requires a 
higher concentration of carbonyl iron to saturate transferrin with iron. However the data 
suggests that holotransferrin, also called diferric transferrin might be regulated by iron and 
this requires further investigation.
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Regulation of hepcidin and iron transporter oene mRNA expression levels in response to iron
loading, iron deficiency and molecules produced by macrophages from hereditary 
haemochromatosis patients in Huh7 cells
In this chapter how hepcidin mRNA expression is regulated by iron in a hepatoma cell line 
was also investigated. The differential effect of blood macrophages from HH1 and controls on 
hepcidin mRNA expression levels in Huh7 cells in culture was also examined.
Hepcidin expression levels in response to iron deficiency and to iron loading was investigated 
by exposing a hepatoma cell line (Huh7) to Desferoxamine (DFO) and to ferric ammonium 
citrate (FAC). In this study Huh7 cells treated with DFO showed a decrease in hepcidin 
expression levels though this failed to reach significance while Huh7 cells treated with FAC 
showed a significant decrease in hepcidin expression levels.
The upregulation of hepcidin in response to high iron has been observed in mice (after iron 
dextran injections) and humans (dietary iron), but not when hepatocytes are exposed to iron 
in vitro (Pigeon et al. 2001). The results of this study support the idea that Huh7 cells lose 
expression of several liver-specific genes due to phenotypic changes that occur with time in 
culture and therefore do not respond to iron as in vivo cells (Ilyin et al. 1998).
Although DMT1 has been proposed as an obvious candidate for NTBI uptake by hepatocytes 
(Chua et al. 2004;Trinder et al. 2000b) due to its optimal iron transport activity at acid pH of 
5.5 (Gunshin et al. 1997) several lines of evidence from cell culture studies do not support 
this notion and therefore it is unlikely that DMT1 contributes to the iron uptake in Huh7 cells. 
Studies from our group have shown that at low pH, when transport by proton-dependent 
DMT1 is optimal, ferrous iron uptake was significantly blocked in differentiated Caco-2 cells 
expressing DMT1 but not in Huh7 cells. This finding suggests that iron uptake in Caco-2 cells 
and in Huh7 cells is pH dependent that although DMT1 is involved in iron uptake in Caco-2 
cells, in Huh7 cells an alternative iron transporter must exist. There was no significant 
increase in DMT1 (+ire) or DMT1 (-ire) expression in Huh7 cells in response to iron loading in
159
this study, confirming that DMT1 is not responsible for the FAC-stimulated NTBI uptake rate. 
These findings are consistent with those of Gunshin et a/(Gunshin et al. 2001) who observed 
no change in mRNA DMT1 expression levels in Hep3B cells in response to iron loading with 
FAC. Exposure of Huh7 cells to DFO had no effect on DMT1 (+ire) expression while DMT1 (- 
ire) expression was slightly (32%) decreased.
The expression of TfRl and TfR2 were also analysed in Huh7 cells after treatment with FAC 
and DFO. Iron depletion caused a significant increased in TfRl although this was 
accompanied by down regulation of iron uptake rate. Expression levels of TfR2 did not 
change with FAC and DFO exposure suggesting that TfR2 does not mediate FAC-induced 
NTBI uptake nor is regulated by iron as reported previously in mouse liver (Fleming et al. 
2000).
As transferrin levels did not have a significant effect on hepcidin expression levels we 
hypothesised that macrophages of HH1 patients could be producing soluble factors that 
regulate hepcidin expression differently in HH1 patients and healthy subjects. In this study, 
Huh7 cells were incubated with conditioned medium from HH1 patients and healthy subjects 
macrophages and either autologous serum or serum from a different genotype. Data shows 
that serum iron levels or conditioned medium from macrophages does not have an effect on 
hepcidin expression levels. Huh7 cells incubated with macrophage-conditioned medium from 
HH1 patients and serum from healthy subjects up regulated significantly hepcidin expression 
although this could be a secondary effect of the presence of LPS in the culture medium. 
Overall, data suggests that peripheral macrophages do not have a role in the production of 
soluble factors that could regulate hepcidin expression levels in HH1 patients.
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Conclusions
In conclusion the study of the regulation of hepcidin and iron transporter genes expression in 
response to dietary iron, apotransferrin and holotransferrin in wt and Hfe KO mice and the 
regulation of hepcidin and iron transporter genes expression in response to iron loading and 
iron depletion in Huh7 cells suggest the presence of a regulatory iron pool in hepatocytes that 
directly regulates hepcidin expression levels.
Our data also suggests that iron regulates hepatic Iregl mRNA expression in a direct manner 
and not through the regulation of hepcidin expression levels. Furthermore our data shows 
that Hfe gene is not necessary for the regulation of Iregl in response to iron in accordance 
with the findings of Bridle and colleagues (Bridle et al. 2003) showing that in HH1 patients 
and in Hfe KO C57BL/6 mice, iron stores regulate hepcidin expression but have no effect on 
Iregl expression. We hypothesised that in cases of disruption of Hfe or when mice are fed an 
iron loaded diet, hepatocytes accumulate the iron in this "regulatory iron pool". When this 
pool reaches a yet unknown iron content level, Iregl expression level in hepatocytes is 
upregulated and the excess iron is exported to avoid oxidative stress and lipid peroxidation in 
the liver. The iron accumulation in this "regulatory iron pool" would regulate hepcidin in the 
same manner, when iron stores reach a certain level, hepcidin is upregulated in order to 
decrease duodenal iron uptake. This would explain why iron loaded diet in Hfe KO mice 
upregulates hepcidin expression.
Taken together from the previously published data and the results obtained in this study we 
can conclude that dietary iron (in SWR mice) or iron loading (in Huh7 cells) does not have a 
direct effect on hepatic DMT1 expression and therefore it is possible that in the case of the 
Hfe KO mice, the Hfe gene might have a role in the regulation of this iron transporter gene 
expression, but this requires further investigation.
In addition we have shown that iron deficient peripheral macrophages lacking the Hfe gene 
do not produce any soluble factors that regulate hepcidin expression in the setting of 
hereditary haemochromatosis compared to healthy subjects.
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Chapter 5
I n fl a m m a t io n  a n d  h e p c id in
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5.1 Introduction
In cases of infection and inflammation the maintenance of body iron homeostasis is 
disregulated resulting in anaemia of inflammation (Al). Anaemia of Inflammation is 
characterised by inadequate erythrocyte production in the setting of low serum iron and low 
iron-binding capacity (i.e. low transferrin) despite preserved or even increased macrophage 
iron stores in the bone marrow. Despite having low serum iron and low transferrin, patients 
with Al have high serum ferritin concentration. The anaemia is caused by increased 
inflammatory cytokines and the changes in iron metabolism are due to the effects of these 
cytokines as described in chapter 1.
Pro-inflammatory cytokines have been shown to act on a number of cell types to decrease 
iron release (Johnson et al. 2004;Ludwiczek et al. 2003;varez-Hernandez et al. 1989;Yang et 
al. 2002) and promote the cellular sequestration of iron in ferritin (Miller et al. 1991;Torti et 
al. 1988). More specifically the pro-inflammatory cytokine IL-6 induces an increased 
production of the iron regulatory hormone hepcidin by hepatocytes, which blocks the release 
of iron from macrophages, hepatocytes, and enterocytes causing hypoferraemia (low serum 
iron). Although this hypoferraemia provides protection against proliferating microorganisms 
(Ashrafian 2003) it also results in the iron deprivation of the developing erythrocytes and 
leads to the development of anaemia (Ganz 2005b).
As iron homeostasis is tightly regulated at the intestinal level and therefore it is important to 
assess the influence of inflammatory cytokines on this transport pathway. Previous work has 
demonstrated that a mixture of pro-inflammatory cytokines (that includes tumour necrosis 
factor a (TNF-a) and interleukin 6 (IL-6) are produced in inflammatory conditions such as 
acute inflammation due to LPS injection (Ganz 2003). TNF-a and IL-6 treatment has shown to 
decrease iron transport in intestinal Caco-2 cells (Han et al. 1997). Furthermore, studies by 
our group and those of others have shown that TNF-a alone can act directly on intestinal 
epithelial cells to regulate the expression of iron transport proteins (Johnson et al. 
2004;Sharma et al. 2005).
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As mentioned previously, hepcidin expression dramatically increases with the onset of 
inflammation (Frazer et al. 2004b;Johnson et al. 2004;Nemeth et al. 2004a;Nicolas et al. 
2002b;Park et al. 2001;Pigeon et al. 2001;Rivera et al. 2005a) and this appears to be co­
ordinated, at least in part, through the actions of IL-6 released by Kupffer cells/ macrophages 
(Nemeth et al. 2003;Nemeth et al. 2004a). High levels of hepcidin, in turn, are known to 
decrease intestinal iron absorption (Laftah et al. 2004;Roy et al. 2004;Roy and Andrews 
2005;Yamaji et al. 2004), and hence this represents an alternative route by which IL-6 might 
influence intestinal iron metabolism. A LPS injection in human subjects dramatically induces 
IL-6 within 3 hours, induces urinary hepcidin and leads to a significant decrease in serum iron 
(Kemna et al. 2005) while IL-6 injection in human volunteers induces hepcidin and 
hypoferremia within just 2 hrs (Nemeth et al. 2004a).
Mice with disruption of the gene encoding IL-6 have been reported to have a small response
to LPS which makes it unclear whether LPS is stimulating the secretion of cytokines other 
than IL-6 that may stimulate hepcidin transcription (Nemeth et al. 2004a).
Recently, it has been reported that IL-6 directly induces hepcidin through STAT3 activation 
and subsequent hepcidin promoter binding. This provides a mechanism by which hepcidin can 
be regulated by inflammation or, in the absence of inflammatory stimuli, by alternative 
mechanisms leading to STAT3 activation (Pietrangelo et al. 2007;Wrighting and Andrews
2006).
Turpentine injections in mice also result in increased liver hepcidin gene expression, a 
reduction in RBC mass, haemoglobin, and serum iron (hypoferremia), leading to anaemia 
(Nicolas et al. 2002b;Weinstein et al. 2002) The finding that the hypoferraemic response to 
turpentine-induced inflammation was absent in the USF2/hepcidin-deficient mice, confirms 
that this response is fully dependent on hepcidin.
In vivo inactivation of Kupffer cells abrogates the stimulatory effect of both LPS and
turpentine on hepcidin expression confirming that macrophages are releasing cytokines that 
up regulate hepcidin in inflammation conditions (Montosi et al. 2005). High levels of hepcidin 
lead to Iregl internalisation and degradation, therefore blocking the pathway for the transfer 
of iron from the enterocyte to plasma (Ganz 2005a) and trapping the iron within the
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macrophages. This proposed model confirms the earlier finding that during inflammation, 
Iregl is downregulated in macrophages (Yang et al. 2002).
The effect of LPS stimulation on hepcidin expression levels in Hfe KO mice and the 
requirement of Hfe or other genes for the up-regulation of hepcidin in inflammation 
conditions is less clear. Some reports have shown that Hfe KO mice do not respond to LPS 
stimulation or develop hypoferremia (Roy et al. 2004), in other reports the response to LPS 
injections differs strikingly from animal to animal (Lee et al. 2004) and a recently published 
paper has reported that although basal hepcidin levels were manifestly dependent on the 
presence of Hfe and on the mouse background, Hfe KO mice were still able to regulate 
hepcidin in situations of altered iron homeostasis such as inflammation by LPS (Constante et 
al. 2006). Injection of IL-6 in TfR2 mutated mice had an effect on hepcidin levels suggesting 
that the signalling pathway activated by IL-6 does not require TfR2 (Lee et al. 2004). The 
contradictory results on the role of Hfe in up regulation of hepcidin by acute inflammation 
suggest that the study of Hfe KO mice in the inflammatory setting requires further 
investigation.
To investigate whether IL-6, like TNF-a could directly regulate intestinal iron transporter 
expression, Caco-2 cells, a model human intestinal epithelial cell line which phenotypically 
resembles small intestinal enterocytes (Chantret et al. 1994;Sharp et al. 2002) were used. 
This cell line was also used to investigate the effect of hepcidin on iron transporter genes, 
namely DMT1 and IREGl. A human hepatoma cell line (Huh7 cells) was also used to 
determine how pro-inflammatory interleukins regulate hepcidin expression levels.
To investigate the effect of acute inflammation on hepcidin expression levels, SWR wt mice 
were injected with Lipopolysaccharide (LPS) for 1.5 hours, 6 hours, the time at which 
maximal response of hepcidin transcription has been noted (Yeh et al. 2004) and 16 hours. 
Mice were also injected with Turpentine oil for 16 hours. To further understand the role of 
the Hfe gene and the up regulation of hepcidin, SWR Hfe KO was also subjected to acute
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inflammation by LPS and Turpentine. The expression of iron transporter genes and liver iron 
content was also studied in both wt and Hfe KO SWR mice after acute inflammation 
treatment.
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5.2 Methods
5.2.1 Pro-inflammatory cvtokines treatment of hepatocytes and enterocytes
Caco-2 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal 
bovine serum for 21 days on Transwell inserts (Coming-Costar, High Wycombe, UK) to 
achieve a fully differentiated monolayer. For the final 24 h of the culture period, the cells 
were incubated in serum-free medium containing lOng/ml of IL-6 (or an equal volume of the 
vehicle in the control groups) added to the basolateral chamber. Huh7 cells were cultured in 
RPMI1640 medium (Sigma) containing L-Glutamine (Sigma), antibiotics and 10% FCS 
(Sigma) and maintained in 5% C02 at 37oC. The cells were seeded in 5cm2 wells till 
confluent. Once confluent, cells were treated with IL-6 (0.5ng/ml & lOng/ml), and TNF-a 
(lOng/ml) for 24 hours. After removing the culture medium, Huh7 and Caco-2 cells were 
washed with PBS and prepared for Real Time PCR amplification as described in section 2.1.
5.2.2 IL-6-stimulated Huh 7 cells conditioned medium treatments of Caco-2 cells
Conditioned medium (CM) was collected from IL-6 stimulated Huh7 cells and added to the 
basolateral chamber of Caco-2 cell containing Transwell plates for 24 hours. In addition the 
produced conditioned medium was incubated in the presence and absence of hepcidin anti­
human antibody (raised in-house) for 20 minutes at room temperature. This conditioned 
medium containing the hepcidin antibody (Hepc Ab-medium) was then added to the Caco-2 
cells for 24 hours as described above. Cells were harvested and prepared for Real Time PCR 
amplification as described in section 2.1.
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5.2.3 Inflammation by LPS and Turpentine in SWR mice
SWR mice were fed on an iron adjusted diet (44 mg iron/kg) for 9 weeks after being weaned 
(3 weeks of age). Two different strategies were used to induce inflammation: 
lipopolysaccharide (LPS) or turpentine oil injections. SWR male mice were given one 
intraperitoneal injection of 5pg of LPS (Sigma, Poole, UK) or an interscapular fat pad injection 
of 0.1mL/20g of body weight of Turpentine oil (Sigma, Poole, UK) in a buffered saline. Mice 
were sacrificed 16 hours after injection; tissues were collected and snap frozen for mRNA 
studies. RNA was extracted and prepared for Real Time PCR analysis as described in section 
2.2.
Liver samples were also collected for hepatic iron content levels as described in section 3.2.2. 
Blood was collected by cardiac puncture and serum iron and transferrin saturation was 
analysed using a commercially available assay (Randox Laboratories Ltd. Antrim, UK).
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5.3 Results
5.3.1 Effect of pro-inflammatory cvtokines
5.3.1.1 Duodenal iron transporter gene expression
Treatment of Caco-2 cells with the cytokine interleukin 6 had no effect on the mRNA 
expression of iron transporters DMT1+IRE or Iregl (Fig. 5.3.1). Work from our group has 
shown that interleukin 6 treatment has also no effect on the protein levels of DMT1 or Iregl 
(personal communication by Dr. Paul Sharp).
DMT1 Iregl
Figure 5.3.1 Effect of IL-6 on mRNA expression levels of iron transporters 
in Caco-2 cells. Quantitative PCR analysis of iron transporter transcripts in Caco-2 
cells demonstrated that DMT1 (+IRE) and IREG1 mRNA expression was unaltered 
following incubation with IL-6 (light blue bars) compared with untreated control 
cells (dark blue bars). Data are expressed as Mean± SEM from 4 separate 
experiments.
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5.3.1.2 Hepatic hepcidin mRNA expression
Inflammation studies in Huh7 cells demonstrated that hepcidin mRNA expression levels 
significantly increase following exposure to IL-6 but not to TNF-a compared to unstimulated 
Huh7 cells. Interleukin 6 treatment of 0.5ng/ml increased the mRNA expression of Hepcidin 
by 2-fold and the treatment of lOng/ml of IL-6, caused a 4-fold increase in Huh7 cells 
compared to non-treated Huh7 Cells. Hepcidin expression was not significantly altered in 
Huh7 cells incubated in the presence of TNF-a (Fig 5.3.2).
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Figure 5.3.2 Quantitative PCR analysis of hepcidin expression in Huh7 cells 
following cytokine treatment. Huh7 cells were incubated for 24 h in the presence 
of either TNF-a (lOng/mi) or IL-6 (0.5ng/mi and lOng/mi). Quantitative PCR analysis 
of total RNA isolated from Huh7 cells demonstrated that hepcidin mRNA levels were 
significantly increased following exposure to IL-6. Hepcidin expression in cells 
stimulated with TNF-a was not significantly different from the unstimulated controls. 
Data are Mean± SEM from 4 separate experiments, **p<0.005.
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5.3.1.3 Duodenal iron transporter aene expression in Caco-2 cells exposed to IL-6-
stimulated Huh7 cells conditioned medium
Caco-2 cells that were exposed (at their basolateral surface) to conditioned medium from IL- 
6-stimulated Huh7 cells showed a decreased in DMT1 (+IRE) mRNA expression though not 
significantly compared to the Caco-2 cells that were exposed to quiescent cells (Fig. 5.3.3). 
Iregl mRNA expression levels were not changed by the conditioned medium containing 
Hepcidin.
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Figure 5.3.3 Iron transporter mRNA expression in Caco-2 cells stimulated 
with hepcidin-containing medium from IL-6 stimulated HuH7 cells. Analysis 
of total RNA isolated from Caco-2 cells exposed to IL-6-conditioned medium 
demonstrated that DMT1 (+IRE) mRNA expression was decreased though not 
significantly, in cells exposed to the hepcidin-containing medium (light blue bars) 
compared with those incubated medium from unstimulated HuH7 cells (dark blue 
bars). IREG1 expression was not altered in these cells. Data are Mean±SEM of 3-4 
measurements in each experimental group.
To further investigate whether the release of hepcidin due to IL-6 treatment was responsible 
for the changes in duodenal DMT1 and Iregl expression, CM (conditioned medium from IL-6- 
stimulated Huh7 cells) was incubated with an anti-human Hepcidin antibody prior to its 
addition to the basolateral chamber of the Caco-2 cell-containing Transwell plates. Results
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show that DMT1 and Iregl expression levels increase significantly in Caco-2 cells treated with 
conditioned medium pre-incubated with an anti-human Hepcidin antibody (Fig. 5.3.4).
Figure 5.3.4 Iron transporter mRNA expression in Caco-2 cells stimulated 
with hepcidin-containing medium from HuH7 cells pre-incubated with anti­
human hepcidin antibody. Analysis of total RNA isolated from Caco-2 cells 
exposed to IL-6-condit/oned medium pre-incubated with anti-human hepcidin 
antibody (Hepc Ab-medium) demonstrated that DMT1 (+IRE) and Iregl (FPN) mRNA 
expression was significantly upregulated in cells exposed to Hepc Ab-medium (grey 
bars) compared with those incubated with CM atone (black bars). Data are 
Mean±SEM of 3-4 measurements in each experimental group, *p<0.05).
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5.3.2 Effect of inflammation on serum iron levels in SWR wt and Hfe KQ mice
Two different strategies were used to induce inflammation in SWR wt and Hfe KO mice: 
lipopolysaccharide (LPS) or turpentine oil (Turps) injections. SWR wt and Hfe KO mice were 
treated with LPS for 1.5, 6 and 16 hours. Treatment for 1.5 hours with LPS in SWR wt mice 
did not cause a change in the serum iron levels. Treatment for 6 hours resulted in a decrease 
in serum iron in wt mice though not significantly and no change in transferrin saturation 
(Table 5.3.1). In addition treatment for 16 hours caused a significant hypoferremia and a 
decrease in transferrin saturation in wt SWR mice. None of the treatments of LPS given to 
Hfe KO mice led to changes in serum iron levels (Table 5.3.1) but transferrin saturation was 
significantly decreased 16 hours post-treatment.
Treatment
Wild type (w t) SWR mice Hfe KO SWR mice
Total Serum 
iron (pm ol/L)
Transferrin 
Saturation f% )
Total Serum 
iron (pm ol/L)
Transferrin 
Saturation (9b)
6 hours
Control 89.4-126.1 (2) 74.5-83.2 (4) 181.5-192.3(2) 77.7-93.5 (4)
LPS 47.5-57.7 (2) 68.9-72.0 (3) 69.7-150.4(3) 85.3-92.4 (3)
16 hours
Control 130.1-205.0 (3) 68.8-84.1 (4) 200.7-499.0(6) 80.0-87.4 (4)
LPS 24.2-49.7(3)** 39.2-40.3 (3 )** 61.8-286.0(4) 45.6-62.2 (3 )**
Table 5.3.1 Total Serum iron and transferrin saturation after LPS treatm ent. Male 
SWR wt and Hfe KO mice 12 weeks old were injected with 5pg of LPS and sacrificed after 
1.5, 6 and 16 hours. Treatment for 1.5 hours did not change the serum iron levels or 
transferrin saturation in either wt or Hfe KO SWR mice. Treatment for 6 hours caused a 
decrease in serum iron in both wt and Hfe KO mice though not significantly and treatment for 
16 hours led to a significant hypoferremia in wt SWR mice ( *p<0.05, **p<0.005). Treatment 
for 16 hours with LPS did not have a significant effect on serum iron levels in Hfe KO mice 
a/though transferrin saturation was significantly decreased in these mice compared with non­
treated animals. Data are Mean±SEM/ number of samples stated in brackets.
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Treatment with turpentine resulted in a significant decrease in total serum iron and 
transferrin saturation in wt SWR mice (Table 5.3.2). Treatment of Hfe KO SWR mice with LPS 
for 16 hours had no effect on serum iron levels or transferrin saturation.
SWR MICE CONTROL TURPENTINE P
w t
Serum total iron 
(pmol/L) 85.2-177.1 (4) 43.1-84.8 (5) <0.01
Transferrin 
Saturation (% ) 70.3-83.2 (3) 41.3-44.0 (3) <0.05
Hfe KO
Serum total iron 
(pmol/L) 221.5-326.6 (6) 274.8-462.0 (7) >0.05
Transferrin 
Saturation (% ) 81.0-92.0 (4) 79.4-95.1 (3) >0.05
Table 5.3.2 Total serum iron and transferrin saturation after Turpentine injection.
SWR wt and Hfe KO mice were injected with turpentine oil (0.1mi/20g body weight) and 
sacrificed after 16 hours. Injection of Turpentine resulted in a significant hypoferremia in wt 
SWR mice accompanied with a significant decrease in transferrin saturation. No change in 
serum iron levels or transferrin saturation was observed in Hfe KO SWR mice injected with 
turpentine oil. Data are Mean±SEM/ number o f samples described in brackets.
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5.3.3 Effect of acute inflammation by LPS and Turpentine on hepatic iron content, hepatic
hepcidin. DMT1 and Ireal gene expression in wt SWR mice
5.3.3.1 Effect of acute inflammation on hepatic iron content in wt SWR mice
Liver iron content was analysed in wt SWR treated with LPS and Turpentine oil for 16 hours. 
Acute inflammation induced by both LPS and turpentine oil treatment had no effect on 
hepatic iron content levels (Fig. 5.3.5).
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Figure 5.3.5 Liver iron content levels in wt SWR mice in acute inflammation
Mice injected with LPS and turpentine were sacrificed after 16 hours; the whole liver 
was removed and divided into five lobes. Iron was quantified in each lobe and the 
average of the iron content in each whole liver was calculated. Treatment of wt SWR 
mice with LPS and turpentine oil had no effect on hepatic iron content levels. Data 
are Mean±SEM/ Control n=6; LPS n=3; Turps n=3.
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Hepatic iron content was analysed in each lobe of the liver and no difference was found 
between the iron content of lobe A and the other four lobes (B-E) in wt SWR mice treated 
with LPS or turpentine oil (Table 5.3.3).
SWR MICE TREATMENT LOBE A IRON 
CONTENT 
(pg/gdryweight)
LOBE B-E IRON 
CONTENT 
(pg/gdryweight)
w t
Saline 136.2±13.4 180.2±22.1
LPS 272.8±14.5 185.6±26.1
Saline 271.2±23.5 265.1±61.8
Turpentine o il 183.2±21.3 126.4±17.9
Table 5.3.3 Hepatic iron in w t SWR mice treated w ith LPS or Turpentine oil for 16 
hours. The liver o f wt mice treated with LPS and turpentine oil mice was divided into five 
lobes as described in chapter 3 and the iron content o f each lobe was quantified. There was 
no difference between the iron content of lobe A and the other four lobes (B-E) in wt SWR 
mice treated with LPS. Data are Mean±SEM/ n=3.
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5.3.3.2 Effect of inflammation on hepatic hepcidin 1 gene expression in wt SWR mice
Hepcidin mRNA expression levels were analysed by Real Time PCR. Treatment with LPS for 
1.5 hours had no effect on hepcidin levels while treatment for 6 hours increased hepcidin 
expression though not significantly. Treatment for 16 hours was found to significantly 
decrease mRNA expression levels (Fig. 5.3.5).
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Figure 5.3.6 Time course effect of acute inflammation on hepatic hepcidin 
expression levels. SWR wt mice were injected with LPS and sacrificed after 1.5, 6 
and 16 hours. Hepcidin mRNA expression levels were analysed by Real Time PCR. 
Treatment for 1.5 hours had no effect while treatment for 6 hours showed an 
increase in hepcidin expression. Treatment for 16 hours decreased significantly 
hepcidin levels *p<0.05. Data are Mean±SEM, n=6 per group.
Treatment of wt SWR mice with turpentine oil for 16 hours did not have a significant effect 
on hepatic hepcidin mRNA expression compared to non-treated mice.
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5.3.3.3 Effect of inflammation on hepatic DMT1 and Ireal aene expression in wt SWR mice
Hepatic iron transporters gene expression, namely DMT1 and Iregl mRNA gene expression 
was analysed in wt SWR mice injected with LPS and Turpentine oil. Hepatic DMT1 decreased 
significantly after the 1.5 hours treatment with LPS compared to control (Control 
0.085±0.029; LPS-treated 0.011±0.003, p<0.05). LPS treatment for 6 hours increased DMT1 
though not significantly. In addition, treatment for 16 hours caused the same increase in 
DMT1 expression as the 6 hours treatment.
Hepatic Iregl expression levels decreased significantly after all the treatments with LPS (1.5, 
6 and 16 hours) as described in Fig. 5.3.7.
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Figure 5.3.7 Effect of acute inflammation on hepatic Ire g l expression.
SWR wt mice were injected with LPS and sacrificed after 1.5, 6 and 16 hours. Iregl 
mRNA expression levels were analysed by Real Time PCR. All treatments with LPS 
lead to a reduction on hepatic Iregl expression levels. Data are Mean±SEM, n=6 per 
group, *p<0.05, **p<0.01.
Turpentine treatment of wt SWR for 16 hours led to an increase in hepatic DMT1 expression 
compared to non-treated mice though not significant (Control 0.09±0.02; Turpentine-treated 
0.22±0.05). Acute inflammation caused by turpentine injection also resulted in a significant 
decrease in hepatic Iregl expression levels (Control 9.04±2.27, turpentine-treated 
0.96±0.14, n= 4 per group, p<0.01).
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5.3.4 Effect of acute inflammation by LPS and Turpentine on hepatic iron content, hepatic
hepcidin. DMT1 and Iregl gene expression in Hfe KO SWR mice
5.3.4.1 Effect of acute inflammation on hepatic iron content in Hfe KO mice
Iron content was analysed in Hfe KO SWR treated with LPS and Turpentine oil for 16 hours. 
Contrary to what it was found in wt mice, acute inflammation induced by both LPS and 
turpentine treatment had no significant effect on hepatic iron content (Fig. 5.3.8).
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Figure 5.3.8 Liver iron content in Hfe KO SWR mice in acute inflammation.
Mice injected with LPS and turpentine were sacrificed after 16 hours; the whole liver 
was removed and divided into five lobes. Iron was quantified in each lobe and the 
average of the iron content in each whole liver was calculated. Treatment of Hfe KO 
SWR mice with LPS and turpentine oil had no significant effect on hepatic iron 
content. Data are Mean±SEM, Control n=6; LPS n=4; Turps n=6.
When the iron content in each lobe was analysed in LPS and turpentine treated mice, there 
was no difference between the iron content of the five lobes of non-treated mice. In LPS- 
treated Hfe KO mice there was no significant difference between the iron content of lobe A
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the remaining lobes was observed (Table 5.3.4) while in turpentine-treated Hfe KO mice iron 
content of lobe A was significantly higher.
SWR MICE TREATMENT LOBE A IRON 
CONTENT 
(pg/gdryweight)
LOBE B-E IRON 
CONTENT 
(lig/gdryweight)
Hfe Knockout
Saline 608.2±139.1a 376.5±66.2a
LPS 1030.1±248.3 b 472.8±79.3 b
Saline 488.5±61.8a 367.7±43.2 a
Turpentine o il 1101.5±144.7C * S U 3 * . ,
Table 5.3.4 Hepatic iron in Hfe KO SWR mice treated w ith LPS or Turpentine oil for 
16 hours. The liver o f Hfe KO mice treated with LPS and turpentine oil mice was divided into 
five lobes as described in chapter 3 and the iron content of each lobe was quantified. There 
was no difference between the iron content of lobe A and the other four lobes (B-E) in Hfe 
KO SWR mice treated with LPS. In  Hfe KO mice treated with turpentine oil, lobe A had 
significantly higher iron content level than lobes B to E (*p<0.05). Data are Mean±SEM, n=3 
per lobe (*), n=4 per lobe (*), n=6 per tobe f ) .
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5.3.4.2 Effect of inflammation on hepatic hepcidin 1 gene expression in wt SWR mice
Treatment of Hfe KO mice with LPS for 1.5 hours increased hepcidin mRNA expression 
though not significantly (Fig. 5.3.9). Hepcidin expression was also increased after LPS 
treatment for 6 hours but to a lesser extent. Interestingly LPS treatment for 16 hours of Hfe 
KO mice showed significantly lower hepcidin 1 expression levels than non-treated animals 
(Fig. 5.3.9). Treatment of SWR Hfe KO mice with Turpentine oil for 16 hours had no effect on 
hepcidin mRNA expression levels.
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Figure 5.3.9 Effect of acute inflammation on hepatic hepcidin expression in
Hfe KO SWR mice. SWR Hfe KO mice were injected with LPS, sacrificed after 1.5, 6 
and 16 hours and hepcidin 1 mRNA expression levels were analysed by Real Time 
PCR. Treatment for 1.5 hours increased hepcidin expression levels though not 
significantly. Treatment for 6 hours was also found to up regulate hepcidin levels but 
to a lesser extent. Treatment for 16 hours significantly decreased hepcidin 1 
expression levels *p<0.05. Data are Mean±SEM, n=6 per group.
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5.3.4.3 Effect of inflammation on hepatic DMT1 and Ireal aene expression in Hfe KO SWR
mice
Hepatic mRNA expression levels of DMT1 and Iregl were analysed in Hfe KO mice treated 
with LPS for 1.5, 6 and 16 hours (Fig. 5.3.10). Hepatic DMT1 RNA expression following LPS 
injection increased significantly after one and an half hours and decreased significantly after 6 
hours remaining at the same level after the 16 hours treatment. Hepatic Iregl did not change 
after the 1.5 hours treatment with LPS but decreased in animals injected with LPS for 6 
hours. Treatment for 16 hours with LPS increased Iregl expression to control levels. Both 
hepatic DMT1 and Iregl expression showed an acute-phase response to inflammation in Hfe 
KO SWR mice.
§ <3 ^  2.00
i |
O  +S
8 I
O) £ 1.00
E i 
£ ®
2. £  o.oo 
£ S.
Hepatic gene transporter expression 
in Hfe KO SWR mice
Control LPS 1.5h LPS 6h
■ DMT1
■ Iregl
LPS 16h
Figure 5.3.10 Expression of mRNA iron transporter genes after acute inflammation 
for 1.5, 6 and 16 hours. Mice were injected with LPS for 1.5, 6 and 6 hours. Hepatic DMT1 
and Iregl mRNA expression were analysed by Real Time PCR. Both hepatic DMT1 and Iregl 
expression showed an acute-phase response to inflammation in Hfe KO SWR mice. Data are 
Mean±SEM, n= 3 per group; *p<0.05, **p<0.01.
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Turpentine injection resulted in a decrease of both hepatic DMT1 and Iregl expression in Hfe 
KO mice though not significantly (Fig. 5.3.11).
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Figure 5.3.11 Hepatic iron transporters mRNA expression in acute 
inflammation by Turpentine. Mice were injected with turpentine oil and sacrificed 
after 16 hours. Hepatic DMT1 and Iregl mRNA expression was analysed by Real 
Time PCR. Hepatic DMT1 and Iregl expression did not change significantly in treated 
mice compared to controls. Data are Mean±SEM/ n= 5 per group.
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5.4 Discussion
In this chapter the regulation of hepcidin expression in response to two different models of 
acute inflammation was investigated in SWR mice. The regulation of hepcidin expression in 
response to pro-inflammatory cytokines was also investigated using a hepatoma cell line. To 
investigate whether the Hfe gene has a role in the regulation of hepcidin by inflammation, 
Hfe KO SWR mice were also investigated in the setting of acute inflammation. Our results 
show that SWR mice respond to acute inflammation by Lipopolysaccharide (LPS) and 
turpentine oil differently and that Huh7 cells do not respond to IL-6 and TNF-a in the same 
manner. In addition, our data shows that the disruption of the Hfe gene has an effect in the 
regulation of hepcidin, Iregl and DMT1 expression levels in response to LPS and Turpentine 
oil treatment.
In this study we have shown that in wt SWR mice, acute inflammation by either LPS or 
Turpentine oil injection for longer than six hours decreases serum iron and transferrin 
saturation levels but has no effect on the hepatic iron content levels. Injection of LPS in Hfe 
KO mice decreased significantly transferrin saturation after 16 hours and serum iron levels 
although this failed to reach statistical significance. In contrast, turpentine injection of Hfe KO 
mice had no effect no serum iron levels. As observed in wt SWR mice, LPS and turpentine oil 
injection had no effect of hepatic iron content of Hfe KO mice.
Hepatic hepcidin expression in wt SWR mice was upregulated up to 6 hours post-treatments 
with LPS in this study in accordance with previously published reports (Pigeon et al. 
2001;Sheikh et al. 2007). In addition, LPS injections for 6 hours was found to upregulate 
hepcidin expression levels in Hfe KO SWR mice. Interestingly hepcidin mRNA expression 
levels were found to be significantly downreguiated in both wt and Hfe KO SWR mice 16 
hours after LPS injections.
Turpentine oil injection for 16 hours decreased hepcidin mRNA expression levels in wt SWR 
mice though this failed to reach statistical significance while in Hfe KO mice, turpentine 
treatment was found to have no effect on hepcidin expression levels.
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Contradictory reports have been published on the effect of LPS stimulation on hepcidin 
expression levels in Hfe KO mice and the requirement of Hfe or other genes for the up- 
regulation of hepcidin in inflammation conditions. In some reports, a response to LPS 
stimulation and hypoferremia are absent (Roy et al. 2004), in others this lack of response is 
attributed to differences from animal to animal (Lee et al. 2004) and in a recently published 
paper it was reported that although basal hepcidin levels are dependent on the presence of 
the Hfe gene, Hfe KO mice are still able to regulate hepcidin in acute inflammation (Constante 
et al. 2006). Here we have shown that Hfe KO mice upregulating hepcidin expression in 
response to LPS-induced inflammation but in turpentine-induced acute inflammation no 
change is observed in hepcidin mRNA expression levels.
Injected LPS is mainly taken up by the Kupffer cells and is responsible for the upregulation of 
IL-6 in the liver (Ganz 2003) while turpentine oil injections lead to an induced local irritation 
which results in the recruitment of inflammatory cells and the upregulation of IL-6 in the 
injured musde. In addition turpentine oil injection results in the production of IL-6, IL-lp and 
TNF-a in hepatocytes (Sheikh et al. 2007). In this study we have shown that when 
hepatocytes are exposed to IL-6, hepcidin expression levels increased by 4-fold confirming 
findings by other groups that IL-6 has a direct effect on hepcidin expression (Nemeth et al. 
2003;Nemeth et al. 2004a).
Our results show that Hfe is not necessary for the upregulation of hepcidin by LPS injection 
as previously shown by other groups (Lee et al. 2004). In addition we have shown that the 
disruption of the Hfe gene abrogates the regulation of hepcidin by turpentine injection. 
Studies in human hepatoma (Huh7) cells have shown that IL-1(3 induces hepcidin expression 
in an IL-6 independent mechanism (Inamura et al. 2005). In this study we have shown that 
TNF-a does not upregulate hepcidin expression in Huh7 cells and therefore it is possible that 
the disruption of the Hfe gene prevents the release of IL-lp in response to acute 
inflammation by turpentine oil injection preventing hepcidin upregulation in Hfe KO mice but 
this requires further investigation.
In cells transfected with the iron exporter Iregl and in macrophages, hepcidin has been 
shown to interact directly with the Iregl protein (De, I et al. 2005;Delaby et al.
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2005;Drakesmith et al. 2005;Knutson et al. 2005;Nemeth et al. 2004b). Our group has shown 
that a course of injections of recombinant hepcidin (synthesised in-house) into mice results in 
a decreased in iron uptake (Laftah et al. 2004). In addition a single injection of hepcidin into 
rats has been shown to downreguiate duodenal Iregl mRNA expression (Rivera et al. 2005b). 
Here have shown that IL-6-induced production of hepcidin by hepatocytes does not alter 
hepatic DMT1 or Iregl protein expression. In addition, acute inflammation by LPS or 
turpentine oil injection in wt SWR mice was shown to decrease hepatic Iregl as previously 
shown (Krijt et al. 2006;Sheikh et al. 2007;Yang et al. 2002). In contrast, LPS injection in 
Hfe KO SWR mice was found to only significantly downreguiate hepatic Iregl expression 6 
hours pos-treatment while turpentine injection for 16 hours had no effect on Iregl expression 
in these mice. As observed with hepcidin expression the results suggest that Hfe gene has a 
vital role in the regulation of Iregl expression in the liver in a turpentine-induced 
inflammatory setting. This finding together with some published reports, also suggest that 
the regulation of hepatic Iregl expression is independent of hepcidin expression in an 
inflammatory setting (Mena et al. 2006;Yeh et al. 2004).
The spleen is one of the major sites of Iregl expression and hypoferremia is thought to occur 
as a consequence of hepcidin mediated inhibition of iron release from reticuloendothelial 
macrophages (resident in spleen and liver) through Iregl. Our group has shown that hepcidin 
treatment of mice and a human macrophage cell line results in a significant decrease in Iregl 
expression in the spleen (personal communication by Dr. Paul Sharp). To investigate further 
the effect of inflammation and the increase of hepcidin expression levels on iron uptake and 
retention in the spleen, we quantified the iron content of the spleen following LPS and 
turpentine treatment. Here we show that LPS and turpentine injection has no significant 
effect on splenic iron content in wt or Hfe KO SWR mice 16 hours post-treatment suggesting 
that although hepcidin injections cause splenic Iregl expression to decrease and thus 
reticuloendothelial macrophages accumulate iron in the spleen, the hepcidin produced as a 
result of inflammatory inducers does not have the same effect. As our results show that 
hepcidin expression levels are decreased after 16 hours post-injection with LPS and
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turpentine oil, it is possible that the levels of hepcidin produced in this setting were not 
sufficiently high to have a significant effect on Iregl expression and thus splenic iron content.
As previously shown in wt rats (Sheikh et al. 2007) our study shows that acute inflammation 
upregulates hepatic DMT1 expression in wt mice. In contrast hepatic DMT1 expression was 
found to be downregulated by l_PS and turpentine treatment in Hfe KO SWR mice. Similarly to 
hepatic Iregl expression, hepatic DMT1 expression appears to be dependent on the presence 
of the Hfe gene and independent of hepcidin expression in an inflammatory setting although 
this requires further investigation.
In this study we have also investigated the role of hepcidin in duodenal iron uptake in an 
inflammatory setting using Huh7 ceils. Incubation of an intestinal epithelial cell line (Caco-2) 
with IL-6 had no effect on intestinal DMT1 or Iregl expression, confirming the previous 
findings that IL-6 has no direct effect on duodenal iron uptake (Raja et al. 2005).
To investigate the possibility that IL-6 is regulating intestinal iron absorption through hepcidin 
expression, conditioned medium from Huh7 cells was used as a source of hepcidin to 
determine its effects on intestinal iron transporter expression.
Applying the conditioned medium from IL-6-stimulated HuH7 cells to the basolateral surface 
of the Caco-2 monolayer for 24 hours significantly decreased the expression of DMT1 (+IRE) 
compared with transporter levels in cells incubated in medium from unstimulated Huh7 cell 
cultures. To further investigate whether the induced hepcidin was responsible for the 
downregulation of duodenal DMT1 and Iregl expression, medium was collected from IL-6 
stimulated Huh7 cells, incubated with anti-human hepcidin antibody and added to Caco-2 cell 
monolayers. Duodenal DMT1 and Iregl was significantly greater in cells exposed to 
conditioned medium pre-treated with the hepcidin antibody suggesting that Hepcidin might 
be the possible component in the medium inhibiting intestinal iron uptake. Recently a report 
has shown that hepcidin released from IL-6-stimulated Huh7 cells decreased iron export in 
THP-1 macrophages using similar methodology to this study (Andriopoulos and Pantopoulos 
2006).
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In conclusion, the results from the present study taken together with previous work from our 
group (Johnson et al. 2004) demonstrate that the pro-inflammatory cytokines TNF-a and IL-6 
can both regulate intestinal iron metabolism. TNF-a seems to act directly with intestinal 
epithelial cells to decrease the expression of the apical iron transporter DMT1, while IL-6 
seems to influence intestinal iron absorption via stimulating the release of hepatic hepcidin. 
Our study of acute inflammation by LPS and Turpentine oil in SWR mice has shown that 
although hepcidin expression is upregulated rapidly as a result of inflammation, hepcidin 
expression levels decreases around 16 hours post-treatment suggesting a feedback loop 
response to the hypoferremia caused by the inflammation. In addition our study has 
confirmed that the two models of inflammation regulate gene expression very differently. Our 
data suggests that the disruption of the Hfe gene abrogates the gene expression of hepcidin, 
hepatic DMT1 and Iregl in response to acute inflammation by turpentine oil but not by LPS 
injection. Furthermore, we have provided evidence that although hepcidin expression levels in 
the inflammatory setting leads to hypoferremia, hepcidin expression does not have a direct 
effect on hepatic DMT1 or Iregl expression levels. Instead the data suggests that the 
changes in hepatic DMT1 and Iregl expression results from a hepcidin independent effect of 
the cytokines produced in acute inflammation.
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Chapter 6
Hy p o x ia  a n d  A n a e m ia  as  h e p c id in  e x p r e s s io n  m o du lato r s
&
H e p c id in  as  a  d u o d e n a l  ir o n  a b s o r p tio n  r eg ulato r
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6.1 Hypoxia and Anaemia as hepcidin expression modulators & Hepcidin as a 
duodenal iron absorption regulator
In humans iron absorption is mainly regulated by iron stores (stores regulator) and the rate 
of erythropoiesis (erythroid regulator). Erythroid stimulation of iron absorption occurs 
regardless of body iron stores, aiming to provide an adequate iron supply for red blood cell 
(erythrocytes) production. Tissue hypoxia is the main stimulus of Erythropoeitin (EPO) 
production. EPO is a glycoprotein hormone produced by the kidneys and the liver that is a 
cytokine that induces the production of erythrocyte precursors in the bone marrow (Jelkmann 
2004;Tan and Ratdiffe 1992). The subsequent development of the erythrocytes depends on 
an iron supply from the diet or from the iron storage pool in macrophages and hepatocytes.
In 1988 Peters et al provided evidence that hypoxia enhances iron uptake by a mechanism 
that is independent of stimulated erythropoiesis (Peters et al. 1988;Raja et al. 1988;Raja et 
al. 1986). The group demonstrated that exposure of splenectomized 89Sr-treated mice to 
hypoxia resulted in an increase in the total intestinal iron uptake, without any change in 
erythropoiesis. This suggested that the increase in intestinal mucosal iron uptake which 
follows hypoxia was not mediated by erythropoietin or other factors associated with increased 
erythropoiesis (Raja et al. 1986). These authors also demonstrated that transgenic mice with 
partial deficiency of erythropoietin due to hypoplastic anemia have increased iron absorption, 
with no increased erythropoiesis (Raja et al. 1997).
Hepcidin has been shown to be homeostatically regulated by hypoxia and anaemia. In 
hypoxic conditions it has been reported that hepcidin expression levels decrease, its inhibitory 
effects on iron absorption diminish and more iron is acquired from the diet and from the 
storage pool in macrophages and hepatocytes (Nicolas et al. 2002b). The low levels of 
hepcidin will allow iron uptake from intestine and recirculation from macrophages and iron 
will be delivered to bone marrow to sustain the production of erythrocytes (erythropoiesis). 
Mice exposed to hypoxia for 3 days have been shown to exhibit a two- to threefold increase 
in iron absorption (Raja et al. 1990). For this reason Hepcidin is suggested to act as the
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erythroid regulator that transmits the erythroid demand of the organism to the enterocyte 
(Fleming and Sly 2001;Nicolas et al. 2001;Nicolas et al. 2002b) and not EPO as previously 
suggested.
Treatment of mice with synthetic hepcidin led to the reduction in iron uptake seen in the 
intestinal cell line and in mice. Injection of Erythropoietin (EPO) in mice was found to also 
decrease liver hepcidin expression but the finding that irradiation prevented this hepcidin 
suppression, ruled out a direct effect of EPO on hepcidin synthesis (Nicolas et al. 
2002b;Vokurka et al. 2006).
Anaemia has been found to regulate hepcidin levels in a similar manner to hypoxia. Mice that 
were bled or had undergone phenylhydrazine-induced hemolysis showed a decrease in 
hepcidin mRNA levels in the liver and duodenum while iron absorption was increased (Bondi 
et al. 2005;Frazer et al. 2004b;Latunde-Dada et al. 2004;Nicoias et al. 2002b;Vokurka et al. 
2006). Anaemia induced by mouse mutations that restrict the uptake of iron in the small 
intestine (s/a and mk mice) also show a significant decrease in hepatic hepcidin mRNA. 
Importantly, anaemia has a stronger effect in the suppression of hepcidin than iron overload 
has on the stimulation of hepcidin, as seen in hemolytic phenylhydrazine-induced iron- 
overloaded mice (with the exception of thalassaemic mice).
Thalassaemia syndromes belong to a group of conditions characterised by anaemia with 
ineffective erythropoiesis which leads to an increased absorption of dietary iron and a 
consequently iron overload (reviewed by Andrews 1999). In 0- thalassaemia major, hepcidin 
levels correlated with parameters of erythropoiesis and anaemia but not with indices of iron 
overload such as liver iron concentrations, ferritin, serum iron or transferrin saturation. There 
was however, a negative correlation between hepcidin levels and Non-Transferrin Bound Iron 
(NTBI) which suggested that low levels of Hepcidin allow the increase of iron flow into 
plasma, leading to saturation of transferrin and NTBI formation. It has been suggested that 
hypoxia and other still undefined signals from the erythroid activity, downreguiate hepcidin
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production which then allows the iron overload of patients with thalassaemia to develop 
(Papanikolaou et al. 2005).
In the murine model of human thalassaemia, the Hbb^37* mice, hepcidin mRNA expression 
was found to be decreased despite the iron overload (Adamsky et al. 2004). Although it has 
been reported that urinary Hepcidin is decreased in patients with Thalassaemia Major, 
hepcidin mRNA expression levels have not yet been described (Papanikolaou et al. 2005). 
Occurrence of anaemia and tissue iron overload is also encountered in mice with transferrin 
deficiency (hpx/hpx) mice. In these mice erythropoiesis is functional though iron restricted or 
ineffective and Hepcidin expression is decreased (Adamsky et al. 2004;Weinstein et al. 2002). 
These findings confirm that the iron overload is less dominant than the anaemia in regulating 
Hepcidin expression in the anaemia setting (Andrews 1999; Finch 1994).
In this study, the human hepatoma-derived cell line, HepG2 was used to investigate the 
effect of hypoxia on hepcidin mRNA expression levels. An animal model of chronic hypoxia, 
equivalent to the partial pressure of inspired oxygen at an altitude of 5000 m above sea level 
was also studied to investigate the changes in iron uptake from the duodenal lumen and its 
transfer to the blood. Hepcidin mRNA expression levels in rat liver before and after direct 
exposure to reduced oxygen were quantified by Real Time-PCR.
Urinary Hepcidin has been reported to be decreased in patients with Thalassaemia Major and 
Thalassaemia Intermedia, but hepcidin mRNA expression levels have not yet been described. 
In this study we investigate hepcidin mRNA expression levels in thalassaemia major and 
thalassaemia minor patients receiving different treatments.
To further investigate the effect of Hepcidin on intestinal iron transport in vivo iron uptake 
was measured and serum iron levels and transferrin saturation were quantified in mice 
injected with Hepcidin.
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6.2 Methods
6.2.1 Short term hypoxia of hepatoma cell line
HepG2 cells were cultured In RPMI1640 medium (Sigma, Poole, UK) containing L-Glutamine 
(Sigma, Poole, UK), antibiotics and 10% FCS (Sigma, Poole, UK) and maintained in 5% C02 
at 37°C till confluent. The medium was changed every 2-3 days. Cells were passaged at 
confluence using 0.5mg/ml trypsin (Sigma, Poole, UK). Prior to the experiment HepG2 cells 
were seeded in 5cm2 wells. Cells were cultured to confluency and the medium was changed 
immediately prior to exposure to hypoxia. HepG2 cells were made hypoxic by placing them in 
stainless steel hypoxia chambers as previously described (Mazure et al. 2002). The chambers 
were evacuated until the desired oxygen partial pressure, deduced by measuring the pressure 
with an electronic pressure sensor (SMC digital pressure sensor; SMCCorporation, Tokyo, 
Japan) was reached. The chambers were then refilled with a gas mixture containing 5% C02 
and 95% N2 and a final concentration of oxygen (02) of 1% used. The chambers were then 
placed in an incubator at 37°C for 24 hours and 48 hours. After hypoxia, the culture medium 
was removed, cells were washed with PBS and RNA was extracted.
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Figure 6.2.1 Hypoxic chamber. Photograph o f an incubator taken from  the web page: 
(h h t://www.brincubator.com/hypoxiachamber.htm)  on the 12/08/2006.
6.2.2 Long term hypoxia of Spraaue-Dawley rats
Sprague-Dawley rats (initial weight 90-100 g) supplied by the Animal Services Centre of the 
Chinese University of Hong Kong, were exposed for 4 weeks to room air mixed with nitrogen 
to reduce oxygen concentration to 10%, or room air alone (Leung et al. 2000). Cages 
containing four rats were kept in sealed Perspex chambers with inflow and outflow ports for 
inspired normal or hypoxic air. Water and rat chow were supplied ad libitum  to the hypoxic 
group and the weight of chow consumed was monitored so that the normoxic group was 
supplied the same amount of chow. Animals were weighed twice-weekly. At the end of 4 
weeks, rats were anaesthetized with pentobarbitone sodium (40mg/kg, i.p.) and sacrificed. 
Livers were removed for gene expression analysis by Real Time PCR. RNA was extracted as 
described in chapter 2.2 and frozen at -80° until required for PCR analysis.
All experimental procedures were approved by the Animal Experimentation Ethics Committee 
of the Chinese University of Hong Kong.
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6.2.3 Hepcidin injections of C57BL/6 mice
Male C57BL/6 mice aged 4 weeks were placed on an iron adjusted diet (44mg Fe/Kg diet) for 
3 weeks prior to experimentation. Mice were given a single intraperitoneal injection of either 
lOpg hepcidin (Peptides International Inc. Louisville, KY) or an equivalent volume of the 
diluent (saline).
6.2.4 Iron uptake across duodenum in C57BL/6 injected with Hepcidin
After four hours, mice were anaesthetized with pentobarbitone sodium (40mg/kg, i.p.) and 
the duodenum was washed through with warm 0.15M NaCI followed by air. The lower end of 
the duodenum segment (proximal to the ligament of Treitz) was tied off and uptake buffer 
(Hepes-buffered saline containing 0.2mM 59Fe2+ complexed with 4mM ascorbate, pH 6.5) was 
instilled proximally from a tied-in syringe. After 15 minutes, during which the animal body 
temperature was maintained at 37° with a thermostatically controlled heating blanket, blood 
samples and the duodenal segment were removed. The tissue was then washed free of 
surface bound iron using a solution containing 2 mM unlabelled iron followed by 0.15 M NaCI, 
and finally dried overnight. The mucosal layer was scraped off, weighed and together with 
weighed blood samples and the animal carcass, was gamma-counted (Packard 5003, Cobra II 
Auto-Gamma, Global Medical Instrumentation, Inc., Minnesota, USA) for the determination of 
59Fe.
Livers were removed for gene expression analysis. RNA was extracted as described in chapter
2.2 and frozen at -80° until required for Real Time PCR analysis. Blood was removed by 
cardiac puncture and serum iron and transferrin saturation was analysed using a 
commercially available assay (Randox Laboratories Ltd. Antrim, UK).
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6.2.5 Liver biopsies of Thalassaemic Maior (TNH and Thalassaemia Intermedia (TO patients
Liver biopsies were obtained from thalassaemia major (TM) patients (n=14, male= 8, 
female= 6) on regular transfusion programmes (3-4 weekly) and from thalassaemia 
intermedia (TI) patients (n=6# male= 4, female= 2) receiving different treatment regimes. Of 
the 6 thalassaemia intermedia (Tl) patients two were not currently receiving transfusion. The 
mean average age of the patients was 25.6±5.1 years of age for the TM patients and 
30±10.5 years of age for TI patients. Data on liver iron, ferritin levels and haemoglobin of the 
patients are described on Table I of appendix I. Ethical permission was obtained from all the 
subjects mentioned in this study. RNA from liver biopsies was extracted as described in 
chapter 2.2 and frozen at -80° until required for Real Time PCR analysis.
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6.3 Results
6.3.1 Hepcidin mRNA expression levels in response to hypoxia in vitro
Hepcidin mRNA expression levels of HepG2 cells were determined by Real Time-PCR after the 
cells were exposed to 1% oxygen for up to 48 hours. When compared to the housekeeping 
gene HPRT, hepcidin mRNA expression was reduced by 24.8% and 50.0% after 24 and 48 
hours of hypoxia respectively, the value at 48 hours being significantly different to the control 
value (Fig. 6.3.1).
Hepcidin mRNA expression in HepG2 cells 
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Figure 6.3.1 Effect of hypoxia on hepatocytes mRNA hepcidin expression levels
HepG2 cells were exposed to 1% oxygen for 24 and 48 hours. Hypoxia for 48 hours was 
shown to significantly decrease hepcidin mRNA expression levels by Real lime PCR. Data 
have been normalized to levels of HPRT and expressed as arbitrary units (AU). Results are 
expressed as Mean±SEM of samples from each 3 (control and 24 hour hypoxia) and 4 (48 
hours hypoxia) cells, *p<0.02.
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6.3.2 Effect of hypoxia in vivo on hepcidin mRNA expression levels
Sprague-Dawley rats made hypoxic for four weeks showed significant reduction in hepcidin 
mRNA expression levels (Fig. 6.3.5). Hypoxia was confirmed by the increased expression of 
the housekeeping gene GAPDH mRNA expression.
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Figure 6.3.2 Effects of hypoxia on liver mRNA Hepcidin expression levels.
Sprague-Dawley rats were exposed to 10% 02 hypoxia for four weeks. Hepatic 
Hepcidin mRNA expression levels were shown to decrease significantly by Real Time 
PCR. Data have been normalized to levels of Actin and expressed as arbitrary units 
(AU). Results are expressed as Mean±SEM of liver samples from each of 3 (control) 
and 4 (hypoxia) animals, *p<0.01.
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The four weeks hypoxia treatment had no effect on animal body weight but caused 
significant increases in blood haemoglobin concentration, haematocrit and erythrocyte count 
(Table 6.3.1).
FINAL BODY 
WEIGHT (g)
HAEMOGLOBIN
(9/dL)
HAEMATOCRIT RED BLOOD CELL 
COUNT (x 1012/L)
Control 210.4±5.6 (18) 12.72±0.41 (5) 0.41±0.01 (5) 7.33±0.48 (5)
| Hypoxic 223.6±6.2 (21) 18.71±0.59* (7) 0.60±0.02* (7) 9.43±0.18* (7)
Table 6.3.1 Effects of hypoxia on final body weight, haemoglobin concentration, 
haematocrit and red blood cell count. Sprague-Dawley rats were exposed for 30 days to 
air containing 10% oxygen or room air. Data are Means±SEM for (n) animals. *p<0.001 
compared to control.
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6.3.3 Hepatic hepcidin expression levels in the Thalassaemia setting
Three patients with high transaminase levels (>80 iu/ml) had low hepcidin mRNA levels (77 ± 
16 %) and increased levels of fibrosis compared to those with lower transaminase levels (106 
± 55%) and only mild fibrosis (personal communication by Dr. Farrah Shah).
Hepcidin mRNA expression levels were not significantly different between the two thalassemia 
groups; Thalassemia Intermedia (3.84±0.83) compared to Thalassemia Major (4.06±0.99). 
However hepcidin mRNA expression levels was significantly lower in thalassemia patients with 
liver iron concentrations >10mg/gdryweight compared to those with lower iron concentrations 
(85 vs 131%, p=0.05) (Table II  in appendix I).
Thalassem ic patients 
mRNA Hepcidin expression
Thalassemic
Figure 6.3.3 Hepcidin mRNA expression levels in thalassemic patients.
Hepcidin expression was investigated in biopsies from thalassemia major (TM) and 
thalassemia intermedia (TI) patients (n=14 and n=6, respectively). Data expressed 
as Mean±SEM.
Hepcidin expression did not vary significantly with anaemia, with ferritin > 3000ng/ml or 
<1500ng/ml (p=0.99). Moreover there was no significant difference between the 
thalassaemia patients (TM and TI) compared with controls (Fig. 6.3.3).
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6.3.4 Hepcidin as a regulator of intestinal iron transport
Mice injected with hepcidin show after 4 hours a significant decrease in serum iron content 
(5.7±2.4 pmol/L) compared to control animals (14.7±0.9 pmol/L). Hypoferremia was 
accompanied by a 27% decrease in transferrin saturation in the hepcidin treated mice 
(control 60.7±9.3%; hepcidin treated 34.0±10.2%. p<0.05).
Uptake and transfer of iron across the duodenal mucosa (Fig. 6.3.4) showed no significant 
difference between control and hepcidin-treated animals (duodenal counts, p>0.93; 
blood/carcass counts, p>0.11 respectively).
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Figure 6.3.4 Effect of hepcidin injections on duodenal iron transport
C57BL/6 male mice were injected with 10 pg of hepcidin and used for studies 4 hours 
later. The duodenum lumen was filled with 200pM 59Fe?+ for 15 minutes and the 
subsequent levels of 59Fe in duodenal mucosa, blood and carcass determined by 
gamma counting. There was no significant difference in mucosa/ iron retention (grey 
bars), mucosa iron transfer (black bars) and total mucosai uptake (white bars) 
between control and hepcidin-treated animals. Data are Mean±SEM of 6 observations 
in each group.
The effect of hepcidin on Iregl protein expression in the duodenum and in the spleen was 
investigated by other members of the group and therefore is not shown here. It was however 
found that in the duodenum hepcidin treatment had no effect on Iregl protein expression
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levels while in the spleen hepcidin-treated animals revealed a 50% reduction in Iregl protein 
levels (personal communication Dr. Paul Sharp).
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6.4 Discussion
Chronic hypoxia requires the erythroid regulator to increase the production of red blood cells 
to carry more oxygen. The subsequent production and development of the erythrocytes 
cannot be compensated by the iron storage pool and therefore depends on an iron supply 
from the diet. Therefore an increase in iron absorption is required to enable the iron to be 
delivered to bone marrow to sustain the production of erythrocytes (erythropoiesis). Recent 
work from our laboratory on rats has shown that increased entry of iron in the body during 
hypoxia occurs by both stimulation of iron entry across luminal membrane into the enterocyte 
and enhanced iron transfer across the basolateral membrane into the perfusing blood (Leung 
et al. 2005). The changes in iron uptake caused by hypoxia were independent of villus length 
implying altered function of individual enterocytes. Previous studies by the same group on 
hypoxia responses suggest that the increased iron movement across the brush border is due 
in part to an increased electrical driving force for proton -mediated iron transport across this 
membrane (O'Riordan et al. 1995). Interestingly in the present study (Leung et al. 2005), 
significantly lower levels of absorbed iron in hypoxic mucosa were found following the in vivo 
transfer study despite the high iron uptake by isolated duodenum. This implies a 
proportionally greater effect of hypoxia on iron transfer across the basolateral membrane to 
the blood.
Hypoxia stimulates the secretion of erythropoietin (EPO) and although the increase in iron 
uptake seen in these hypoxic rats could be a result of stimulated erythropoiesis, studies have 
shown that EPO does not have a direct effect on the regulation of iron absorption (Peters et 
al. 1988;Raja et al. 1988;Raja et al. 1986;Raja et al. 1997).
Evidence is emerging that intestinal iron transport is under hormonal control; studies suggest 
a humoral effect on iron transport is linked to an inflammatory response (Raja et al. 1990). 
Since then Hepcidin has been identified as a negative regulator of duodenal iron transport 
homeostatically regulated by hypoxia and anaemia. In hypoxic conditions it has been 
reported that hepcidin expression levels decrease, its inhibitory effects on iron absorption 
diminish and more iron is acquired from the diet and from the storage pool (Laftah et al.
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2004;Nicolas et al. 2002b). These low levels of Hepcidin will then allow iron uptake from 
intestine to increase as required. Consequently Hepcidin is thought to act as the erythroid 
regulator that transmits the erythroid demand of the organism to the enterocyte (Fleming and 
Sly 2001;Nicolas et al. 2001;Nicolas et al. 2002b).
In this study, four weeks hypoxia significantly decreased hepatic hepcidin mRNA expression 
levels in rats. The increased iron transport seen could therefore be a consequence of the 
decrease in hepcidin expression. However, this increase in iron absorption could also be a 
consequence of low levels of iron in the liver due to its mobilization to the erythroid marrow. 
The published autoradiographic findings of our group (Leung et al. 2005) show that hypoxia 
stimulates iron uptake by both mature enterocytes at the upper villus as well as newly 
differentiated cells at the base of the villus. Although previous studies have shown a close 
relationship between hepcidin expression, duodenal iron transporters and iron absorption 
(Frazer et al. 2002), how hypoxia-induced changes in transport along the villus relate to the 
distribution profile of the hepcidin receptor is still unknown due to the lack of a suitable 
antibody to Hepcidin.
The effect of hypoxia on hepcidin mRNA expression levels was further investigated in HepG2 
cells and Huh7 cells, human hepatoma-derived cell lines. Hepcidin mRNA expression was 
significantly reduced after 48 hours of exposure to 1% oxygen. Our data suggests that at 
least part of the response to hypoxia in rats is due to a direct action of low oxygen partial 
pressure on hepatocytes. Cell culture experiments used a lower level of oxygen 
(approximately 7.6 mm Hg partial pressure), than that used in the rat study because, even 
under normal conditions, the partial pressure of oxygen in blood supplying hepatocytes is 
considerably lower than the value present in systemic blood since a large proportion of 
hepatic blood has undergone partial deoxygenation during its passage through the 
mesenteric circulation. The level of oxygen in blood supplying hepatocytes in rats breathing 
normal or 10% oxygen is unknown.
The human Hepcidin promoter contains several binding sites for the hypoxia-inducible factor 
1 (HIF-1) and it has been reported that iron deficiency activates HIF-1. A direct action of 
hypoxia on hepcidin expression involving the binding of HIF to a hypoxia response element
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on hepcidin mRNA is unlikely as this would result in an increase of hepcidin expression. It is 
therefore likely that HIF works through another transcription factor to regulate hepcidin 
levels.
In iron deficient conditions without changes in iron stores or increased erythropoiesis, iron 
uptake increases significantly, duodenal expression of DcytB, DMT1 and Iregl increases while 
hepatic hepcidin and transferrin saturation decreases (Frazer et al. 2002). As all these 
changes happen before any haematological or iron storage changes it is likely that there is 
another factor regulating gene expression. Serum transferrin saturation was a possible 
candidate for this regulatory factor as transferrin saturation was the only parameter to 
correlate with gene expression (Frazer et al. 2002) but this is not yet fully understood.
Hepcidin expression levels have been shown to respond to anaemia in a similar manner to 
the response to hypoxia. Mice that were bled or had undergone phenylhydrazine-induced 
hemolysis showed a decrease in hepcidin mRNA levels in the liver while iron absorption 
increased (Bondi et al. 2005;Latunde-Dada et al. 2004;Nicolas et al. 2002b;Vokurka et al.
2006). In thalassaemia syndromes despite the anaemia, an increased absorption of dietary 
iron leads to iron overload (reviewed by Andrews 1999). Although it has been shown that 
urinary hepcidin is decreased in patients with Thalassaemia Major and Thalassaemia 
Intermedia, hepcidin mRNA expression levels have not yet been described (Papanikolaou et 
ai. 2005). Our results show that hepcidin mRNA expression levels were not significantly 
different between the two thalassaemia groups; Thalassaemia Intermedia compared to 
Thalassaemia Major and that overall there was no significant difference between the 
thalassaemia patients (TM and TI) compared with healthy controls. The finding that hepcidin 
mRNA expression levels were significantly lower in thalassaemia patients with high liver iron 
concentrations and that hepcidin expression did not vary significantly with ferritin greater 
than 3000ng/ml or less than 1500ng/ml, suggests that hepcidin expression becomes 
disregulated above a critical level of iron burden.
A recent paper on the iron metabolism in a mouse model of p-thalassaemia reported 
intriguing results. In the early stages of the disease, hepcidin is low and this is associated 
with increased iron absorption, however, in older animals Hepcidin levels are raised and
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duodenal Iregl expression and intestinal iron absorption are also increased (Gardenghi et al.
2007). Again it is possible that in this case Hepcidin expression becomes disregulated above a 
critical level of iron burden resulting from the iron accumulation through time. This would 
explain the failure of Hepcidin expression to increase with further elevations in the iron 
accumulation and the inappropriately high iron absorption in already heavily iron-loaded 
patients.
To investigate the direct effects of hepcidin on intestinal iron transport we injected Hepcidin 
into male C57BL/6 mice fed on an iron adjusted diet and measured in vivo duodenal iron 
transport and changes in serum iron levels. Following administration of hepcidin mice showed 
a rapid decrease in serum iron, in accordance with published data reporting the association of 
high levels of hepcidin and hypoferremia (Rivera et al. 2005a). Our group has found that 
Iregl expression was significantly decreased in the spleen of mice injected with hepcidin 
which confirms that hypoferremia occurs as a consequence of hepcidin-mediated inhibition of 
iron release from reticuloendothelial macrophages through Iregl. Previous data from our 
group have also shown that in a macrophage cell line Iregl expression decreases significantly 
after treatment with Hepcidin for 24 hours (personal communication by Dr. Paul Sharp).
Despite the presence of hypoferremia, there was no difference in duodenal iron transport 
between the hepcidin-treated and control animals. Hepcidin treatment was also found to 
have no effect on Iregl expression in mice duodenum or in Caco-2 cells (personal 
communication by Dr. Paul Sharp).
Previous work from our group has shown that mice subjected to prolonged exposure to 
Hepcidin and Caco-2 cell monolayers expososed to high levels of Hepcidin, significantly 
decrease duodenal iron transport (Yamaji et al. 2004). The analysis of the iron transport data 
from both of our previous reports (Laftah et al. 2004;Yamaji et al. 2004) and from the study 
by Mena et al (Mena et al. 2006) suggests that the major effect of Hepcidin in intestinal 
epithelia is on the DMT1 uptake pathway and not on the Iregl-mediated efflux.
A survey of the literature on the association between hepcidin levels and intestinal transport 
reveals a cloudy picture. When hepcidin expression is low as is the case in anaemia and in
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hypoxic conditions, intestinal iron transport is elevated (Frazer et al. 2004b;Leung et al. 2005) 
however, the significant molecular changes were in the expression of DMT1 and Dcytb and 
not in the Iregl expression.
From this study, we have shown that the decrease in hepcidin mRNA expression levels seen 
in both the hypoxic animals and hypoxic cells may be responsible for the increased iron 
uptake reported (Leung et al. 2005). The events that culminate in reduced expression of the 
peptide at the hepatocyte level are still unknown and so the increase in iron transport might 
be a consequence of a direct effect of low oxygen via the transcription factor HIF and not the 
decrease in hepcidin expression levels.
Our study has also shown that hepcidin mRNA expression is not decreased in patients with 
Thalassaemia Major and Thalassaemia Intermedia. We have also shown that Hepcidin 
expression was significantly lower in thalassaemia patients with high liver iron concentrations, 
suggesting that hepcidin expression becomes disregulated above a critical level of iron 
content. In addition, the fact that thalassaemia patients still accumulated a high 
concentration of iron confirms that iron overload in the thalassaemia setting is less dominant 
than the anaemia in regulating Hepcidin expression.
The intestinal iron transport data obtained from the Hepcidin treated mice together with 
previous work from our group showing that the onset of hypoferremia does not coincide 
temporally with changes in duodenal iron transport, suggest that there is either a differential 
sensitivity to Hepcidin and/or a different mode of action of hepcidin at the recycling 
macrophage and the duodenal enterocyte. As mentioned in chapter 1, Iregl mutations lead 
to Ferroportin disease which is characterised by severe iron loading of the reticuloendothelial 
macrophages (reviewed by Pietrangelo 2004b). Interestingly in this disease enterocytes do 
not become iron loaded (Corradini et al. 2004) suggesting that Iregl expression in different 
cells respond differently to a Hepcidin challenge. This possibility is supported in part by the 
work of Drakesmith and colleagues who demonstrated that some mutant forms of Iregl are 
partially resistant to the actions of Hepcidin (Drakesmith et al. 2005). In addition, it might be 
possible that another as yet unidentified hepcidin "receptor", in addition to Iregl may be
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present on the plasma membranes of different cell types. Further studies will be required to 
clarify these important issues and some of them will be discussed in chapter 7 of this thesis.
208
Chapter 7
General Discussion
209
Regulation of iron homeostasis
The discovery of the Hfe gene, the identification of Hfe gene mutations as the main cause of 
hereditary Haemochromatosis and the identification of Hepcidin as a key regulator of iron 
homeostasis have contributed to our understanding of the molecular control of iron 
metabolism in recent years. In addition, the study of human diseases and the generation of 
genetically altered mice have led to the discovery and identification of new genes involved in 
iron homeostasis, but much remains to be understood.
The studies described in this thesis are aimed to analyse some regulatory components of iron 
homeostasis in a newly generated mouse model for hereditary Haemochromatosis type 1, 
SWR Hfe KO mice.
SWR Hfe KO as an animal model for hereditary haemochromatosis type 1
Hereditary Haemochromatosis type 1 (HH1) is an autosomal recessive disorder of iron 
metabolism caused by mutations in the Hfe gene. HH1 is characterised by defective 
regulation of dietary iron absorption that leads to excessive iron accumulation, mainly in the 
liver. The increased iron absorption in hemochromatosis is in part responsible for elevated 
transferrin saturation and transferrin-bound iron transport, which leads to cellular uptake of 
excess circulating iron and pathological expansion of body iron stores. This in turn results in 
the increased formation of the iron storage molecules ferritin and haemosiderin, especially in 
parenchymal cells of the liver. Progressive hepatic iron accumulation in humans leads to 
fibrosis, cirrhosis and subsequent increased morbidity and mortality. Several mouse strains 
have had their Hfe gene knocked out in order to study this disease but the full pathological 
picture of the cirrhotic liver seen in HH1 is still not observed in these animal models (Knutson 
et al. 2001). To address this problem we generated a new mouse model for HH1, the SWR 
Hfe KO mice. SWR mouse strain has been reported to have a higher basal iron status in the 
liver than other mouse strains (Clothier et al. 2000) and therefore could be an ideal candidate 
for the study of the development of fibrosis due to iron overload. In this study we have
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shown that when the murine Hfe allele was disrupted in the SWR strain, despite the higher 
basal iron status of this strain, hepatic iron contents were not similar to the ones seen in HH1 
patients nor were significantly higher than Hfe KO mice of other strains (Chapter 3). Iron 
loading in SWR Hfe KO mice was also shown to be insufficient to cause fibrosis. In humans it 
has been shown a differential distribution of iron content in the liver of patients with iron 
overload conditions (Ambu et al. 1995;Clark et al. 2003) but there is no information on iron 
content levels in the different hepatic lobes. Here we have shown that the disruption of the 
Hfe gene causes a preferential accumulation of iron in the caudate lobe of the SWR mouse 
liver. As the caudate lobe is one of the lobes studied when investigating cirrhosis in HH1 
patients the significantly higher accumulation of iron is this lobe might be of relevance for the 
study of how iron overload leads to the development of fibrosis. Overall our study suggests 
that the SWR Hfe KO mouse is not the ideal and most accurate mouse model for studying 
HH1 but it might help us elucidate the role of Hfe in the regulation of hepcidin expression in 
mice.
Regulation of hepcidin expression by dietary iron, apotransferrin, holotransferrin 
in SWR w t and Hfe KO mice
How hepcidin expression levels are regulated is still not clear and although the study of 
human diseases and animal models has led to the discovery and identification of new genes 
involved in iron homeostasis much remains to be understood. The expression of Hfe has 
profound effects on cellular iron status although changes in cellular iron status have little 
effect on the expression of Hfe. The precise function of the Hfe protein remains unknown but 
the discovery of hepcidin has contributed to our understanding of this protein. In hereditary 
haemochromatosis caused by Hfe mutations (HH1), inappropriately low levels of hepcidin 
expression have been observed (Ahmad et al. 2002;Bridle et al. 2003;Muckenthaler et al. 
2003). In addition, when Hfe KO mice were crossed with mice overexpressing hepcidin their 
iron overload status was normalized (Nicolas et al. 2003). These studies suggest that Hfe 
participates in the regulation of intestinal iron absorption by modulating hepcidin expression.
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To understand the role of Hfe in the regulation of hepcidin expression by iron, wt and Hfe KO 
SWR mice were fed diets with different iron contents (Chapter 4). Our data suggests the 
presence of a "regulatory iron pool" that directly regulates the expression of hepcidin, DMT1 
and Iregl expression in the liver. According to this proposed mechanism, the accumulation of 
a yet unknown level of iron content in this "regulatory iron pool" would result in an 
upregulation of Iregl and hepcidin expression in order to export the excess iron to avoid 
oxidative stress and lipid peroxidation in the liver and; decrease duodenal iron uptake, 
respectively. No difference in gene expression was found that could account for the 
differential iron accumulation between the lobes of Hfe KO SWR mice and therefore further 
investigation is required on the physiology of the murine liver. In SWR mice fed an iron 
overload diet the Hfe gene was shown not to be necessary for the regulation of Iregl in 
response to iron in accordance to the findings of Bridle and colleagues (Bridle et al. 2003). In 
contrast dietary iron was found to have no effect on hepatic DMT1 expression and therefore 
it is possible that Hfe might have a role in the regulation of this iron transporter in the liver. 
We have also found that apotransferrin or holotransferrin injections have no effect on 
hepcidin, hepatic DMT1 or Iregl expression in SWR mice and that iron deficient peripheral 
macrophages lacking the Hfe gene and do not produce any soluble factors that regulate 
Hepcidin expression in the setting of hereditary haemochromatosis differently to healthy 
subjects.
Regulation of hepddin expression by acute inflammation in SWR mice and pro- 
inflammatory cytokines in Huh7 cells
Injected LPS is mainly taken up by the Kupffer cells and is responsible for the upregulation of 
IL-6 in the liver (Ganz 2003) while turpentine oil injections lead to an induced local irritation 
which results in the recruitment of inflammatory cells and the upregulation of IL-6 in the 
injured muscle. In addition turpentine oil injection results in the production of IL-6, IL-lp and 
TNF-a in hepatocytes (Sheikh et al. 2007). In this study acute inflammation by LPS and 
turpentine oil was shown to be very different as models of inflammation in SWR mice
212
(Chapter 5). Inflammation by LPS injection in wt and Hfe KO mice was similar suggesting that 
Hfe does not have a role in the upregulation of hepcidin in response to LPS inflammation. In 
contrast, the disruption of the Hfe gene in SWR Hfe KO mice was shown to abrogate the 
gene expression of hepcidin, hepatic DMT1 and Iregl in response to turpentine oil injection. 
We have also found that TNF-a does not have an effect on hepcidin, hepatic DMT1 or Iregl 
despite having a direct effect on duodenal DMTl+ire expression. In addition IL-6 was shown 
to upregulate hepcidin levels on hepatocytes but have no effect on the expression of iron 
transporter genes in the enterocyte as previously suggested (Raja et al. 2005). Studies in 
human hepatoma (Huh7) cells have shown that IL-lp induces hepcidin expression in an IL-6 
independent mechanism (Inamura et al. 2005). Taken together the data obtained in this 
study suggest that the disruption of the Hfe gene prevents the release of IL-lp in response to 
acute inflammation by turpentine oil injection preventing hepcidin upregulation in Hfe KO 
mice (Fig. 7.1).
Wild-type SWR mice
LPS injection
Turpentine
injectionIL-6)IL-6, il - i p ;
TNF-a ;
IL-6,
HEPCIDIN
Hfe KO SWR mice
LPS injection
Turpentine
injectionIL-6IL-6, iL - ip ,
T N F-a /
HEPCIDIN
Figure 7.1 Proposed mode of action of LPS and Turpentine oil-induced cytokines in 
the regulation of Hepcidin. Injected LPS is mainly taken up by the Kupffer cells and is 
responsible for the upregulation of IL-6 while turpentine oil injections lead to an induced local 
irritation which results in the recruitment of inflammatory cells and the upregulation of IL-6 in 
the injured muscle. In addition turpentine oil injection results in the production of IL-6, IL-lp  
and TNF-a in hepatocytes. Our findings lead us to postulate that the disruption of the Hfe
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gene prevents the release of cytokines such as IL -lp  in response to acute inflammation by 
turpentine oil injection preventing hepcidin upregulation in Hfe KO SWR mice.
Regulation of hepddin expression by hypoxia and anaemia
Hypoxia and anaemia have been shown to decrease hepcidin expression levels and it is 
thought that by doing so iron absorption increases to enable the iron to be delivered to bone 
marrow to sustain the production of erythrocytes (erythropoiesis) (Bondi et al. 2005;Latunde- 
Dada et al. 2004;Nicolas et al. 2002b;Vokurka et al. 2006). Recent work from our laboratory 
on rats has shown that increased entry of iron in the body during hypoxia occurs by both 
stimulation of iron entry across luminal membrane into the enterocyte and enhanced iron 
transfer across the basolateral membrane into the perfusing blood (Laftah et al. 2004;Leung 
et al. 2005;Nicolas et al. 2002b). In this study we describe for the first time the long term 
effect of hypoxia on hepcidin levels in rats (Chapter 6). We have shown that not only does 
hepcidin decrease significantly after 4 weeks hypoxia but work by our group has shown that 
hypoxia stimulates iron uptake by both mature enterocytes at the upper villus as well as 
newly differentiated cells at the base of the villus (Leung et al. 2005). The events that cause 
reduced expression of the hepcidin are still unknown and so the increase in iron transport 
induced by hypoxia could be a consequence of a direct effect of low oxygen via the 
transcription factor HIF and not the decrease in hepcidin expression levels. How hypoxia- 
induced changes in transport along the villus relate to the distribution profile of the hepcidin 
receptor is still unknown due to the lack of a suitable antibody.
Iron uptake has been shown to increase significantly in iron deficient conditions without 
changes in iron stores or increased erythropoiesis. In these conditions duodenal DMT1 and 
Iregl are increased and hepcidin and transferrin saturation are decreased (Frazer et al. 
2002). One such condition is thalassaemia where despite of the anaemia setting, an 
increased absorption of dietary iron leads to iron overload (Andrews 1999). Although it has 
been shown that urinary hepcidin is decreased in patients with Thalassaemia Major (TM) and 
Thalassaemia Intermedia (TI) (Papanikolaou et al. 2005), hepcidin mRNA expression levels 
have not yet been described. Our study shows that mRNA expression of the peptide is not
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different between thalassaemia patients and healthy controls or even between the two types 
of thalassaemia (TM and TI). An interesting finding was that hepcidin expression levels were 
significantly lower in thalassaemia patients with high liver iron concentrations suggesting that 
hepcidin expression becomes disregulated above a critical level of iron burden. Recently a 
mouse model of ^-thalassaemia demonstrated that in the early stages of the disease, 
hepcidin is low and this is associated with increased iron absorption, however, in older 
animals hepcidin levels are raised and duodenal Iregl expression and intestinal iron 
absorption were also increased (Gardenghi et al. 2007). It is possible that the iron 
accumulation through time in thalassaemia patients results in the failure of hepcidin 
expression to increase with further elevations in the iron accumulation and with the 
inappropriately high iron absorption in already heavily iron-loaded patients.
Hepddin as a regulator of iron metabolism
After studying the modulators of hepcidin expression, we investigated the direct effect of 
Hepcidin on iron metabolism. Our results show that administration of Hepcidin in mice 
decreases serum iron levels as shown in inflammatory conditions. Work by our group has also 
shown that Iregl expression was significantly decreased in the spleen of mice injected with 
hepcidin which confirms that hypoferremia occurs as a consequence of hepcidin-mediated 
inhibition of iron release from reticuloendothelial macrophages through Iregl. Despite 
becoming hypoferremic, there was no difference in duodenal iron transport between the 
Hepcidin-treated and control animals or in duodenal Iregl expression levels. This data 
suggests that there is either a differential sensitivity to Hepcidin and/or a different mode of 
action of Hepcidin at the recycling macrophage and the duodenal enterocyte. Some mutant 
forms of Iregl have been shown to be partially resistant to the actions of Hepcidin 
(Drakesmith et al. 2005) and this could explain the lack of Iregl expression changes after 
Hepcidin treatment. In addition, it might be possible that other as yet unidentified Hepcidin 
"receptor", in addition to Iregl may be present on the plasma membranes of different cell 
types.
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Condusions
From the collective studies described in this thesis we can conclude that:
• SWR Hfe KO mice does not produce the full pathological features seen in HH1 
patients liver,
• the disruption of the Hfe gene causes a preferential accumulation of iron in the 
caudate lobe of the SWR mouse liver and this differential deposition of iron is not due 
to gene expression differences in the hepatic lobes,
• Upregulation of hepcidin expression in iron loaded condition or in inflammation does 
not have a direct effect on hepatic DMT1 and Iregl instead it is possible that a 
"regulatory iron pool" exists in the hepatocytes that could regulate these iron 
transporter genes expression in the liver,
• Constant high levels of hepcidin appear to have a direct effect on duodenal iron 
transporter gene expression although this requires further investigation,
• Hfe gene has a vital role in the upregulation of hepcidin in acute inflammation 
induced by turpentine oil but not by LPS, suggesting that IL-lp might have a relevant 
role in the up regulation of hepcidin caused by turpentine oil-induced inflammation,
And finally, our knowledge of the regulation of duodenal iron uptake, the relevant 
modulator genes and the recent finding that the liver plays a central role in iron 
homeostasis, signify that the role of hepatic iron transporter gene expression and how 
they are regulated deserves further investigation. Studies described here contribute to 
the understanding of how the hepatocyte responds to iron status, hypoxia and 
inflammation and the relevance of the Hfe gene in the regulation of hepcidin, DMT1 and 
Iregl expression in the liver however, further studies are required to elucidate the 
systemic and integrative homeostasis of iron.
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Future W ork
The development of the SWR Hfe KO mice resulted in elevated liver iron levels but this did 
not lead to fibrosis. This might be due to the inability to reach high liver iron levels equivalent 
to those found in HH1 patients. More likely it is due to other modifier genes and 
environmental factors. In order to improve this model, SWR Hfe KO mice should be studied at 
later stages (two years), and fed on iron overload diet for longer periods of time. In addition, 
other factors such as alcohol and viral infections should be introduced to this model on top of 
gene knockout.
We were unable to say whether holotransferrin or apotransferrin are detected by the liver to 
sense body iron status. Therefore further studies investigating the effect of holotransferrin 
and apotransferrin together with studying the resulting levels of TfR2, Hfe, hemojuvelin, iron 
transporters and hepcidin expression need to be studied at both mRNA and protein levels to 
determine if there is a sensing mechanism involving holotransferrin and if so what is the 
mechanism.
In order to investigate further the role of Hfe in the turpentine oil effect on hepcidin 
expression, more experiments need to be performed. The effect of turpentine oil in a time 
dependent manner on cytokines and hepcidin expression needs to be investigated.
Once an array of cytokines which are produced and their appearance and disappearance with 
time is worked out then individual cytokines need to be injected into mice to investigate their 
effect on hepcidin and serum iron status. The link between hepcidin and iron efflux from 
duodenum and macrophages needs to be further investigated.
In this study we have dearly shown that expression of hepcidin and iron transporters in 
hepatocytes is not dependent of total liver iron levels but possibly on a "regulatory iron pool". 
This pool needs to be defined in the Hfe KO model and wild type mice.
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Disease or condition Gene
responsible
Human
mutation/s
Mouse
model
Strains of
Mouse
Model
References *
Haemochromatosis
HFE
R74X, G93fs
(nonsense
mutations)
HFE KO
C57BL/6
(Bahram et al. 
1999;Bensaid et 
al. 2004;Chua et 
al. 2004;Dupic 
etal.
2002a; Fleming 
etal.
2001;Knutson et 
al. 2001;Lebeau 
etal.
2002;Trinder et 
al. 2002b)
DBA (Bensaid et al. 
2004;Dupic et 
al. 2002a)
AKR (Fleming et al.
C3H 2001)
C282Y
C282Y KO (Levy et al. 
1999b)
C294Y (Tomatsu et al. 
2003)
H63D H67D
C57BL/6J
HJV HJV KO
(Huang et al. 
2005)
At least 30
(Niederkofler et 
al. 2005)
USF2 (Nicolas et al. 
2001)
C/EBPa BALB/cJ (Courselaud et 
al. 2002)
TFR2
At least 5 TFR2 KO
C57BL/6J
(Wallace et al. 
2005)
X250Y TFR2Y245X (Fleming et al. 
2002)
Ferroportin Disease IREG1 At least 12 Fpn
(null/null)
N/A (Donovan et al. 
2005)
Acaeruiopiasminemia CP several CP KO black Swiss- 
Webster
(Harris et al. 
1999)
A transferrinaemia Transferrin Only 3 cases 
to date
jrfhpx/hpx BALB/q (Craven et al. 
1987;Trenor, I I I  
et al. 2000)
Table I  Mouse models of primary iron overload diseases
* References are representative publications that refer to the mouse models and not to the 
human diseases mentioned
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Parameters Hepddin
mRNA (% of 
control)
SEM P
Liver iron >10 mg/g dry weight (n=5) 85 12
0.3Liver iron>5 <10 mg/g dry weight (n=8) 131 32
Liver iron <5 m g/g dry weight (n=5) 131 16 0.05*
Ferritin >3000ng/m i (n=6) 1178 34
NSFerritin <1500ng/m i (n=7) 116 29
AST>80iu/i (n=4) 67.0 11.9
NSAST<80iu/t (n=12) 106.9 15.8
Table I I  Factors affecting hepddin expression in all Thalassaemic patients 
fThalassaemia Maior and Thalassaemia Interm edia). Aspartate transaminase (AST), *  
Denotes significant difference in hepcidin expression between subjects with liver iron greater 
than 10 mg/g dry weight compared to subjects with liver iron below 5 mg/g dry weight; 6 
Ferritin >  1501 and <2999 ng/ml (n = 7 ), not shown on the table, hepcidin values (mRNA % )  
similar to those described on the table.
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Abstract.
Clearance of plasma non-transferrin bound iron (NTBI) occurs predominantly by 
hepatocytes and is enhanced by iron loading, through poorly defined mechanisms. Using 
iron:citrate and human hepatoma HuH7 cells to model hepatocyte NTBI uptake, we show 
this occurs through T-type but not L-type voltage dependent calcium channels (VDCC). 
Uptake saturates at 6pM extracellular iron, is maximal at neutral pH, is enhanced by 
ascorbate and by extracellular Ca2+ and is directly proportional to intracellular iron 
concentrations. Ferrous and ferric iron uptake is inhibited by a range of divalent cations 
but metabolic and endocytic inhibitors have minimal effect. DMT1 antibody fails to inhibit 
uptake, in contrast to CaCo2 cells, and DMT1(±IRE) mRNA is unaffected by iron loading 
of HuH7 cells. Enhancement of iron uptake by membrane depolarisation with KC1 or by 
iron loading is attenuated by T- but not L-type VDCC inhibitors. Enhanced iron uptake 
by cellular iron preloading may be post-transcriptional because this failed to up-regulate 
T-type VDCC mRNA and because inhibitors of mRNA or protein synthesis did not 
abrogate this enhancement. As the iron uptake mechanism into hepatocyte like cells differs 
from that reported for cardiac myocytes (L-type VDCC), selective therapeutic inhibition of 
the latter may be feasible.
word count 197
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Introduction
Plasma transferrin becomes saturated in iron overload conditions or when haematopoiesis 
is interrupted (Hershko, Graham et al. 1978); (Batey, Lai Chung Fong et a l 1980; Bradley, 
Gosriwitana et al. 1997), leading to non-transferrin bound iron species in plasma at 
concentrations up to 10pM (Porter, Abeysinghe et al. 1996). Plasma NTBI is chemically 
heterogeneous but a significant proportion is bound to plasma citrate (Grootveld, Bell et al. 
1989) and some is loosely associated with plasma proteins such as albumin (Lovstad 1993; 
Loban, Kime et al. 1997). The distribution of NTBI uptake into tissues differs from transferrin 
mediated uptake (Craven, Alexander et a l 1987) and is responsible for the iron loading of 
pancreas, anterior pituitary and cardiac myocytes in transfusional iron overload. The liver is the 
predominant site of iron storage in iron overload and clears 60-80% of NTBI by first pass 
extraction (Zimelman, Zimmerman et a l 1977; Brissot, Wright et a l 1985). The mechanism of 
NTBI uptake into hepatocytes however is still unclear and is addressed in this paper. A second 
question that is addressed is how iron loading or iron depletion of cells may modulate NTBI 
uptake. A number of studies have shown that NTBI uptake into hepatocytes is up-regulated by 
iron loading (Randell, Parkes et al. 1994; Parkes, Randell et al. 1995; Scheiber-Mojdehkar, 
Zimmermann et al. 1999) whilst others have failed to see any effect (Wright, Brissot et al. 1986; 
Baker, Baker et al. 1998).
Studies on NTBI uptake mechanisms in intact animals (Craven, Alexander et al. 1987), 
liver perfusion models (Brissot, Wright et al. 1985; Wright, Brissot et al. 1986; Wright, Fitz et 
al. 1988), primary cultures of rat hepatocytes (Thorstensen 1988; Thorstensen and Romslo 1988; 
Barisani, Berg et al. 1995; Baker, Baker et al. 1998; Graham, Morgan et al. 1998; Graham, 
Morgan et al. 1998) or human hepatoma cells (Randell, Parkes et al. 1994; Parkes, Randell et
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al. 1995; Trinder and Morgan 1998), favour the involvement of a temperature-sensitive, 
saturable, carrier-mediated process, which has a pre-requisite for ferric iron reduction, is driven 
by a transmembrane potential difference, is calcium-dependent and is inhibited by other divalent 
cations. A candidate for hepatocellular NTBI uptake is the divalent metal transporter, DMT1, 
but there is conflicting evidence regarding its role (Trinder, Oates et al. 2000; Gunshin, Allerson 
et al. 2001; Gunshin, Fujiwara et al. 2005). In this paper we have investigated the possible role 
of DMT 1-mediated iron uptake and have examined the possibility of alternative mechanisms.
A common feature of tissues susceptible to iron overload is the large number and activity 
of voltage-dependent calcium channels (VDCC) (Catterall 2000; Muth, Varadi et al. 2001; Peri, 
Triggle et al. 2001). Recently, it has been shown that VDCC may provide a major pathway for 
iron entry into cardiac cells under conditions of iron overload (Oudit, Sun et al. 2003; Oudit, 
Trivieri et al. 2006). However studies with L-type specific calcium channel antagonists in 
HepG2 cells (Randell, Parkes et al. 1994) and neonatal cardiac myocytes (Parkes, Olivieri et al. 
1997) reported little or no effect on iron uptake. In human liver, five different subtypes of 
VDCC are known to be expressed; the L-type Cay 1.1, 1.2 and 1.3 and the T-type Cav 3.1 and 3.2, 
although their function is not known (Williams, Washburn et al. 1999; Okamoto, Jeong et al. 
2001). Currently, pharmacological differentiation is the best means for distinguishing between 
the different channel types. The L-type channels are blocked by organic calcium channel 
antagonists, including dihydropyridines (e.g. nifedipine), phenylalkylamines (e.g. verapamil) and 
benzothiazepines (e.g. diltiazem). The N, P/Q and R-type channels are relatively insensitive to 
the L-type calcium channel antagonists but are blocked by specific polypeptide toxins, including 
the conotoxins and agatoxins (Abernethy and Schwartz 1999; Triggle 1999). The T-type 
channels are resistant to both the organic antagonists and to the polypeptide toxins but are
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preferentially blocked by the benzimidazole, mibeffadil (Martin, Lee et al. 2000) and by the 
diphenylbutylpiperidines, such as pimozide and penfluridol (Enyeart, Biagi et al. 1992).
Here we have used the HuH7 cell line, derived from human hepatoma cells and iron 
citrate at physiologically-relevant concentrations as a model for NTBI uptake into hepatocytes. 
HuH7 cells produce liver-specific enzymes, G6Pase and FDPase, in addition to a range of 
plasma proteins and retain differentiated functions of hepatocytes when grown in fully defined 
synthetic medium (Nakabayashi, Taketa et a l 1982), unlike primary hepatocyte cultures which 
may loose differentiated functions. This cell line has also been previously used to characterise 
hepatic NTBI uptake (Trinder and Morgan 1998). In this study we demonstrate for the first time 
that hepatic NTBI uptake can be mediated by T-type VDCC.
Intro 761 words
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Materials- 59Iron(III) chloride (in 0.1 M HC1) was purchased from GE Healthcare (Amersham, 
Bucks, UK). RPM1 1640 medium containing L-glutamine and 25 mM HEPES buffer, was 
purchased from Gibco BRL (Invitrogen Life Technologies Inc, Paisley, UK). Foetal calf serum 
was from PAA Laboratories (Somerset, UK). Pronase was purchased from Roche Diagnostics 
Ltd (East Sussex, UK). Deferoxamine (Desferal®) was obtained from Novartis (Basel- 
Switzerland). Iron atomic absorption standard solution and 2,4-dinitrophenol were from Aldrich 
Chemical Company Inc (Dorset, UK). Manganese(II) chloride, calcium chloride 2-hydrate, 
copper (II) chloride 2-hydrate, zinc (II) chloride, cadmium (II) chloride 1-hydrate, cobalt (II) 
chloride 6-hydrate, nickel (II) chloride 6-hydrate, iron (II) sulphate 7-hydrate and citric acid, 
potassium chloride were purchased from VWR International, Dorset, UK. Dulbecco’s modified 
Eagle’s minimal essential medium (DMEM), penicillin, gentamicin, streptomycin, Trypan blue, 
ferric ammonium citrate (FAC), ascorbic acid, dimethyl sulfoxide (DMSO), Bafilomycin Ai 
(from Streptomyces griseus), verapamil, nifedipine, mibefradil, NNC 55-0396, pimozide, 
penfluridol, amiloride, ethosuximide, BayK8644, kurtoxin, cycloheximide, actinomycin D and 
MOPS (3-[N-Morpholino] propanesulfonic acid) were from Sigma (Dorset, UK). All chemicals 
were of analytical grade. De-ionized water produced by a Millipore Ultrapure system 
(Simplicity 185, Millipore, Watford, UK) was used throughout.
Antibodies- DMT1 (Divalent Metal Transporter 1) polyclonal antibody, raised in rabbit against a 
synthetic peptide corresponding to amino acids 310-330 of the human DMT1 sequence, was 
prepared as described previously (Tandy, Williams et al. 2000). Non-immunized rabbit serum 
was purchased from DakoCytomation (Denmark).
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Cell Culture- The HuH7 human hepatoma cell line was obtained from Dr Nikolai Naoumov 
(Institute of Hepatology, UCL, London, UK). HuH7 cells were grown in monolayer culture in 
RPMI 1640 medium containing L-glutamine and 25 mM HEPES buffer, supplemented with 10% 
heat-inactivated foetal calf serum, 100 U/ml penicillin and 50 pg/ml gentamicin. Caco-2 TC7 
cells were cultured in DMEM supplemented with 10% heat-inactivated foetal calf serum, 100 
U/ml penicillin and 0.1 mg/ml streptomycin. Cells were seeded at a density of 1.5-2.0 x 105 cells 
per 80-cm2 flask (Nunclon, Nunc Brand) and grown at 37°C in a humidified atmosphere of 5% 
CO2 in air. Cell viability was determined by Trypan blue dye exclusion.
Non-Transferrin Bound Iron (NTBI) Preparation
Ferric(III) citrate complex- A stock solution of ferric citrate was prepared by mixing 10 pM of 
labelled (59FeCl3) and unlabeled FeCh in 0.1 M HC1 (iron atomic absorption standard solution) 
with 100-fold molar excess of citrate (1 mM). The solution was diluted 1:10 in serum-free 
RPMI medium to give a final pH of 7.4, before adding to cells. Where a low pH was required, 
the RPMI medium was adjusted with concentrated HC1 to the required pH prior to diluting the 
ferric citrate complex.
0  4-Ascorbate-reduced ferric citrate- In order to measure ferrous (Fe ) uptake in the Caco-2 cells, 
ferric citrate was prepared by mixing a 10 pM solution of 59FeCl3/ FeCh (in 0.1 M HC1) with 
100-fold molar excess of citrate (1 mM) and 100-fold molar excess of ascorbate (1 mM). The 
solution was diluted 1:10 in serum-free DMEM to give a final pH of 7.4, before adding to cells. 
Where a low pH was required the DMEM was adjusted with concentrated HC1 before using to 
dilute the complex. For HuH7 cells, the ascorbate-reduced ferric citrate complex was prepared
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in RPMI medium in place of DMEM. The specific activity of all preparations was in the range 
of 150-200 cpm/pmol Fe.
NTBI Uptake Measurement - HuH7 cells were plated in 60/15 mm CellStar™ tissue culture 
dishes (Greiner Bio-One) at a density of 2 x 106 cells/dish and grown for 24 h in RPMI medium 
supplemented with 10% FCS, 100 U/ml penicillin and 50 pg/ml gentamicin, until confluent 
monolayers were formed. To minimize contamination with transferrin, on the day of the uptake 
experiment the cells were washed twice in serum-free RPMI medium, incubated for 1 h in 
serum-free medium to allow recycling of internalized transferrin-receptor complexes, and 
washed a third time with medium prior to the addition of label. The cells were then incubated 
with 1 ml of 1-10 pM of the [59Fe]-NTBI label, usually for up to 1 h at 37°C. 0.5 pCi of 59Fe 
was added per plate which was equivalent to adding -150 000 cpm per plate. At the end of the 
incubation period, the label was removed and the cells washed four times in ice-cold serum-free 
RPMI medium to terminate uptake. Internalized and membrane-associated iron were determined 
by incubating cells with 1 mg/ml pronase at 4°C for 30 min. This procedure also released the 
cells from the culture dishes. The resulting cell suspension was then centrifuged at 10 400 rpm 
for 30 s and the radioactivity in the cell pellet (internalized iron) and supernatant (membrane- 
bound iron) was counted in a LKB Wallac 1282 Compugamma Universal gamma counter 
(Perkin-Elmer, Bucks, UK).
For Caco-2 iron uptake, cells were plated at low density (1x10s cells/ 60 mm plate) and grown 
for 20 days in supplemented DMEM (10% heat-inactivated foetal calf serum, 100 U/ml
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penicillin and 0.1 mg/ml streptomycin) by which time they became fully differentiated and 
displayed a small intestine phenotype, as has been described previously (Chantret, Rodolosse et 
al. 1994). Cells were washed before incubating with ascorbate-reduced 59[Fe]-ferric citrate and 
processed as described for the HuH7 cells, except that the RPMI medium was replaced with 
DMEM throughout.
All determinations were made in triplicate within each experiment. Experiments were repeated 
up to three times, and the data shown is representative of a typical experiment. The results are 
expressed as mean ± SD. The rate of 59Fe uptake is expressed as pmol/min/2 x 106 cells. The 
rate was not corrected for protein as the pronase added to the cells at the end of uptake 
experiment was found to give variable protein determinations, causing large variations in the 
protein corrected rate. Expressing the rate as pmol per min per number of cells plated (2 x 106) 
was shown to be a reliable parameter; changes in the rate of iron uptake were found to be 
consistent when the rate of iron uptake expressed as pmol/min/number of cells plated was 
compared to the protein corrected rate, pmol/min/mg protein, obtained when the pronase digest 
had been omitted.
Modulation of Iron Status- Iron loaded cells were obtained by incubating HuH7 monolayers (in 
60 mm cell culture dishes) with supplemented RPMI medium containing various amounts of 
ferric ammonium citrate (FAC; 17.5% Fe by weight) for 24 h, as described by (Parkes, Randell 
et al. 1995). Iron depleted cells were obtained by incubating monolayers with supplemented 
RPMI medium containing various concentrations of the iron chelator, desferoxamine (DFO) for 
24 h. At the end of the incubation period, the FAC/DFO media was removed and the cells
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washed extensively with serum-free RPMI medium to remove extracellular iron. Control cells 
were treated in the same way, except that the FAC and DFO were omitted from the medium. 
The rate of NTBI uptake was determined as described above. For RT-PCR analysis, cells were 
scraped in 1 ml of KNAlater® (Ambion, Cambs, UK) to preserve the RNA and the cell 
suspension spun and the pellet retained for subsequent RNA isolation.
Quantitation o f Intracellular Iron Content- The total iron content of control and iron loaded 
HuH7 cells was measured by the colorimetric ferrozine-based assay as described by (Riemer, 
Hoepken et al. 2004). Briefly, cells were lysed with 50 mM NaOH overnight in a humidified 
atmosphere. To release iron complexed to cellular proteins the cell lysate was incubated with an 
acidic KMn04 solution for 2 h at 60°C before adding the ferrozine reagent. The samples were 
transferred to a 96-well plate and the absorbance measured at 595 nm on an Anthos 2001 
microplate reader (Anthos Labtec Instruments GmbH, Austria). The iron content of the cell 
sample was calculated by comparing its absorbance to that of a range of FeCh standards 
prepared in the same way and the results normalized against the protein content of the cell lysate.
Determination o f Protein Content- The protein content of the cell lysates was determined with 
the Coomassie Plus™ (Bradford) Protein Assay Kit (Perbio Science UK Ltd) using bovine 
serum albumin as the standard.
Modulators o f NTBI Uptake
Ascorbate, Calcium, and KCl- Stock solutions of ascorbate, calcium chloride and potassium 
chloride were prepared in water and subsequently diluted in RPMI medium to the required
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concentration. All solutions were sterile-filtered by passing through Minisart 0.2 pm syringe 
filters (Sartorius Ltd, Surrey, UK) before adding to the cells. For these experiments the specific 
modulator was added concurrently with the addition of the [59Fe]-NTBI label and the rate of 
NTBI uptake determined as described.
Divalent Metal Ion Competition- the effect of divalent cations on NTBI uptake was determined 
by adding 0-100 pM of Cu2+, Zn2+, Cd2+, Co2+, Ni2+, Mn2+ or Fe2+ to lpM  [59Fe]-ferric citrate 
(Fe3+ uptake) or to lpM  [59Fe]-ferric citrate plus 100 pM ascorbate (Fe2+ uptake). All competing 
metals were used as their chloride salts except Fe2+, which was added as ferrous sulphate.
Metabolic and endocytic inhibitors- Stock solutions of the ATP synthesis inhibitor 2,4- 
dinitrophenol (2,4-DNP) and of the pinocytosis inhibitor, Bafilomycin Ai were prepared in 
DMSO and subsequently diluted in serum-free RPMI medium to achieve the desired 
concentration. For these studies, the cells were pre-incubated for 1 h at 37°C with the indicated 
concentration of inhibitor which was removed before adding the [59Fe]-NTBI, to prevent the 
DMSO precipitating the iron in the label. Control cells received the same concentration of 
DMSO (0.5-2% v/v).
Protein Synthesis Inhibitors- Stock solutions of the protein synthesis inhibitor cycloheximide and 
the mRNA synthesis inhibitor actinomycin D were prepared in DMSO and subsequently diluted 
in serum-free RPMI medium to the required concentration. Cells were pre-incubated for 1 h at 
37°C with 350 pM cycloheximide or 3.98 pM actinomycin D and the inhibitors removed before 
determining the rate of iron uptake with [59Fe]-NTBI. Control cells received the same
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concentration of DMSO (0.5% v/v). To determine the involvement of de novo protein synthesis 
on FAC stimulated iron uptake, cells were incubated with medium containing FAC and the 
protein synthesis inhibitors for 24 h after which the cells were washed extensively before 
determining the rate of iron uptake. Control cells were incubated with FAC medium only.
Calcium Channel Inhibitors- Stock solutions of the L-type calcium channel modulators 
verapamil, nifedipine, (i?)-(+)-Bay K8644, (S)-(-)-Bay K8644 and the T-type calcium channel 
blockers pimozide, penfluridol and amiloride were prepared in DMSO whilst the water-soluble 
T-type antagonists, mibeffadil, NNC 55-0396 and kurtoxin were prepared in water. 
Ethosuximide was prepared in ethanol. Stock solutions were diluted in serum-free RPMI to the 
required concentration. Cells were treated with the inhibitors for 1 h at 37°C which were 
removed before determining the rate of [59Fe]-NTBI uptake. Control cells received the same 
concentration of DMSO or ethanol (0.5-2% v/v). To determine the involvement of calcium 
channels in FAC-stimulated iron uptake, cells were incubated with medium containing FAC and 
the appropriate calcium channel inhibitor for 24 h after which cells were washed extensively 
before determining the rate of iron uptake. Control cells were incubated with FAC medium only.
Antibody Blocking Studies- Unless stated otherwise, cells were pre-incubated with DMT1 
antibody for 30 min at 37°C, at dilutions of 1:20-l :50. The antibody solution was removed prior 
to measuring the rate of NTBI uptake. Control cells were incubated with the same dilution of 
pre-immune sera from the same rabbit or with commercially obtained non-immunized sera from 
clinically healthy normal rabbits.
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RNA Isolation- RNA was extracted from HuH7 cells treated with RNAlater® (Ambion, Cambs, 
UK), using the RNAqueous™-PCR kit for isolation of DNA-ffee RNA (Ambion, Cambs, UK), 
according to the manufacturer’s instructions.
RT-PCR Analysis- Primers to the genes of interest in the HuH7 cells were designed using the 
LightCycler-probe design software (Version 1.0, Daho Technology Inc., 2001). 1 pg of total 
RNA was used for cDNA synthesis with the Abgene Reverse-iT First Strand Synthesis Kit using 
the PTC-100 Thermal Cycler (MJ Research, Essex, UK). Real-time quantitative gene analysis 
was performed using a LightCycler System (Roche Molecular Biochemicals, Mannheim, 
Germany), and QuantiTect SYBR Green PCR Kit (Qiagen, Crawley, UK). The PCR reaction 
conditions were as suggested in the manufacturer’s protocol. This included an initial hot start at 
95°C for 15 min, followed by PCR cycling: denaturation at 94°C for 15 sec, annealing at 60°C 
for 20 sec, extension at 72°C for 30 sec. The temperature was increased to 2°C below the 
product melting temperature for 5 sec before fluorescent acquisition at the end of each PCR 
cycle. Melting curve analysis was performed after each PCR run to determine the specificity of 
the completed reaction. Each run was performed in duplicate. To quantitate the initial amount 
of template in each reaction the second derivative maximal method was used. This method 
determined the cycle number at which there was the maximum acceleration to the log linear 
phase of PCR, this was termed the threshold cycle (Ct). Standard curves were produced for all 
primer sets. Purified DNA from PCR amplification using primers were serially diluted 10-fold. 
Standards were run in duplicate alongside glyceraldehyde phosphate dehydrogenase (GAPDH) 
standards produced in a similar fashion. RT-PCR was performed and the dilution range of the
NTBI Uptake Mechanisms in Human Hepatoma Cells 14
starting template was adjusted to give a linear range covering 20-25 cycles. All standard curves 
covered a dynamic range of at least 5 logarithmic orders.
The relative amounts of the target and the reference genes in the samples were then calculated 
based on the crossing-point analysis (Relative Quantification Software, version 1.01, Roche); the 
second derivative maximum method was used to automatically determine the crossing point for 
individual samples. To correct for differences in both RNA quality and quantity between 
samples, data were normalized using the ratio of the cDNA of interest to that of the 
housekeeping gene, GAPDH which were assessed in parallel during each experimental run.
RNA isolation was performed using Qiagen RNAeasy Kit (Qiagen, Sussex, UK), and 1 g of total 
RNA was used for cDNA synthesis with ABgene Reverse-iT 1st Strand Synthesis Kit (ABgene, 
Surrey, UK). RNA concentration and purity were determined by spectrophotometry. The 
resulting cDNA transcripts were used for real time polymerase chain reaction PCR (RT-PCR), 
amplification using the Roche Lightcycler (Roche Diagnostics, Germany) and QuantiTect SYBR 
Green PCR kit (Qiagen, Sussex, UK), according to the manufacturers’ protocol. Primers to the 
genes of interest and the to the constitutively expressed gene glyceraldehydes phosphate 
dehydrogenase (GAPDH) in the Huh7 cells were designed from the human sequences using the 
Lightcycler-probe design software (Version 1.0, Daho Technology Inc., 2001).
To quantify mRNA expression of the genes of interest, standard curves were generated with 
known amounts of each gene product. A ratio of relative abundance of the gene of interest to 
GAPDH was calculated by the Lightcycler Relative Quantification software version 1.0 (Roche
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diagnostics, Germany). Melting curve analysis was carried out to ensure primer specificity. PCR 
product were also analysed by gel eletrophoresis and visualised using a Bio-Rad multilmager 
(Bio-Rad, Herts, UK).
Statistical Analysis- The Student’s t test (unpaired) was employed to compare significant 
differences between two data sets. Differences were considered significant at p < 0.05.
(Words 2294)
Results 
General Characterisics of NTBI Uptake Mechanism
Effects o f Iron and Citrate Concentration. The uptake of internalized iron from increasing 
concentrations of ferric citrate (1:100) at 37°C saturated at an iron concentration of 
approximately 6 pM, suggesting an iron-carrier mediated process may be involved. Less than 
10% of the total uptake was associated with the membrane under these conditions (Fig. 1 A).
The effect of increasing citrate:iron ratio on ferric citrate uptake was determined by incubating 
cells with iron citrate species prepared with increasing concentrations of citrate (1-10 mM) and a 
constant iron concentration of 1 pM. Optimal iron uptake was observed at ironxitrate ratios of 
1:1 to 1:100 whilst at the higher ratios (>1:500) uptake was reduced by 60-80% (Fig. IB). 
Interestingly, polymeric iron uptake (no citrate) was taken up almost as efficiently as oligomeric 
and dimeric iron citrate species (1:1-1:100 iron: citrate).
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Fig. 1. Effect of iron and citrate concentration on iron uptake in HuH7 cells. (A) Effect o f increasing iron 
concentration on iron citrate uptake in human hepatoma cells. HuH7 cells were incubated with increasing 
concentrations of 59Fe-citrate at a constant iron citrate ratio of 1:100, for 60 min at 37°C. The figure shows 
intracellular ( ♦ )  and membrane-associated (□) uptake. (B) Effect of increasing citrate concentration on iron 
citrate uptake in human hepatoma cells. HuH7 cells were incubated with increasing concentrations o f citrate at a 
constant iron concentration o f 1 pM, for 60 min at 37°C. The figure shows intracellular (solid bars) and membrane- 
associated (open bars) uptake. Results are expressed as mean ± SD of triplicate determinations.
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Effect o f Ascorbate. To determine what effect the redox state of iron had on the NTBI uptake 
mechanism, increasing concentrations of ascorbate (0-1000 pM) were used to reduce ferric iron 
to the ferrous form. Uptake of iron citrate was stimulated by ascorbate in a concentration- 
dependent manner up to a concentration of 500 pM ascorbate at which maximal stimulation of 
260% was observed (Fig. 2). Higher concentrations had no further stimulatory effect. These 
results suggest uptake of iron is dependent on the reduction of ferric iron to ferrous iron prior to 
internalization and are consistent with a divalent ion transport mechanism.
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Fig. 2. Effect o f ascorbate on NTBI uptake in human hepatoma cells. HuH7 cells were incubated with 1 |iM iron 
citrate (1:100) and increasing concentrations o f ascorbate, for 60 min at 37°C. The figure shows intracellular ( ♦ )  
and membrane-associated (□) uptake. Results are expressed as mean ± SD of triplicate determinations.
Effect o f Divalent Cations. To determine whether a shared transport mechanism was involved in 
the uptake of ferric and ferrous iron, we looked at the pattern of competition by the following 
divalent metal ions; Cu2+, Zn2+, Cd2+, Co2+, Ni2+, Mn2+ and Fe2+. The results are summarized in 
Fig 3.
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Fig. 3. Divalent metal ion inhibition o f NTBI uptake in human hepatoma cells. 0-100 pM of each divalent metal 
ion was added to lpM  [59Fe]-ferric citrate (Fe3+ uptake) [solid bars] or to lpM  [59Fe]-ferric citrate plus 100 pM 
ascorbate (Fe2+ uptake) [open bars], and the rate of iron uptake determined over 30 min at 37°C. The results are 
calculated as a percentage o f control uptake (no competing metal ion) and expressed as mean ± SD o f triplicate 
determinations. Iron uptake was inhibited in a concentration-dependent manner for all divalent ions tested, with the 
exception of nickel and cobalt. The results shown are for inhibition at a divalent metal ion concentration o f 10 pM 
only.
The pattern of inhibition by the divalent metal ions was generally very similar for both ferrous 
and ferric uptake in the HuH7 cells, in keeping with a common transport process. Cadmium, 
manganese, zinc and copper were the strongest inhibitors of iron uptake, inhibiting by 50% or 
more whilst nickel and cobalt were the least inhibitory, particularly for ferrous uptake. These 
results are consistent with a shared or non-selective divalent cation transport mechanism.
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Role of DMT1 in Transmembrane NTBI Uptake
DMT1 Blocking Antibody. HuH7 cells were incubated with DMT1 antisera (rabbit anti-human, 
middle antibody raised against 4th extracellular loop of DMT 1) at a dilution of 1:20 for 30 min at 
37°C. Ferric citrate (1:100) uptake was measured at both physiological pH (7.4) and at low pH 
(6.5), as DMT1 is a proton-dependent transporter and has optimal function at low pH. Antibody 
blocking had no effect on ferric citrate (Fe3+) uptake at either low or high pH when compared to 
unblocked cells and cells blocked with pre-immune serum (data not shown).
As DMT1 is a divalent transporter, the blocking experiment was repeated with Fe2+ by using 
ascorbate-reduced iron citrate, and compared in HuH7 cells and differentiated Caco2 cells. 
When Caco2 cells are grown for 20 plus days they become fully differentiated and display a 
small intestine-phenotype with a well defined brush border and positive DMT1 expression 
(Fleet, Wang et al. 2003). Iron uptake was measured at pH 7.4 and pH 5.5 (Fig. 4A). At pH 7.4 
both Caco2 and HuH7 cells pre-incubated with DMT1 antisera (1:20) showed little change in the 
rate of iron uptake compared to control cells treated with pre-immune sera (1:20). However, at 
pH 5.5, iron uptake in the Caco2 cells blocked with DMT1 antisera was significantly reduced by 
45% (p = 0.0098) when compared to cells treated with pre-immune sera (1:20). In contrast, no 
blocking of iron uptake was observed in the HuH7 cells at pH 5.5 (Fig. 4A). This data suggests 
that whilst DMT1 is involved in iron uptake in differentiated Caco2 cells it is unlikely to be 
involved in the uptake of iron at the membrane surface of HuH7 cells.
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Fig. 4. Role of DMT1 in pH-dependent iron uptake in HuH7 and Caco-2 cells. (A) Effect o f DMT1 blocking 
antibody on iron uptake in Caco2 cells and HuH7 cells. Caco2 cells (hatched bars) and HuH7 cells (filled bars) 
were pre-incubated with a 1:20 dilution o f DMT1 antisera or pre-immune sera (open bars), for 30 min at 37°C. The 
rate o f iron uptake was measured at pH 5.5 and pH 7.4 with 1 pM ferric citrate (1:100) in the presence of 100 pM 
ascorbate, for 30 min at 37°C. (B) pH-dependence of iron uptake in HuH7 and Caco-2 cells. HuH7 cells (■ )  were 
incubated with 1 pM ferric citrate in pH-adjusted RPMI medium. Caco-2 cells ( O )  were incubated with 1 pM ferric 
citrate plus 100 pM ascorbate, in pH-adjusted DMEM. Iron uptake was determined over 60 min at 37°C. Results 
are expressed as mean ± SD of triplicate determinations. Student’s unpaired t test, * *  p < 0.01.
This data is consistent with the pH-dependence of iron uptake in these two cell lines. Iron 
internalisation, expressed as a ratio of intracellular: membrane-associated iron uptake, was most 
efficient at pH 7.4 for HuH7 cells and at pH 5.5 for Caco-2 cells (Fig. 4B), supporting the role of 
DMT1 in iron uptake in Caco-2 cells and of an alternative iron-transporter in the HuH7 cells. 
Furthermore, DMT1 expression was not up-regulated by iron loading in the HuH7 cells, as will 
be discussed later.
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Modulation of NTBI Uptake by Iron Loading and Iron Depletion
Effect on NTBI Uptake. Regulation of NTBI uptake in response to modulations in iron status 
was investigated by iron loading cells with ferric ammonium citrate (FAC) or depleting cells 
with deferoxamine (DFO). Stimulation of cellular NTBI uptake in response to iron loading 
occurred in a time- and concentration-dependent manner. The time-course of NTBI uptake 
stimulation was determined over a 48 h incubation period with FAC. Although an increase in 
the rate of NTBI uptake was observed after an 1 h incubation with FAC, a 4 h incubation was 
required for the increase in the NTBI uptake rate to attain significance. At 24 h, the stimulation 
of NTBI uptake was optimal and by 48 h reached a plateau (data not shown). Hence, a 24 h 
incubation time with FAC was used for all iron loading experiments. Iron loading with 0-40 pg 
Fe/ml FAC stimulated the rate of cellular ferric citrate uptake at all concentrations of FAC, with 
maximal stimulation occurring at a FAC concentration of 10 pg Fe/ml (178 pM) after which the 
increase in the rate began to fall, as shown in Fig 5A. The decline in the iron uptake rate at 
higher FAC concentrations may be due to the cytotoxic effects of prolonged exposure to high Fe 
concentrations.
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Fig. 5. Effect o f iron loading or depletion on NTBI uptake in human hepatoma cells. (A) HuH7 cells were iron 
loaded by incubating with supplemented RPMI medium containing increasing concentrations o f ferric ammonium
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citrate for 24 h at 37°C. Cells were washed extensively before determining the rate of NTBI uptake with 1 pM iron 
citrate (1:100) for 60 min at 37°C. The figure shows intracellular ( ♦ )  and membrane-associated (□ ) uptake.
Results are expressed as mean ± SD of triplicate determinations. (B) HuH7 cells were iron depleted by incubating 
with supplemented RPMI medium containing increasing concentrations of deferoxamine for 24 h at 37°C. Cells 
were washed extensively before determining the rate of NTBI uptake with 1 pM iron citrate (1:100), for 60 min at 
37°C. The figure shows intracellular ( ♦ )  and membrane-associated (□ ) uptake. Results are expressed as mean ±
SD of triplicate determinations. (C) Correlation between the intracellular iron content and the rate of NTBI uptake 
in human hepatoma cells. The rate of NTBI uptake was determined with 1 pM iron citrate (1:100), after loading 
cells with various concentrations of ferric ammonium citrate. Total cellular iron content was determined by a 
ferrozine-based assay, as described under methods. R = 0.972, p < 0.0001.
Treating normal cells with 100 pM DFO for 24 h resulted in no detectable levels of iron, when 
measured by the total cellular iron assay. Iron depletion with DFO for 24 h resulted in a dose- 
dependent decrease in the rate of cellular iron citrate uptake (Fig 5B). Although this may be due 
to down-regulation of the NTBI uptake mechanism due to depletion of intracellular iron levels, 
we cannot rule out the toxic effects of DFO on cell function, especially at the higher 
concentrations. This is supported by the fact that even after a 24 h recovery period from DFO in 
normal RPMI medium supplemented with FCS, the rate of NTBI uptake remained suppressed 
(data not shown).
Using FAC concentrations less than 20 pg Fe/ml, a strong linear correlation (R = 0.972, p  < 
0.0001) between the rate of NTBI accumulation and total intracellular iron content (measured by 
ferrozine assay) was observed, suggesting the NTBI uptake rate is modulated by intracellular
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iron levels (Fig 5C). This data is consistent with an iron-regulated mechanism of NTBI uptake 
in the HuH7 cells.
Effect on mRNA for Iron Transport Proteins. The effect of iron loading and depletion on mRNA 
expression of key iron transport molecules was determined by RT-PCR analysis. RNA was 
isolated from HuH7 cells which had been pre-incubated with 10 pg Fe/ml FAC or 100 pM DFO 
for 24 h at 37°C. The results are shown in Table 1. No statistically significant changes were 
observed in the expression of DMT1(+IRE) or DMT 1 (-IRE) in response to iron loading and iron 
depletion, although DMT 1 (-IRE) was down-regulated by 32% in response to 24 h treatment with 
100 pM DFO. These data suggest that DMT1 is not involved in the FAC-stimulated NTBI 
uptake mechanism as it is not significantly up-regulated in response to iron loading. However, 
DMT 1 (-IRE) may be involved in internal iron trafficking as its expression is reduced when the 
rate of iron uptake is down-regulated by DFO. A highly significant 3-fold increase in TfR l 
expression was observed in response to iron depletion whilst iron loading had no effect, 
suggesting this receptor is not important for mediating the FAC-stimulated NTBI uptake. In 
contrast, TfR2 which is highly expressed in hepatocytes, was unaffected by changes in iron 
status and hence does not appear to be regulated by iron.
Table I. Regulation of iron transport molecules in response to iron loading and depletion, in HuH7 cells. RT-PCR 
analysis (20-25 cycles) o f molecules involved in iron transport and homeostasis was performed on RNA isolated 
from cells iron loaded with FAC or iron depleted with DFO for 24h and from control cells (no treatment) using gene-
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specific primers, as described under Experimental Procedures. Values were normalized to the corresponding 
GAPDH value and are in arbitrary units (mean ± SD, n=4-9). ***p <0.001; significantly different from control.
mRNA levels x 10‘2 (a.u)
Control FAC DFO
+IRE-DMT1 0.710 ±0.09 0.840 ± 0.260 0.680 ±0.100
-IRE-DMT1 0.470 ±0.160 0.380 ±0.180 0.320 ±0.270
TfR l 0.110 ±0.010 0.104 ±0.020 0.301 ± 0.05***
TfR2 1.80 ±0.370 1.70 ±0.510 1.90 ±0.380
T-VDCC (Cav3.2) 15.0 ± 11.0 18.0 ± 10.0 36.0 ± 16.0
L-VDCC (Cav1.3) 88.0 ± 14.0 51.0 ± 13.0* 96.0 ± 43.0
Role of Voltage Dependent Calcium Channels (VDCQ in NTBI Uptake
Effect o f extracellular Calcium on NTBI uptake. The effect of calcium on NTBI uptake was 
investigated by adding increasing concentrations of calcium chloride (0-5 mM) to the labelling 
medium (Fig. 6). Although calcium chloride was not added to control cells, they were not in a 
completely calcium-free medium as the RPMI medium has a calcium concentration of 0.424 
mM. The uptake of internalized ferric citrate was stimulated at calcium concentrations > 1 mM 
and reached maximal values at physiological concentrations (2.5 mM), with a 6-fold increase in 
the rate of uptake. At higher concentrations (> 3mM) the iron uptake began to fall. Calcium had 
little effect on the membrane-associated iron uptake. The uptake of ferrous iron (ascorbate- 
reduced ferric citrate) was stimulated by calcium to a similar extent as ferric iron uptake (data 
not shown).
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Fig. 6. Effect of calcium on NTBI uptake in human hepatoma cells. HuH7 cells were incubated with 1 pM iron 
citrate (1:100) label to which had been added increasing concentrations o f calcium chloride, and uptake determined
at 37°C over 60 min. The figure shows intracellular ( ♦ )  and membrane-associated (□ ) uptake. Results are 
expressed as mean ± SD of triplicate determinations.
The effect of calcium on the FAC-stimulated NTBI uptake rate was investigated by adding 
increasing concentrations of calcium chloride (0-3 mM) to the FAC incubation medium. The 
FAC-stimulated rate was significantly (p< 0.01) enhanced further by up to 150% in the presence 
of 2 mM calcium at all FAC concentrations used (0 -  20 ug Fe/ml). Stimulation of the basal and 
FAC-loaded NTBI uptake rate by calcium suggests a calcium-dependent iron transporter may be 
involved.
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VDCC Modulators. To explore the possibility of alternative iron transport mechanisms, the 
involvement of calcium channels in iron uptake was investigated with selective modulators of L- 
and T-type VDCC (Fig. 7).
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Fig. 7. Effect o f selective VDCC modulators on iron uptake in human hepatoma cells. (A) HuH7 cells were pre- 
incubated for 1 h with selective high affinity L-type (open bars), selective high affinity T-type (filled bars) or low- 
affinity, non-selective T-type (hatched bars) VDCC modulators, before measuring NTBI uptake with 1 pM iron
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citrate (1:100) at 37°C over 30 min. The graph shows results at a modulator concentration of 100 pM, with the 
exception of Kurtoxin which was added at a concentration of 0.1 pM. (B) Effect of VDCC blockers on FAC- 
enhanced iron uptake. HuH7 cells were iron loaded with supplemented RPMI medium containing 10 pg Fe/ml 
ferric ammonium citrate (FAC) in the absence (open bar) or presence of L-type (grey bar) and T-type (black bars) 
VDCC inhibitors for 24 h at 37°C. Cells were washed extensively before determining the rate of NTBI uptake with 
1 pM iron citrate (1:100) for 60 min at 37°C. (C ) Effect of VDCC blockers on KCl-stimulated iron uptake. HuH7 
cells were pre-incubated with L-type (grey bar) or T-type (black bar) VDCC inhibitors for lh  before measuring iron 
uptake with 1 pM iron citrate (1:100) in the presence o f 5 mM KC1, for 60 min at 37°C. A ll results are calculated as 
a percentage of control uptake (no inhibitor) and expressed as mean ± SD of triplicate determinations. *p < 0.05, 
**p  < 0.01, ***p  < 0.001; significantly different from control uptake. The VDCC modulators had no effect on the 
membrane-associated uptake (not shown).
The L-type inhibitors verpamil and nifedipine had no effect on the rate of NTBI uptake at 
concentrations up to 100 pM, as shown in Fig 7A. Although 20-50% inhibition was observed at 
higher concentrations (1 mM) of these inhibitors (data not shown), this may have been due to 
non-specifc toxic effects. The dihydropyridine stereoisomers of Bay K 8644 act as L-type 
calcium channel blockers (R-isomer) and activators (S-isomer), whilst T-type channels can be 
weakly blocked by both (Lievano, Bolden et al. 1994; Vassort and Alvarez 1994). We observed 
weak inhibition (5-15%) of NTBI uptake with 100 pM of both stereoisomers, with the inhibition 
by (R)-(+)-Bay K 8644 attaining statistical significance (p = 0.03). This data suggests T- rather 
than L-type channels may be mediating iron uptake. This was further investigated with 
mibefradil which is a highly selective T-type channel blocker, having 10-30 fold selectivity for 
T- over L-type VDCC (Martin, Lee et al. 2000). We observed a significant reduction of 55 ± 5.2 
% in the iron uptake rate with 100 pM mibefradil (p = 0.00013) as shown in Fig 7A. Significant 
levels of inhibition (30-50 %, p < 0.01) were also observed with lower concentrations (50 -  75
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pM) of mibefradil (not shown). The block of high-voltage-activated L-type channels by 
mibefradil occurs through the production of an active metabolite by intracellular hydrolysis. 
NNC 55-0396 is a non-hydrolyzable analog of mibefradil that exerts a selective inhibitory effect 
on the T-type channels (Huang, Keyser et al. 2004). Treating cells with 100 pM of this analog 
caused similar levels of inhibition in the iron uptake rate (55 ± 3.8 %, p= 0.00160) as mibefradil, 
confirming uptake occurs predominately through the low-voltage calcium channel route. The 
neuroleptic agents pimozide and penfluridol are preferential inhibitors of T-type channels (Santi, 
Cayabyab et a l 2002). Pre-incubating cells with 100 pM pimozide for 1 h significantly 
inhibited iron uptake by 45 ± 2.9 % (p = 0.00009) whilst penfluridol had little effect under these 
conditions (Fig 7A). However, pre-incubating cells with lower concentrations of penfluridol (10 
pM) for a longer duration (24 h) resulted in a 55 ± 13.1 % reduction in the iron uptake rate (p= 
0.00307), which may reflect the 10 times slower blocking rate of T-type channels by penfluridol 
compared to pimozide reported by (Santi, Cayabyab et al. 2002). A number of earlier studies 
indicated that nickel sensitivity was a characteristic feature of low-voltage activated (T-type) 
calcium channels. However, more detailed analysis has shown that this apparent high 
sensitivity actually consists of high (Cav3.2 or a jH) and low (Cav3.1 and Cav3.3 or otic and an) 
affinity sites (Lee, Gomora et al. 1999; Lacinova, Klugbauer et al. 2000). Hence, sensitivity to 
nickel may help differentiate between different T-channel subtypes. Our data showed that iron 
uptake was sensitive to inhibition by nickel with a 32 ± 7.4 % reduction (p = 0.00193) in the 
uptake rate at a nickel concentration of 100 pM, as shown in Fig. 7. Even at lower nickel 
concentrations (10 pM) we observed a 25 ± 9.5 % inhibition (p = 0.0064) of the iron uptake rate. 
This data would indicate that iron uptake is predominately mediated via the Cav3.2 (a iH) T- 
channel subtype. The scorpion toxin, kurtoxin, is a high affinity blocker of both Cav3.1 and
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Cav3.2 channels (Chuang, Jaffe et a l 1998). We found iron uptake was significantly inhibited 
by 27 ± 7.5 % (p = 0.0034) with 100 nM kurtoxin. Surprisingly, higher concentrations of the 
toxin appeared to facilitate iron uptake (data not shown). Although ethosuximide and amiloride 
are thought to be weak non-selective T-type channel inhibitors, lack of sensitivity of T-type 
channels to these inhibitors has been reported by many authors (Yimker 2003). We also 
observed relative resistance to these inhibitors, as micromolar concentrations did not inhibit iron 
uptake (Fig. 7A), whilst milimolar concentrations (1-5 mM) only weakly inhibited (-15% ). 
uptake (not shown).
The effect of the VDCC modulators on the iron loaded enhancement of the iron uptake rate was 
investigated by loading cells with FAC (10 pg Fe/ml) in the presence of 10 pM of selective T- 
and L-type channel inhibitors (Fig 7B). The FAC-stimulated rate was significantly attenuated by 
77% with mibefradil (p = 0.0238) and completely abolished by penfluridol (p = 0.0149). 
Although, the FAC-enhanced rate was also abrogated by pimozide, this did not attain statistical 
significance. In contrast, the L-type inhibitor verapamil had no effect on the FAC-stimulated 
rate (Fig 7B).
Previously, it had been shown that NTBI uptake can be stimulated by extracellular potassium, 
via cell membrane depolarization (Musilkova and Kovar 2001). We found adding 5 mM KC1 to 
the labelling medium significantly enhanced the basal and FAC-loaded iron uptake rates by 115- 
130 % (p < 0.05), as shown in Fig 1C. To investigate whether this increase in iron uptake was 
due to activation of VDCC by KCl-induced membrane depolarisation, we pre-incubated HuH7 
cells with 100 pM of L- and T-type channel inhibitors for 1 h, before measuring iron uptake in
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the presence of 5 mM KC1. Mibefradil completely abolished the KCl-stimulated rate of iron 
uptake whilst verapamil had no effect (Fig 1C). These results suggest that membrane 
depolarization enhances iron uptake by activation of T- but not L-type channels in HuH7 cells.
Collectively, the data with the VDCC modulators is consistent with a component of hepatic 
NTBI uptake being mediated selectively by T- rather than L-type VDCC and this pathway 
becomes more significant under conditions of iron overload.
Regulation of VDCC Expression by Iron Status. The effect of iron loading and depletion on 
expression of L-type (Cav1.3 or a iD) and T-type (Cav3.2 or a iH) VDCC was determined by RT- 
PCR analysis. RNA was isolated from HuH7 cells which had been pre-incubated with 10 pg 
Fe/ml FAC or 100 pM DFO for 24 h at 37°C. RT-PCR analysis showed T-type channel 
expression was unaffected by iron loading and was up-regulated ~2.5 fold by iron chelation with 
DFO, whilst the L-type channel was significantly down-regulated (~ 2-fold) by iron loading (p = 
0.0145), as shown in Table 1. Thus, stimulation of hepatocyte NTBI uptake by FAC loading is 
unlikely to involve transcriptional effects on T- or L-type channels and modulation may occur at 
a post-transcriptional level possibly involving activation of the T-type VDCC.
Effect of Metabolic/ Endocytic and Protein Synthesis Inhibitors on NTBI Uptake
Metabolic Inhibitors. The mitochondrial uncoupler 2,4-dinitrophenol (2,4-DNP), an inhibitor of 
ATP synthesis, significantly inhibited (p = 0.042) the uptake of ferric citrate by 32 ± 2.9 % at a 
concentration of 0.5 mM. Higher concentrations of 2,4-DNP had no further inhibitory effect on
NTBI Uptake Mechanisms in Human Hepatoma Cells 31
the uptake rate. This data suggests that the uptake mechanism is partially energy-dependent but 
occurs predominately by passive, rather than active, transport.
Endocytic Inhibitors. Bafilomycin A j, is a specific inhibitor of endosomal acidification and 
inhibits both receptor-mediated and fluid-phase endocytosis. Incubating cells with Bafilomycin 
Ai had no effect on the uptake rate of ferric citrate even at concentrations up to 4 pM. Thus the 
NTBI uptake mechanism does not involve the trafficking of iron through acidic endosomes and 
supports an endocytosis-independent mechanism such as facilitated or carrier-mediated diffusion 
which could include permeation through an ion channel.
Protein Synthesis Inhibitors. The mRNA synthesis inhibitor, actinomycin D (3.98 pM), and the 
protein synthesis inhibitor, cycloheximide (350 pM), had no effect on ferrous or ferric uptake 
when pre-incubated with HuH7 cells for 1 h, suggesting sufficient endogenous transporters are 
available after 1 h to mediate iron uptake (data not shown). However, pre-incubating cells with 
these inhibitors for 24 h caused a significant reduction (64 ± 5.5%, p= 0.00015) in the basal iron 
uptake rate but had no effect on the FAC-stimulated rate, suggesting de novo protein synthesis is 
not required for the enhanced uptake observed in the iron-loaded cells but rather the mechanism 
involves the recruitment or activation of an existing transporter(s).
(words incl legends 3978)
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Discussion
This paper has addressed two key questions: how is NTBI taken up into hepatocytes and 
how is this process is regulated. HuH7 hepatoma cells and iron citrate were chosen for these 
studies for the reasons explained in the introduction. This study shows for the first time that at 
least half of this uptake is likely to be through T-type calcium cannels but that L-type VDCC are 
unlikely to be involved.
DMT1.
Before investigating the putative role of VDCCs, an obvious candidate for NTBI uptake 
was the proton-dependent transporter, DMT1, which has optimal iron transport activity at acid 
pH of 5.5 (Gunshin, Mackenzie et al. 1997). Indeed this has been proposed as a possible 
mechanism for NTBI uptake into hepatocytes (Trinder, Oates et al. 2000) (Chua et al, 2000). 
However several lines of evidence do not support DMT1 as an uptake mechanism into HuH7 
cells. Firstly our studies with DMT1 antibody showed that ferrous iron uptake was significantly 
blocked in differentiated Caco2 cells expressing DMT1, but not in HuH7 cells at low pH i.e. 
when transport by proton-dependent DMT1 is optimal (Figure 4A). These findings reflect the 
pH-dependence of iron uptake in the two cell lines; iron internalization was most efficient at pH 
7.4 for HuH7 cells and at pH 5.5 for Caco-2 cells (Figure 4B), supporting a role for DMT1 in 
iron uptake in Caco-2 cells and of an alternative iron-transporter in the HuH7 cells. Secondly we 
failed to observe a significant increase in the expression of DMT1(+IRE) or DMT 1 (-IRE) in 
response to iron loading, suggesting that up-regulation of this transporter is not responsible for 
the FAC-stimulated NTBI uptake rate (Table 1). These findings are consistent with those of 
Gunshin, Allerson et al. (2001) who observed no change in mRNA DMT1 levels in liver Hep3B
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cells in response to iron loading with FAC and Trinder et al, who found no differences in the 
expression of DMT 1 (± IRE) with varying iron status in rat liver (Trinder, Oates et a l 2000). 
However, Trinder et al (2000) did observe that DMT1 protein staining on hepatocytes plasma 
membranes was highest in iron loaded rats and absent in iron deficient rats, suggesting post- 
transcriptional regulation of DMT1 by iron. Although we did not look at the regulation of 
DMT1 protein expression in response to iron in our HuH7 cells, it is difficult to reconcile a role 
for this proton-dependant iron transporter in the trans-membrane uptake of NTBI as it would 
require a low pH environment at the hepatocyte membrane surface to function optimally 
(Gunshin, Mackenzie et al. 1997). Thirdly the finding that zinc was highly inhibitory (up to 
80%, Figure 3) of iron uptake in our HuH7 cells favors a DMT1 independent mechanism of iron 
uptake. Despite early reports demonstrating Zn2+-dependent conductances in oocytes expressing 
DMT1 (Gunshin, Mackenzie et al. 1997), several lines of evidence suggest that zinc is not 
significantly taken up by DMT1. For example, zinc is the weakest metal inhibitor of DMT1- 
dependent iron uptake in enterocyte-like Caco2 cells (25% inhibition) (Tandy, Williams et al. 
2000) and uptake in Caco2 cells is unaffected by decreasing DMT1 expression unlike the that of 
iron {Tandy, Williams et al. 2000) (Tallkvist, Bowlus et al. 2000; Yamaji, Tennant et al. 2001). 
Furthermore lack of Zn2+ transport was also demonstrated in K562 and HEK-T cells transfected 
with DMT1 DNA (Conrad, Umbreit et al. 2000). A limited role for DMT-1 in iron loading of 
the liver is also supported by the observation that global inactivation of the DMT1 gene in 
animal models (Gunshin, Fujiwara et al. 2005) or functional mutations of this gene in humans 
(Mims, Guan et al. 2005; Beaumont, Delaunay et al. 2006; Iolascon, d ’Apolito et al. 2006), 
whilst leading to severe microcytic anemia, fail to prevent excess hepatic iron deposition.
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Hence, the possibility of alternative mechanisms of NTBI uptake into liver need to be 
considered.
Other dismissed mechanisms
Several other putative uptake mechanisms for NTBI uptake into HuH7 cells were 
investigated but were not supported by our observations. An endocytosis driven mechanism is 
unlikely because Bafilomyicn Ai, a specific inhibitor of endosomal acidification that inhibits 
both receptor-mediated and fluid-phase endocytosis and blocks cellular acquisition of iron from 
transferrin (Yang, Goetz et al. 2002), failed to have any impact on NTBI uptake. In our model, 
iron citrate at a ratio of 1:100 was used which represents physiologically relevant concentrations 
and at this ratio iron is predominantly monomeric (Evans et al, 2007?). Iron uptake from citrate 
was saturable (Figure 1), in agreement with previously reported data in HuH7 cells (Trinder and 
Morgan 1998) and suggests the involvement of an iron carrier. Inhibition of cellular energy 
metabolism with the mitochondrial uncoupler 2,4-dinitrophenol (2,4-DNP), partially inhibited 
the uptake of iron from citrate in our HuH7 cells, suggesting the uptake mechanism is energy- 
dependent to some extent but occurs predominately by passive, rather than active, transport such 
as facilitated diffusion. This relative insensitivity of NTBI uptake to inhibitors of cellular energy 
metabolism and endocytosis in hepatic cells is consistent with earlier studies (Wright, Brissot et 
al. 1986; Baker, Baker et a l 1998; Graham, Morgan et al. 1998). Iron uptake via transferrin is 
very unlikely because experiments were done in serum free medium. Furthermore iron depletion 
of HuH7 cells with deferoxamine caused a 3-fold increase in TfR l mRNA expression (Table 1) 
but this was accompanied by down-regulation of the iron uptake rate (Fig 5B), whilst iron 
loading caused an increase in the iron uptake rate (Fig 5A) but had no effect on TfR l expression. 
TfR2 expression in our HuH7 cells was unaffected by changes in iron status and hence does not
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appear to mediate FAC-induced NTBI uptake or be regulated by iron (Table 1) as reported 
previously in mouse liver (Fleming, Migas et al. 2000).
T-type channels.
The significant pharmacological inhibition of iron uptake with a range of T-type VDCC 
inhibitors such as mibeffadil, NNC 55-0396, pimozide, penfluridol, nickel and kurtoxin (p < 
0.05) at micromolar concentrations provides strong evidence that T-type channels are key 
transporters in HuH7 cells. L-type channels do not seem to be involved, in contrast to the 
reported uptake into cardiac myoctyes (Oudit, Sun et al. 2003). Thus the L-type inhibitors, 
verapamil, nifedipine and Bay K8644 had little or no effect on NTBI uptake at comparable 
concentrations (Fig. 7A). Voltage-gated ion channels such as VDCC are usually closed at the 
resting potential of the cell. Upon activation, the membrane depolarizes resulting in opening of 
the pore and ion entry into the cell. This is followed by a refractory period during which the 
channel becomes inactivated and is no longer able to conduct ions. Distinguishing features of T- 
type VDCC are that they require only small depolarizations of the plasma membrane (- 50 mV) 
to open (low-voltage activated), they close slowly upon repolarization of the membrane (slowly 
deactivating) and inactivate quickly (transient). The activation and steady-state inactivation 
curves of T-type channels have a significant overlap, occuring over a similar voltage range, 
which means channels can open but do not inactivate completely. In fact, T-type channels are 
known to display a window current in the range of the cell membrane resting potential, providing 
a latent pathway for constant Ca2+ (Talavera and Nilius 2006), and possibly Fe2+ influx . Low 
concentrations of ferrous iron have been shown to depolarize hepatocyte plasma membranes
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(Wright, Fitz et al. 1988). Thus exposure of cells to iron could provide a direct mechanism for 
activation of VDCC and subsequent iron entry. Cell membrane depolarization by extracellular 
potassium has been shown to stimulate the uptake of NTBI in HeLa and K562 cells, (Musilkova 
and Kovar 2001). We observed enhancement of both the basal and FAC-loaded iron uptake rates 
by extracellular potassium in our HuH7 cells (Figure 7C). We also found that mibeffadil 
completely abolished the KCl-stimulated rate of iron uptake whilst verapamil had no effect, 
suggesting that membrane depolarization enhances iron uptake by activation of T- but not L-type 
channels in HuH7 cells.
Calcium stimulation
The stimulation of the basal and FAC-loaded NTBI uptake by calcium in HuH7 cells 
(Figure 6) is consistent with observations in hepatocytes (Wright, Brissot et al. 1986; Barisani, 
Berg et al. 1995; Baker, Baker et al. 1998) and with the involvement of a calcium-dependent 
iron transporter. The mechanism of calcium enhancement of uptake is not known but is unlikely 
to result from simple displacement of Fe3+ from citrate as suggested by Mwanjewe, Martinez et 
al, (2000) because we found pre-incubation of our HuH7 cells with calcium, followed by its 
removal prior to adding iron citrate label, still resulted in enhanced iron uptake. It is also 
unlikely that the calcium functions intracellularly since increasing cytosolic Ca2+ levels in 
fibroblasts with epidermal growth factor had no effect on the iron transport rate, whilst treating 
cells with the permeable ester of EGTA did not inhibit the iron uptake (Kaplan, Jordan et al. 
1991). Interestingly calcium added to HuH7 cells in the presence of calcium channel inhibitors 
stimulated iron uptake despite being unable to enter the cells (unpublished observation), 
suggesting the calcium acts extracellularly to enhance iron uptake. Calcium can decrease
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plasma membrane fluidity of rat hepatocytes both directly, taking 10-15 min, and indirectly 
taking about 75 min, through modulation of membrane-bound enzymes that alter the lipid 
composition (Livingstone and Schachter 1980; Storch and Schachter 1985). Changes in 
membrane lipid composition and fluidity can influence membrane functions, such as receptor 
binding, enzyme activity and transmembrane transport including ion permeability (Benga and 
Holmes 1984; Mills, Meier et a l 1987; Wang and Zhang 2005). Calcium may also activate iron 
uptake by acting directly on the VDCC. Evidence suggests that the T-type Cav 3.2 channel may 
be uniquely modulated by calcium, which slows the activation and inactivation kinetics of this 
channel but not of Cav 3.1 or Cav 3.3 (Klockner, Lee et a l 1999). For example, increasing 
concentrations of extracellular calcium have been shown to potentiate T-type currents in adrenal 
glomerulosa cells (Lu, Fern et a l 1994).
Metal inhibition.
The inhibition of uptake by a range of divalent cations (Figure 3) also support the 
involvement of VDCC in the uptake process. Although calcium channels are primarily 
employed for transporting Ca2+, both high- (L-type) and low- (T-type) voltage dependent 
calcium channels (VDCC) transport a range of other divalent cations including Sr2+ (Hess, 
Lansman et a l 1986; Kaku, Lee et a l 2003), Ba2+ (Hess, Lansman et a l 1986; Kaku, Lee et a l  
2003), Cd2+ (Lansman, Hess et a l 1986; Shaikh, Blazka et a l 1995; Todorovic and Lingle 
1998), Zn2+ (Busselberg, Michael et a l 1992; Atar, Backx et a l 1995; Shaikh, Blazka et a l 
1995; Todorovic and Lingle 1998; Jeong, Park et a l 2003), Mn2+ (Castelli, Tanzi et a l 2003; 
Kaku, Lee et a l 2003), Cu2+ (Shaikh, Blazka et a l 1995; Castelli, Tanzi et a l 2003; Jeong, Park 
et a l 2003), N i2+ (Winegar, Kelly et a l 1991; Funakoshi, Inoue et a l 1997; Todorovic and
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Lingle 1998; Lee, Gomora et al. 1999), Co2+ (Winegar, Kelly et a l 1991; Castelli, Tanzi et a l 
2003) and Fe2+ (Winegar, Kelly et a l 1991; Tsushima, Wickenden et a l 1999). The sensitivity of 
hepatic transferrin-independent iron uptake to transition metals is well documented in the 
literature where zinc, manganese and cadmium show most inhibition whilst cobalt, copper and 
nickel show the least (Wright, Brissot et a l 1986; Randell, Parkes et a l 1994; Baker, Baker et 
a l 1998; Graham, Morgan et a l 1998; Chua, Olyrtyk et a l 2004). In HuH7 cells, cadmium, 
manganese, zinc and copper were the strongest inhibitors of iron uptake, inhibiting by 50% or 
more, whilst nickel and cobalt were the least inhibitory. Cadmium, the strongest inhibitor of iron 
uptake, is known to be taken up by calcium channels in hepatocytes (Blazka and Shaikh 1991) 
and human hepatic cell lines (Souza, Bucio et a l 1997). Inhibition of iron uptake showed no 
obvious relationship to ironic radius: N i and Co which have smaller or similar ionic radii to 
Fe2+ were the least inhibitory whilst larger competing ions such as Cd2+ and Zn2+ were potent 
inhibitors (Fig. 3). The effectiveness of the transition metals to compete with iron transport is 
more likely to reflect the affinity of the transporter for the various metals.
Iron stimulation of uptake.
An important objective of this study was to determine if  and how modulation of cellular 
iron content affects NTBI uptake. Key findings are that NTBI uptake is directly proportional to 
intracellular iron content (Figure 5C) and that up-regulation of NTBI uptake is abrogated in 
HuH7 cells by blocking with known inhibitors in T-type but not L-type channels (Figure 7B). 
Enhancement of transferrin-independent iron uptake by iron loading has been previously 
reported in a variety of cell types (Kaplan, Jordan et a l 1991) (Oshiro, Nakajima et al. 1993),
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(Parkes, Hussain et al. 1993) (Randell, Parkes et al. 1994; Parkes, Randell et al. 1995; 
Scheiber-Mojdehkar, Zimmermann et al. 1999). However an abrogation of enhancement of iron 
uptake by VDCC inhibitors has not been previously reported. The mechanism by which iron 
loading of cells might stimulate calcium channel mediated iron uptake requires further 
consideration. Because maximal enhancement in iron uptake was seen after a 24 h incubation 
period with FAC, we initially considered that this would require up-regulation of synthesis of the 
iron transporter, in this case T-type VDCC. However, T-type VDCC mRNA expression was 
unaffected by iron loading with FAC, whilst L-type VDCC expression was down-regulated by 
iron loading. Furthermore in our HuH7 cells, treatment with protein synthesis inhibitors 
(actinomycin D and cycloheximide) had no effect on the FAC-stimulated rate, suggesting de 
novo protein synthesis is not required for activation of FAC-induced iron uptake. Hence, post- 
translational effects are likely to be responsible, consistent with the recruitment or activation of 
existing transporters) (Kaplan, Jordan et al. 1991). A possible mechanism of enhanced NTBI 
uptake would be that iron can permeate VDCC channels and effect the kinetics of these channels. 
Ferrous iron slows the inactivation of L-type VDCC currents in myocytes resulting in increased 
iron entry (Tsushima, Wickenden et al. 1999). The slowing of Ca2+ current inactivation by Fe2+ 
can arise from competition between Fe2+ and Ca2+ for the C-terminal cytoplasmic Ca2+ binding 
site involved in Ca2+-mediated inactivation of L-type VDCC (de Leon, Wang et al. 1995). Thus 
Fe2+-induced slowing of Ca2+ current inactivation may prolong the duration of the channel’s 
active open state, allowing an increase in iron flux into the cells.
Conclusion
NTBI Uptake Mechanisms in Human Hepatoma Cells 40
In conclusion our findings provide persuasive evidence for DMT 1-independent T-type 
VDCC-dependent uptake of non-transferrin bound iron, in the form of iron citrate, in HuH7 
cells. This human cell line has many features of mature hepatocytes and many aspects of NTBI 
uptake that we observed in HuH7 are similar to those previously reported in primary hepatocytes 
(Barisani, Berg et al. 1995; Baker, Baker et al. 1998; Graham, Morgan et al. 1998) or whole 
organ perfusion systems (.Brissot, Wright et al. 1985; Wright, Brissot et al. 1986). Our finding of 
a maximum of 55 % uptake inhibition with mibeffadil suggests that additional NTBI uptake 
mechanisms may exist in hepatocytes. Candidates could include Zip 14, a member of the 
SLC39A zinc transporter family, found to mediate NTBI uptake into cells (Liuzzi, Aydemir et al. 
2006). Our finding that, in contrast to observations in murine cardiac cells (Oudit, Trivieri et al. 
2006), L-type inhibitors have no effect on basal or iron induced NTBI uptake provides a possible 
therapeutic avenue where iron loading of the heart might be prevented in transfusional iron 
overload by specific inhibitors of L-type mediated iron uptake, without compromising the main 
site of NTBI clearance, namely the liver.
Discussion 2574 (with refs)
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2Abstract
Reticuloendothelial macrophages together with duodenal enterocytes co-ordinate body iron 
homeostasis and are believed to be the main target sites for the regulatory actions of 
hepcidin. In this study we have investigated the rapid effects of hepcidin on serum iron and 
duodenal iron transport in vivo in mice injected with a synthetic hepcidin peptide. Within 4 h 
of injecting hepcidin, mice developed hypoferremia, which was associated with a significant 
decrease in ferroportin protein levels in the macrophage-rich red pulp of the spleen. Despite 
this dramatic decrease in serum iron levels, there was no effect of hepcidin on duodenal iron 
transport or duodenal ferroportin protein expression in the same mice. These data suggest 
the rapid response to a rise in hepcidin is tissue-specific. Upon its release hepcidin initially 
targets macrophage iron recycling. The duodenum appears to be less sensitive to this initial 
increase in hepcidin levels. The fact that macrophages respond more acutely to a hepcidin 
challenge is fully consistent with their central role in maintaining body iron homeostasis.
3Introduction
Body iron homeostasis is maintained through the absorption of 1 -2 mg/day of iron from the 
diet by the duodenal enterocytes, to replace endogenous iron losses, together with the 
recycling of some 20-25 mg of iron from effete erythrocytes via the reticuloendothelial 
macrophages. In addition, there is normally a physiological reserve of iron in the 
hepatocytes (approximately 1g) which further protect against imbalances in body iron 
homeostasis. The co-ordination and regulation of all of these processes has been ascribed 
to hepcidin, a 25 amino acid peptide hormone which is produced in the liver (1, 2). Hepcidin 
expression is dramatically regulated by the levels of iron in the hepatic stores -  expression is 
increased when liver iron is high and down regulated when the stores are depleted (3). In 
addition to modulation by stored iron, hepcidin expression also responds to changes in the 
erythroid requirement for iron. Phlebotomy (4), hemolysis (4, 5) and elevated erythropoietin 
levels (4), major stimuli for reticulocytosis, all inhibit hepcidin production, and result in 
increased iron assimilation from the diet. Furthermore hepcidin expression is increased in a 
number of chronic diseases and by inflammation (2, 4, 6) indicating that pathological 
imbalances in hepcidin levels have severe consequences for body iron metabolism.
Once released, hepcidin acts as a negative regulator of intestinal iron absorption (7) and 
macrophage iron recycling (8). In chronic disease for example, this is thought to lead to the 
underlying anemia that characterizes many disorders (9). The cellular targets and the mode 
of action of hepcidin have been the subject of much recent work. In vitro studies with 
transfected cell lines, suggest that hepcidin interacts directly with the ferroportin protein 
resulting in its internalization and degradation (10-12).
The in vitro effects of hepcidin on ferroportin expression are rapid with maximal inhibition 
achieved 3-4 hours following exposure to peptide (10). In in vivo studies the effects of 
hepcidin on serum iron levels are also rapid. Hypoferremia is evident within 1 hour in mice
4injected with hepcidin (13). Interestingly serum iron reaches its nadir 2-4 hours post injection 
suggesting that the time course for the actions of hepcidin is similar both in vitro and in vivo. 
In animals with normal iron status serum iron is regulated largely by two separate pathways, 
macrophage recycling of iron from erythrocytes and duodenal iron absorption. The purpose 
of the present study was to determine whether the rapid effects of hepcidin on serum iron 
noted previously (13) were due to inhibition of one or both of these pathways. To address 
this issue, we injected hepcidin into male C57BL/6 mice fed a normal iron diet and measured 
changes in serum iron levels and duodenal iron transport 4 h later. In addition, spleen (an 
abundant source of reticuloendothelial macrophages) and duodenum from control and 
hepcidin-treated animals were used to measure ferroportin transporter expression.
5Methods
Animals and Treatments
All procedures were approved by the Local Animal Ethics committee and were carried out in 
accordance with current UK Home Office legislation. Male C57BL/6 mice aged 4 weeks 
were housed in the Comparative Biology Unit at UCL (Hampstead campus) and placed on 
an iron replete diet (44mg Fe/Kg diet) for 3 weeks prior to experimentation. During this time, 
animals were allowed ab libitum access to water. On the day of study, mice were given a 
single intraperitoneal injection of either 10pg hepcidin (Peptides International Inc. Louisville, 
KY) or an equivalent volume of the diluent (saline) and used for experiments 4 hours later. 
The commercially hepcidin peptide is air-oxidized and has been used successfully in a 
number of studies (8, 12, 14).
Since there are no robust methods readily available to measure serum hepcidin levels in 
mice we based our calculation of circulating hepcidin levels on previously published data 
(13). Extrapolating from this study we estimated that serum hepcidin in our animals would be 
approximately 300 -  500 nM, which is close to the in vitro IC50(700 nM) for the inhibitory 
effects of hepcidin on ferroportin expression (10).
Blood was collected by cardiac puncture from all animals of the end of the experimental 
period to measure serum iron and transferrin saturation using a commercially available 
assay (Randox Laboratories Ltd, Antrim, UK).
6Iron uptake
Animals were anaesthetized with pentobarbitone sodium (60 mg/kg, i.p.) and the duodenum 
was washed through with warm 0.15M NaCI followed by air. The lower end of the duodenal 
segment (proximal to the ligament of Treitz) was tied off and uptake buffer (0.15M NaCI, 
10mM Hepes, pH 6.5) containing 0.2mM 59Fe2+ complexed with 4mM ascorbate, was 
instilled proximally from a tied-in syringe. After 10 min, during which time animal body 
temperature was maintained at 37°C with a thermostatically controlled heating blanket, blood 
samples and the duodenal segment were removed. The duodenal lumen was emptied of its 
contents and was flushed thoroughly with buffer containing 2 mM unlabelled iron, followed 
by 0.15 M NaCI, and finally dried overnight. The mucosa was weighed and, together with 
weighed blood samples and the animal carcass, were gamma-counted for determination of 
59Fe activity. Mucosal iron retention, mucosal iron transfer and total mucosal iron uptake 
were calculated as described previously (7).
Cell culture
Caco-2 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% 
fetal bovine serum for 21 days on Transwell inserts (Corning-Costar, High Wycombe, UK) to 
achieve a fully differentiated monolayer (15). THP-1 cells, grown in RPMI 1640 medium 
containing 10% fetal bovine serum, were seeded at 5x105 cells per well in 6-well plates and 
treated with phorbol myristate acetate (100 nM) to induce differentiation and plate 
attachment. The day prior to experimentation, cells were placed in serum-free medium. The 
next morning the culture medium was replaces with fresh serum-free medium and the cells 
were exposed to hepcidin (1 pM) for up to 24h. In Caco-2 cell experiments hepcidin was 
added only to the basolateral chamber of the Transwell plate.
7Western blotting
Total plasma membranes from tissue samples and from cultured cells were prepared as 
described previously (16, 17). All procedures were performed at 4°C. Briefly, the duodenal 
mucosae were separated from their underlying musculature by scraping with a glass slide. 
Splenic tissue was rinsed with PBS and chopped into fragments prior to homogenization. 
Cultured cells were removed from Transwell plates (Caco-2) and plastic dishes (THP-1) 
using cell scrapers. Tissue and cell samples were homogenized in phosphate buffered 
saline (PBS) containing protease inhibitor cocktail (Sigma-Aldrich, Dorset, UK) with an Ultra 
Turrax homogenizer (2x30 s pulses on full speed). The ensuing homogenates were 
subjected to a brief centrifugation step (1500 g for 5 min) to precipitate unbroken cells and 
nuclei and the resulting supernatant was centrifuged for 30 min at 15,000 g to give a total 
plasma membrane fraction which was resuspended in PBS containing protease inhibitor 
cocktail, 10% NP-40 and 1% Triton X-100 .
Membranes (40pg) were solubilized in sample loading buffer and subjected to SDS-PAGE. 
Following immobilization on nitrocellulose, the proteins were exposed to a commercially 
available anti-ferroportin antibody (Alpha Diagnostics Inc., San Antonio, TX). Cross­
reactivity was observed using an HRP-linked secondary antibody (Dako, Cambridgeshire, 
UK) and ECL Plus (GE Healthcare, Buckinghamshire UK). Band densities were semi­
quantified using Scion Image software (Scion Corporation, Frederick, MD). At the end of the 
experiment, the nitrocellulose membranes were stripped (Western Stripping Buffer, Perbio 
Science Ltd, Northumberland, UK) and re-probed with antibodies to actin (Sigma-Aldrich) or, 
for Caco-2 cell studies, villin (Santa Cruz Biotechnology Inc, Santa Cruz, CA) which acted as 
loading controls.
8Immunofluorescence
Tissues from mice injected with hepcidin or saline were perfusion-fixed in situ prior to 
harvesting. Briefly, the abdominal aorta of anaesthetized animals was cannulated and each 
mouse was perfused with Hanks balanced salt solution (HBS, Sigma-Aldrich) to remove 
blood, followed by perfusion with HBS containing 2% paraformaldehyde. The spleen and 
duodenum from each animal were removed, embedded in OCT compound (Merck, Dorset, 
UK) and frozen in isopentane, pre-cooled in liquid nitrogen and stored at -80 °C until use.
Cryostat sections (7 pm) of spleen and duodenum were mounted onto poly-L-lysine-coated 
slides (Sigma-Aldrich) and air-dried for 1 h. Sections were washed for 5 min in 0.1 M PBS 
(pH 7.4) and then blocked for 30 min with PBS containing 10 % normal goat serum (NGS) 
(Sigma-Aldrich) and 1 % Triton X-100. Sections were briefly washed with PBS and incubated 
overnight at 4 °C with ferroportin antibody (1:100 dilution). Following overnight incubation, 
sections were washed (3 x10 min, 0.1 M PBS) and then incubated with FITC-conjugated 
swine anti-rabbit IgG (Dako) (1:100 dilution) for 1 h at room temperature. Subsequently, 
sections were washed (3 x10 min, 0.1 M PBS) and mounted with Vectashield mounting 
medium containing propidium iodide (Vector Laboratories Ltd, Peterborough, UK). Images 
were subsequently captured using a Leica TCS laser scanning confocal microscope and the 
manufacturer’s dedicated software.
Statistics
Data are presented as mean ± S.E.M. Statistical differences (P<0.05) between groups were 
determined using Student’s unpaired t-test or one-way analysis of variance followed by 
Tukey’s post hoc test, where appropriate, using SPSS statistical package (SPSS UK Ltd, 
Surrey, UK).
9Results
Serum iron levels are decreased in hepcidin-treated mice
A major consequence of hepcidin release is the inhibition of iron recycling from 
reticuloendothelial macrophages (reviewed in 18). Accordingly, in serum samples taken 
from mice injected with hepcidin (10pg) we observed a substantial decrease in serum iron 
content (control 14.7 ± 0.9 pmol/L; hepcidin-treated 5.7 ± 2.4 pmol/L. P<0.01). Hypoferremia 
was accompanied by a 40% decrease in transferrin saturation in the hepcidin-treated mice 
(control 60.7 ± 9.3 %; hepcidin-treated 34.0 ± 10.2 %. P<0.1).
Short-term exposure to hepcidin does not alter intestinal iron transport
As well as controlling the rate of iron release from reticuloendothelial macrophages into the 
circulation, hepcidin also acts directly on duodenal enterocytes to regulate the rate of dietary 
iron absorption (7). Therefore, to determine the effects of hepcidin on duodenal iron 
transport we employed an in vivo technique that allowed us to measure both mucosal iron 
uptake and its subsequent transfer across the intestinal epithelium into the animal carcass. 
Surprisingly, despite the dramatic hepcidin-mediated decrease in serum iron levels, neither 
duodenal iron uptake nor the subsequent transfer of iron across the duodenal mucosa was 
altered in hepcidin-treated mice (Figure 1). Taken together, these data suggest that upon its 
release into the circulation the initial effects of hepcidin are likely to occur at the level of the 
recycling macrophage rather than the duodenal enterocyte.
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Effect of hepcidin on ferroportin levels in spleen and duodenum
The above functional data imply that the initial actions of hepcidin on serum iron occur as a 
consequence of inhibiting macrophage iron recycling following down-regulation of the 
ferroportin transporter, which is believed to act as the hepcidin receptor on target cells (10). 
Furthermore, our duodenal iron transport data suggest that we should see no change in 
duodenal ferroportin expression. To investigate these possibilities, we isolated spleen (an 
abundant source of reticuloendothelial macrophages) and duodenum from control and 
hepcidin-treated animals and measured the expression of ferroportin protein by both 
immunofluorescence and semi-quantitative western blotting.
In the spleen, ferroportin immunoreactivity was associated with the macrophage-rich red 
pulp and was substantially reduced in the hepcidin-treated animals (Figure 2a). Quantitative 
analysis of ferroportin levels in splenic tissue using western blotting were in agreement with 
the immunofluorescence data and revealed a 60% (P<0.001) reduction in ferroportin 
expression in hepcidin-treated animals (Figure 2b). These findings support our assertion 
that the recycling macrophage is a major target for the rapid effects of hepcidin on serum 
iron levels.
In the duodenum, ferroportin was localized to the basolateral membrane of enterocytes. In 
addition, a number of strongly stained ferroportin-positive cells (most probably 
macrophages) were also noted in the lamina propria. Ferroportin immunoreactivity in the 
enterocyte layer was not altered following hepcidin treatment in duodenal tissue (Figure 3a). 
Interestingly, the ferroportin-positive cells that were evident in the lamina propria of the 
control animals were absent from the hepcidin-treated mice. Densitometric analysis of the 
ferroportin western blots from duodenal tissue revealed a small (25%) and statistically 
insignificant decrease (P>0.28) in ferroportin expression in hepcidin-treated mice (Figure 3b).
11
Taken together with the immunofluorescence images this decrease may be accounted for in 
part by the absence of the ferroportin-positive macrophage-like cells in the lamina propria of 
the hepcidin-treated mice, though we cannot rule out a minor effect of hepcidin on 
enterocyte ferroportin levels. Importantly, the lack of a significant change in ferroportin 
expression in the duodenum following hepcidin treatment is completely consistent with the 
duodenal iron transport data (Figure 1) further supporting the notion that the rapid effects of 
hepcidin occur at the recycling macrophage and not the duodenal enterocyte.
Effect of hepcidin on ferroportin levels in macrophages and intestinal epithelial cells
Since the spleen and duodenum are formed of heterogeneous cell population we wanted to 
study further the effects of hepcidin on macrophages and enterocytes in isolation. 
Unfortunately, while it is feasible to isolate and culture macrophages from a number of body 
sites it is not possible to sustain isolated enterocytes in culture. Therefore, for these studies 
we decided to utilize two well characterized human cell lines, the THP-1 monocyte/ 
macrophage line and the enterocyte-like Caco-2 cell. In these studies, hepcidin (1pM) was 
added to the cell culture medium for up to 24 h and cell extracts were analyzed by western 
blotting for changes in ferroportin protein expression.
In differentiated THP-1 cells (which exhibit a macrophage phenotype) there was a rapid 
decrease in ferroportin protein levels (occurring 1-4 hours following exposure to hepcidin) 
which remained suppressed in the presence of hepcidin for the duration of the study (Figure 
4a). In contrast, ferroportin levels in enterocyte-like Caco-2 cells were not altered at any 
time point following exposure to hepcidin (Figure 4b). While one must exercise some 
caution in interpreting data from neoplastic cell lines, the data from THP-1 cells and Caco-2 
cells are consistent with the results from the in vivo study and further support the hypothesis 
that macrophages are more sensitive to a hepcidin challenge than enterocytes.
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Discussion
Hepcidin is recognized as a major regulator of body iron metabolism. A number of studies 
have demonstrated that hepcidin regulates cellular iron homeostasis by controlling 
ferroportin expression (8, 10-12, 14). In this model, hepcidin is believed to bind directly to 
ferroportin and rapidly (within 1-4 hours) induce its internalization and degradation (10). This 
in turn impairs the release of iron from its target cells (namely the reticuloendothelial 
macrophages and the duodenal enterocytes) into the circulation. In support of this 
hypothesis, a recent study in which radio-labeled hepcidin was injected into mice revealed 
that the peptide concentrates in tissues with the highest concentrations of ferroportin, 
namely the spleen, liver and duodenum (13).
A number of studies have reported an association between elevated hepcidin levels in vivo 
and subsequent hypoferremia (5, 6, 13, 20, 21). In an elegant study, in which mice were 
injected with hepcidin, Rivera and colleagues demonstrated that the initial effects of hepcidin 
on serum iron levels were rapid and dose-dependent (13). Interestingly, the lowest level of 
serum iron occurred approximately 2-4 hours post-injection. Taken together with the in vitro 
data for the actions of hepcidin on ferroportin expression (10) these two studies suggest that 
the time course for the actions of hepcidin are similar both in vitro and in vivo. In each case 
the maximal effects of hepcidin are evident approximately 4 hours after exposure to hepcidin 
and we have therefore used this time-point in our studies.
The major contributing pathways controlling serum iron levels are dietary iron absorption via 
the duodenum and macrophage recycling of iron from senescent erythrocytes. Our starting 
hypothesis was that hepcidin would affect both of these pathways to exert its rapid 
hypoferremic effects. To address this issue we injected mice with hepcidin and measured 
serum iron and duodenal iron transport 4 hours later. In agreement with previous studies
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(13) serum iron was dramatically decreased in our hepcidin-treated mice. However, in the 
same group of animals duodenal iron transport was not altered following injection of 
hepcidin. This would imply that initially hepcidin targets the macrophage recycling pathway 
to exert its hypoferremic effects. This notion is supported by recent data from an in vitro 
erythrophagocytosis model showing that exposure to hepcidin results in decrease ferroportin 
levels inhibition of iron efflux (8).
To determine whether hypoferremia in our animals could be explained by diminution of 
ferroportin levels in recycling macrophages we isolated the spleen (a rich source of 
reticuloendothelial macrophages) from hepcidin-treated mice. Ferroportin expression in the 
spleen was largely associated with the macrophage-rich red pulp, and transporter protein 
levels were significantly decreased in the hepcidin-treated mice. Since the spleen is a 
composite of a number of cell types we wanted to confirm that the macrophage is a major 
target cell type for the actions of hepcidin. For these studies we utilized THP-1 cells which 
are a well established monocyte/macrophage line. In agreement with our observations in 
mouse spleen, THP-1 ferroportin levels were decreased significantly within 4 hours of 
exposure to hepcidin. Similar findings following hepcidin treatment have also been observed 
in mouse J774 macrophages (8) and mouse bone marrow derived macrophages (14). All of 
these studies support the published model for the cellular actions of hepcidin (10) and 
support a scenario whereby hepcidin binds to ferroportin in macrophages, decreases cell 
surface expression of the transporter and thereby inhibits iron release into the circulation 
resulting in hypoferremia.
Along with the spleen, the duodenum is one of the major sites of ferroportin expression (22-
24) and as such would be expected to respond appropriately to a hepcidin challenge. We 
were surprised therefore to observe that despite the presence of hypoferremia in the 
hepcidin-treated animals there was no significant difference in duodenal iron transport or 
ferroportin expression following the acute exposure to hepcidin. These data are in contrast
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to previous studies by our group (7,19) and by others (25) which have reported decreased 
intestinal iron transport following chronic hepcidin treatment. Intriguingly, analysis of the iron 
transport data from all three studies appears to indicate that the major effect of hepcidin in 
intestinal epithelial cells is on the uptake route rather than the efflux pathway which may 
indicate that ferroportin is less sensitive to the actions of hepcidin in intestinal cells than in 
macrophages.
What is the basis for this apparent differential sensitivity of the macrophage and intestinal 
epithelial cell to hepcidin? Previous work has shown that the effects of hepcidin of serum 
iron levels are clearly dose-dependent (13) so does the duodenum simply require a higher 
concentration of hepcidin to elicit a response? From our previous work this would not 
appear to be the case since there is no impairment in duodenal iron transport in animals 
injected with 50pg of hepcidin peptide 4 hours previously (see Table 2 in ref. 7). In addition, 
in our in vitro work with Caco-2 cells presented both here and previously (19), there is no 
evidence for a dose-dependent effect of hepcidin on ferroportin expression.
A second possibility is that there are tissue-specific differences in the temporal kinetics of the 
response to hepcidin, i.e. the macrophage responds faster than the enterocyte. Our 
previous data supports this option. In mice given multiple injections of hepcidin over a 24-72 
hour period there is a decrease in duodenal iron transport (7). In addition, Caco-2 cells 
incubated with hepcidin over a similar time course also display decreased iron transport (19,
25). This possible mechanism is further supported by a recent study with transgenic mice 
containing an inducible hepcidin vector, which exhibit a significant decrease in duodenal 
ferroportin expression following chronic hepcidin exposure for 3 weeks (26).
Furthermore, we also believe that the basal level of hepcidin will be important in determining 
the duodenal response to hepcidin. There is clear evidence that when there is a marked 
hepcidin deficiency, e.g. in iron deficiency (27), hemolytic anemia (5), hypoxia (28) USF2-
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null mice (29), and chronic alcohol loading (30), intestinal iron transport and ferroportin 
transporter expression is elevated. In hemochromatosis also, there is a clear association 
between hepcidin levels, which are inappropriately low, and duodenal iron absorption, which 
is inappropriately high (reviewed in 31). These studies all support the hypothesis that 
chronic changes in hepcidin expression alter duodenal iron transport. We also believe that it 
is likely that the duodenum’s temporal response to hepcidin might change dramatically in 
models where baseline hepcidin levels are low or absent and it would be interesting to study 
this in the recently described hepcidin 1 knockout mouse model (32).
Finally, it is possible that the relative abundance of ferroportin in different tissues may 
contribute lack of a homogeneous response to hepcidin. Anecdotally we found ferroportin 
much easier to detect in spleen and THP-1 cells than in duodenum and Caco-2 in our 
western blotting studies. In addition, different ferroportin proteins species (33) and splice 
variants (34) have been proposed in various cell-types and it is possible that there may be 
subtle differences in the way these ferroportin isoforms respond to a hepcidin challenge -  
though obviously further studies would need to be performed to establish this possibility.
In conclusion, our study has shown for the first time that there is a differential tissue-specific 
sensitivity in response to a rapid increase in hepcidin levels. Following its release into the 
circulation the initial rapid effects of hepcidin occur at the level of the recycling macrophage 
resulting in down-regulation of ferroportin protein levels. These changes are associated with 
the hepcidin-induced hypoferremia. In contrast there were no commensurate changes in 
either duodenal iron transport or enterocyte ferroportin levels. However, our previous data 
(7) suggest that duodenal iron transport does decrease at a later stage (24-72 hours post 
administration of hepcidin). Since reticuloendothelial macrophages recycle some 20-25 mg 
Fe/day from senescent red blood cells, compared with the 1-2mg Fe/day assimilated from 
the diet by the duodenal enterocytes, we believe that the acute effects of hepcidin on 
macrophages is fully consistent with their central role in body iron homeostasis.
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Figure legends
Figure 1. No effect of hepcidin on duodenal iron transport. Mice were injected with 
10|jg hepcidin and used for studies 4 h later. The duodenal lumen was filled with 200pM 
59Fe2+ for10 min and the subsequent levels of 59Fe in duodenal mucosae and the blood and 
carcass determined by gamma counting. There was no significant difference in mucosal iron 
retention (grey bars, P>0.92), mucosal iron transfer (black bars, P>0.52) or total mucosal 
uptake (white bars, P>0.48) iron uptake between the control and hepcidin-treated animals. 
Data are mean ± S.E.M. of 6 observations in each group.
Figure 2. Ferroportin level are decreased by hepcidin treatment in mouse spleen.
Hepcidin-treated mice showed a marked hypoferremia after 4 h. To determine whether this 
occurred as a consequence of down-regulation of ferroportin levels in the reticuloendothelial 
system we analyzed transporter expression in spleen, (a) Representative ferroportin- 
immunofluorescence images. Ferroportin was associated with the macrophage-rich red pulp 
(arrow) and was not expressed in the immune-cell rich white pulp (*). In hepcidin-treated 
mice ferroportin immunofluorescence was diminished compared with the saline injected 
control animals, (b) Western blotting of splenic tissue from hepcidin-treated mice showed a 
significant decrease in ferroportin (FPN) levels compared with the control group. Expression 
of the housekeeper protein actin was not altered by hepcidin treatment. Densitometry data 
are mean ± S.E.M. from 6 spleens in each group *P<0.001.
Figure 3. Ferroportin expression in mouse duodenum is not altered following hepcidin 
treatment (a) Ferroportin was localized to the basolateral membrane of duodenal 
enterocytes. Immunoreactivity was not altered following hepcidin treatment. Ferroportin- 
positive cells (probably macrophages) were also noted in the lamina propria of the duodenal 
villi from the control but not the hepcidin-treated mice. Representative images presented
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here were obtained using the duodena from the same animals used in figure 2. (b) In 
support of the immunofluorescence data, there was no significant difference in ferroportin 
levels in mouse duodenum from control and hepcidin-treated animals (P>0.28). Expression 
of the housekeeper protein actin was not altered by hepcidin treatment. Densitometry data 
are mean ± S.E.M. from 6 duodena in each group.
Figure 4. Expression of ferroportin in THP-1 macrophages and Caco-2 cells following 
exposure to hepcidin. THP-1 macrophages and Caco-2 cells were incubated for up to 24 
h with hepcidin (1 pM). Cells were harvested, homogenised and subjected to Western 
blotting, (a) In the macrophages, ferroportin (FPN) protein levels were significantly 
decreased after 4 h of hepcidin treatment compared with basal levels and remained 
suppressed for the duration of the study, (b) In contrast, in Caco-2 cells, ferroportin levels of 
were not significantly different from basal levels at either the 4 h or 24 h time point. 
Expression levels of the housekeeper proteins actin in THP-1 cells and villin in Caco-2 cells 
were not altered by hepcidin treatment. Densitometry data are presented as the mean ±
S.E.M. of 4 experiments in each group. *P<0.01 (one-way ANOVA and Tukey’s post hoc 
test) compared with the basal transporter levels.
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